<?xml version="1.0" encoding="UTF-8"?>
<patent-document ucid="EP-2170834-B1" country="EP" doc-number="2170834" kind="B1" date="20140108" family-id="39885097" file-reference-id="270079" date-produced="20180826" status="corrected" lang="EN"><bibliographic-data><publication-reference fvid="146588255" ucid="EP-2170834-B1"><document-id><country>EP</country><doc-number>2170834</doc-number><kind>B1</kind><date>20140108</date><lang>EN</lang></document-id></publication-reference><application-reference ucid="EP-08781893-A" is-representative="NO"><document-id mxw-id="PAPP154850447" load-source="docdb" format="epo"><country>EP</country><doc-number>08781893</doc-number><kind>A</kind><date>20080716</date><lang>EN</lang></document-id></application-reference><priority-claims><priority-claim mxw-id="PPC140551921" ucid="US-2008070180-W" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>2008070180</doc-number><kind>W</kind><date>20080716</date></document-id></priority-claim><priority-claim mxw-id="PPC140550324" ucid="US-94988607-P" load-source="docdb"><document-id format="epo"><country>US</country><doc-number>94988607</doc-number><kind>P</kind><date>20070716</date></document-id></priority-claim></priority-claims><dates-of-public-availability><intention-to-grant-date><date>20130723</date></intention-to-grant-date></dates-of-public-availability><technical-data><classifications-ipcr><classification-ipcr mxw-id="PCL1989325085" load-source="ipcr">A61K  31/416       20060101ALI20090212BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325086" load-source="ipcr">A61P  35/00        20060101ALI20090212BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325087" load-source="ipcr">C07D 261/20        20060101ALI20090212BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325088" load-source="ipcr">C07D 231/56        20060101AFI20090212BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325089" load-source="ipcr">A61K  31/423       20060101ALI20090212BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325090" load-source="ipcr">A61K  31/428       20060101ALI20090212BHEP        </classification-ipcr><classification-ipcr mxw-id="PCL1989325091" load-source="ipcr">C07D 275/04        20060101ALI20090212BHEP        </classification-ipcr></classifications-ipcr><classifications-cpc><classification-cpc mxw-id="PCL1989624624" load-source="docdb" scheme="CPC">C07D 275/04        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989625898" load-source="docdb" scheme="CPC">C07D 261/20        20130101 LI20130101BHEP        </classification-cpc><classification-cpc mxw-id="PCL1989649479" load-source="docdb" scheme="CPC">C07D 231/56        20130101 FI20130101BHEP        </classification-cpc></classifications-cpc><invention-title mxw-id="PT132369398" lang="DE" load-source="patent-office">INDAZOLE, BENZISOXAZOLE UND BENZISOTHIAZOLE ALS HEMMER VON PROTEINKINASEN</invention-title><invention-title mxw-id="PT132369399" lang="EN" load-source="patent-office">INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES</invention-title><invention-title mxw-id="PT132369400" lang="FR" load-source="patent-office">INDAZOLES, BENZISOXAZOLES ET BENZISOTHIAZOLES EN TANT QU'INHIBITEURS DES PROTÉINES KINASES</invention-title></technical-data><parties><applicants><applicant mxw-id="PPAR919525818" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>ABBVIE INC</last-name><address><country>US</country></address></addressbook></applicant><applicant mxw-id="PPAR919521797" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>ABBVIE INC.</last-name></addressbook></applicant></applicants><inventors><inventor mxw-id="PPAR919532089" load-source="docdb" sequence="1" format="epo"><addressbook><last-name>DAI YUJIA</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919536267" load-source="docdb" sequence="1" format="intermediate"><addressbook><last-name>DAI, YUJIA</last-name></addressbook></inventor><inventor mxw-id="PPAR919022268" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>DAI, YUJIA</last-name><address><street>1557 Camden Drive</street><city>Gurnee, Illinois 60031</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919525246" load-source="docdb" sequence="2" format="epo"><addressbook><last-name>ZHIQIN JI</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919517052" load-source="docdb" sequence="2" format="intermediate"><addressbook><last-name>ZHIQIN, JI</last-name></addressbook></inventor><inventor mxw-id="PPAR919022270" load-source="patent-office" sequence="2" format="original"><addressbook><last-name>ZHIQIN, JI</last-name><address><street>1103 Tamarack Lane</street><city>Libertyville, Illinois 60048</city><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919541442" load-source="docdb" sequence="3" format="epo"><addressbook><last-name>MICHAELIDES MICHAEL R</last-name><address><country>US</country></address></addressbook></inventor><inventor mxw-id="PPAR919523224" load-source="docdb" sequence="3" format="intermediate"><addressbook><last-name>Michaelides, Michael R.</last-name></addressbook></inventor><inventor mxw-id="PPAR919022269" load-source="patent-office" sequence="3" format="original"><addressbook><last-name>Michaelides, Michael R.</last-name><address><street>4452 West Gavin Lane</street><city>Libertyville, Illinois 60048</city><country>US</country></address></addressbook></inventor></inventors><assignees><assignee mxw-id="PPAR919022272" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>AbbVie Inc.</last-name><iid>101346105</iid><address><street>1 North Waukegan Road</street><city>North Chicago, IL 60064</city><country>US</country></address></addressbook></assignee></assignees><agents><agent mxw-id="PPAR919022271" load-source="patent-office" sequence="1" format="original"><addressbook><last-name>Modiano, Micaela Nadia</last-name><iid>100048066</iid><address><street>Modiano Josif Pisanty &amp; Staub Ltd Thierschstrasse 11</street><city>80538 München</city><country>DE</country></address></addressbook></agent></agents></parties><international-convention-data><pct-or-regional-filing-data ucid="US-2008070180-W"><document-id><country>US</country><doc-number>2008070180</doc-number><kind>W</kind><date>20080716</date><lang>EN</lang></document-id></pct-or-regional-filing-data><pct-or-regional-publishing-data ucid="WO-2009012312-A1"><document-id><country>WO</country><doc-number>2009012312</doc-number><kind>A1</kind><date>20090122</date><lang>EN</lang></document-id></pct-or-regional-publishing-data><designated-states><ep-contracting-states><country mxw-id="DS549891128" load-source="docdb">AT</country><country mxw-id="DS549923323" load-source="docdb">BE</country><country mxw-id="DS549784101" load-source="docdb">BG</country><country mxw-id="DS549871715" load-source="docdb">CH</country><country mxw-id="DS549800697" load-source="docdb">CY</country><country mxw-id="DS549891129" load-source="docdb">CZ</country><country mxw-id="DS549923324" load-source="docdb">DE</country><country mxw-id="DS549800698" load-source="docdb">DK</country><country mxw-id="DS549800699" load-source="docdb">EE</country><country mxw-id="DS549868641" load-source="docdb">ES</country><country mxw-id="DS549784102" load-source="docdb">FI</country><country mxw-id="DS549784103" load-source="docdb">FR</country><country mxw-id="DS549923325" load-source="docdb">GB</country><country mxw-id="DS549800700" load-source="docdb">GR</country><country mxw-id="DS549923326" load-source="docdb">HR</country><country mxw-id="DS549891130" load-source="docdb">HU</country><country mxw-id="DS549871716" load-source="docdb">IE</country><country mxw-id="DS549800705" load-source="docdb">IS</country><country mxw-id="DS549784104" load-source="docdb">IT</country><country mxw-id="DS549800706" load-source="docdb">LI</country><country mxw-id="DS549783244" load-source="docdb">LT</country><country mxw-id="DS549876301" load-source="docdb">LU</country><country mxw-id="DS549783253" load-source="docdb">LV</country><country mxw-id="DS549783254" load-source="docdb">MC</country><country mxw-id="DS549876306" load-source="docdb">MT</country><country mxw-id="DS549891131" load-source="docdb">NL</country><country mxw-id="DS549868646" load-source="docdb">NO</country><country mxw-id="DS549871717" load-source="docdb">PL</country><country mxw-id="DS549783255" load-source="docdb">PT</country><country mxw-id="DS549891132" load-source="docdb">RO</country><country mxw-id="DS549871718" load-source="docdb">SE</country><country mxw-id="DS549784109" load-source="docdb">SI</country><country mxw-id="DS549868647" load-source="docdb">SK</country><country mxw-id="DS549876307" load-source="docdb">TR</country></ep-contracting-states><ep-extended-states><ep-extended-state-data><country>AL</country></ep-extended-state-data><ep-extended-state-data><country>BA</country></ep-extended-state-data><ep-extended-state-data><country>MK</country></ep-extended-state-data><ep-extended-state-data><country>RS</country></ep-extended-state-data></ep-extended-states></designated-states></international-convention-data><office-specific-data><eptags><ep-no-a-document-published>*</ep-no-a-document-published></eptags></office-specific-data></bibliographic-data><description mxw-id="PDES63960680" lang="EN" load-source="patent-office"><!-- EPO <DP n="1"> --><p id="p0001" num="0001">This application claims priority to <patcit id="pcit0001" dnum="US94988607P"><text>U.S. Provisional Patent Application Serial No. 60/949,886 filed July 16, 2007</text></patcit>.</p><heading id="h0001">FIELD OF THE INVENTION</heading><p id="p0002" num="0002">This invention pertains to compounds that inhibit protein kinases such as Aurora-kinases, and compositions containing the compounds. Methods of treating diseases using the compounds are also disclosed.</p><heading id="h0002">BACKGROUND OF THE INVENTION</heading><p id="p0003" num="0003">Mitosis is a process by which a complete copy of a duplicated genome is segregated by the microtuble spindle apparatus into two daughter cells. Aurora-kinases, key mitotic regulators required for genome stability, have been found to be overexpressed in human tumors. There is therefore an existing need in the therapeutic arts for compounds which inhibit Aurora-kinases, compositions comprising the inhibitors and methods of treating diseases during which Aurora-kinases are unregulated or overexpressed.</p><p id="p0004" num="0004"><patcit id="pcit0002" dnum="WO03078402A"><text>WO 03078402</text></patcit> is directed to substituted indazoles, compositions containing said substituted indazoles and the use thereof. In particular, the kinase-inhibiting activity of such substituted indazoles and their therapeutic use, especially in the field of oncology, is disclosed.</p><p id="p0005" num="0005"><patcit id="pcit0003" dnum="US2005020603A"><text>US 2005/020603</text></patcit> and <patcit id="pcit0004" dnum="US2004235892A"><text>US 2004/235892</text></patcit> are directed to variously substituted indazoles, benzisoxazoles and benzisothiazoles which are effective in inhibiting protein tyrosine kinases. In particular, the substituted indazoles, benzisoxazoles, and benzisothiazoles herein disclosed are useful in the treatment of cancer.<!-- EPO <DP n="2"> --></p><heading id="h0003">SUMMARY OF THE INVENTION</heading><p id="p0006" num="0006">The present invention is defined as per appended claims 1-4.</p><p id="p0007" num="0007">One embodiment of this invention, therefore, pertains to compounds that inhibit Aurora-kinases, the compounds having Formula I
<chemistry id="chem0001" num="0001"><img id="ib0001" file="imgb0001.tif" wi="30" he="33" img-content="chem" img-format="tif"/></chemistry>
and therapeutically acceptable salts thereof, wherein
<ul><li>X is S, O or NG<sup>1</sup>;<!-- EPO <DP n="3"> --></li><li>G<sup>1</sup> is H or is alkyl</li><li>A<sup>1</sup> is C(O)NHR<sup>1</sup>;</li><li>B<sup>1</sup>, C<sup>1</sup>, and D<sup>1</sup> are independently selected OR<sup>1</sup>, H, F, Br, Cl, or I;</li><li>R<sup>1</sup> is R<sup>2</sup> or R<sup>5</sup>;</li><li>R<sup>2</sup> is phenyl;</li><li>R<sup>5</sup> is alkyl which is unsubstituted or substituted with one, two, three, four or five of independently selected R<sup>6</sup>, OH, F, Cl, Br or I;</li><li>R<sup>6</sup> is R<sup>7</sup> or R<sup>9</sup>;<!-- EPO <DP n="4"> --></li><li>R<sup>7</sup> is phenyl;</li><li>R<sup>9</sup> is heterocycloalkyl;</li><li>wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected R<sup>10</sup>, NHC(O)R<sup>10</sup>, NHC(O)NHR<sup>10</sup>, F, Cl, Br or I;</li><li>R<sup>10</sup> is R<sup>11</sup>, R<sup>12</sup> or R<sup>14</sup>;</li><li>R<sup>11</sup> is phenyl;</li><li>R<sup>12</sup> is heteroaryl;<!-- EPO <DP n="5"> --></li><li>R<sup>14</sup> is alkyl which is unsubstituted or substituted with one, two, three, four or five of independently selected R<sup>15</sup>, NH<sub>2</sub>, NHC(O)R<sup>15</sup>, NHC(O)NHR<sup>15</sup>, F, Cl, Br or I;</li><li>R<sup>15</sup> is R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> or R<sup>19</sup>;</li><li>R<sup>16</sup> is phenyl;</li><li>R<sup>17</sup> is heteroaryl;</li><li>R<sup>18</sup> is cycloalkyl;</li><li>R<sup>19</sup> is alkyl, each of which is substituted with R<sup>20</sup>;</li><li>R<sup>20</sup> is phenyl;</li><li>wherein the moieties represented by R<sup>11</sup>, R<sup>12</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>20</sup> are independently unsubstituted or substituted with one or two or three of independently selected R<sup>21</sup>, OR<sup>21</sup>, SR<sup>21</sup>,<!-- EPO <DP n="6"> --> CN, CF<sub>3</sub>, OCF<sub>3</sub>, F, Cl, Br or I; and</li><li>R<sup>21</sup> is alkyl which is unsubstituted or substituted with one or two or three of independently selected F, Cl, Br, I, OH.</li></ul></p><p id="p0008" num="0008">Methods of treating diseases involving overexpression or unregulation of Aurora-kinases in a mammal are herein disclosed, the methods comprising administering thereto a therapeutically effective amount of a compound having Formula I,
<chemistry id="chem0002" num="0002"><img id="ib0002" file="imgb0002.tif" wi="31" he="33" img-content="chem" img-format="tif"/></chemistry>
and therapeutically acceptable salts, prodrugs and salts of prodrugs thereof, wherein
<ul><li>X is S, O or NG<sup>1</sup>;</li><li>G<sup>1</sup> is H or is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R<sup>6</sup>, OR<sup>6</sup>, NH<sub>2</sub>, NHR<sup>6</sup>, N(R<sup>6</sup>)<sub>2</sub>, OH or (O);</li><li>at least one of A<sup>1</sup>, B<sup>1</sup>, C<sup>1</sup>, and D<sup>1</sup> is R<sup>1</sup>, C(O)NHR<sup>1</sup>, C(O)N(R<sup>1</sup>)<sub>2</sub>, NHC(O)R<sup>1</sup>, NR<sup>1</sup>C(O)R<sup>1</sup>, NHC(O)NHR<sup>1</sup>, NHC(O)N(R<sup>1</sup>)<sub>2</sub>, NR<sup>1</sup>C(O)NHR<sup>1</sup>, NR<sup>1</sup>C(O)N(R<sup>1</sup>)<sub>2</sub>, SO<sub>2</sub>NHR<sup>1</sup>, SO<sub>2</sub>N(R<sup>1</sup>)<sub>2</sub>, NHSO<sub>2</sub>R<sup>1</sup>, NR<sup>1</sup>SO<sub>2</sub>R<sup>1</sup>, OC(O)OR<sup>1</sup>, NHC(O)OR<sup>1</sup>, NR<sup>1</sup>C(O)OR<sup>1</sup>, OR<sup>1</sup> or SR<sup>1</sup>; and the remainder are independently selected H, F, Br, Cl or I;</li><li>R<sup>1</sup> is R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup> or R<sup>5</sup>;<!-- EPO <DP n="7"> --></li><li>R<sup>2</sup> is phenyl which is unfused or fused with benzene, heteroarene or R<sup>2A</sup>; R<sup>2A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>3</sup> is heteroaryl which is unfused or fused with benzene, heteroarene or R<sup>3A</sup>; R<sup>3A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>4</sup> is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R<sup>4A</sup>; R<sup>4A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>5</sup> is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R<sup>6</sup>, OR<sup>6</sup>, SR<sup>6</sup>, S(O)R<sup>6</sup>, SO<sub>2</sub>R<sup>6</sup>, CO(O)R<sup>6</sup>, OC(O)R<sup>6</sup>, OC(O)OR<sup>6</sup>, NH<sub>2</sub>, NHR<sup>6</sup>, N(R<sup>6</sup>)<sub>2</sub>, NHC(O)R<sup>6</sup>, NR<sup>6</sup>C(O)R<sup>6</sup>, NHS(O)<sub>2</sub>R<sup>6</sup>, NR<sup>6</sup>S(O)<sub>2</sub>R<sup>6</sup>, NHC(O)OR<sup>6</sup>, NR<sup>6</sup>C(O)OR<sup>6</sup>, NHC(O)NH<sub>2</sub>, NHC(O)NHR<sup>6</sup>, NHC(O)N(R<sup>6</sup>)<sub>2</sub>, NR<sup>6</sup>C(O)NHR<sup>6</sup>, NR<sup>6</sup>C(O)N(R<sup>6</sup>)<sub>2</sub>, C(O)NH<sub>2</sub>, C(O)NHR<sup>6</sup>, C(O)N(R<sup>6</sup>)<sub>2</sub>, C(O)NHOH, C(O)NHOR<sup>6</sup>, C(O)NHSO<sub>2</sub>R<sup>6</sup>, C(O)NR<sup>6</sup>SO<sub>2</sub>R<sup>6</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>6</sup>, SO<sub>2</sub>N(R<sup>6</sup>)<sub>2</sub>, C(O)OH, C(N)NH<sub>2</sub>, C(N)NHR<sup>6</sup>, C(N)N(R<sup>6</sup>)<sub>2</sub>, CNOH, CNOCH<sub>3</sub>, OH, (O), CN, N<sub>3</sub>, NO<sub>2</sub>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, OCF<sub>3</sub>, OCF<sub>2</sub>CF<sub>3</sub>, F, Cl, Br or I;</li><li>R<sup>6</sup> is R<sup>7</sup>, R<sup>8</sup>, R<sup>9</sup> or R<sup>9B</sup>;</li><li>R<sup>7</sup> is phenyl which is unfused or fused with benzene, heteroarene or R<sup>7A</sup>; R<sup>7A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>8</sup> is heteroaryl which is unfused or fused with benzene, heteroarene or R<sup>8A</sup>; R<sup>8A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>9</sup> is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R<sup>9A</sup>; R<sup>9A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>9B</sup> is alkyl, alkenyl or alkynyl;<!-- EPO <DP n="8"> --></li><li>wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected R<sup>10</sup>, OR<sup>10</sup>, SR<sup>10</sup>, S(O)R<sup>10</sup>, SO<sub>2</sub>R<sup>10</sup>, C(O)R<sup>10</sup>, CO(O)R<sup>10</sup>, OC(O)R<sup>10</sup>, OC(O)OR<sup>10</sup>, NH<sub>2</sub>, NHR<sup>10</sup>, N(R<sup>10</sup>)<sub>2</sub>, NHC(O)R<sup>10</sup>, NR<sup>10</sup>C(O)R<sup>10</sup>, NHS(O)<sub>2</sub>R<sup>10</sup>, NR<sup>10</sup>S(O)<sub>2</sub>R<sup>10</sup>, NHC(O)OR<sup>10</sup>, NR<sup>10</sup>C(O)OR<sup>10</sup>, NHC(O)NH<sub>2</sub>, NHC(O)NHR<sup>10</sup>, NHC(O)N(R<sup>10</sup>)<sub>2</sub>, NR<sup>10</sup>C(O)NHR<sup>10</sup>, NR<sup>10</sup>C(O)N(R<sup>10</sup>)<sub>2</sub>, C(O)NH<sub>2</sub>, C(O)NHR<sup>10</sup>, C(O)N(R<sup>10</sup>)<sub>2</sub>, C(O)NHOH, C(O)NHOR<sup>10</sup>, C(O)NHSO<sub>2</sub>R<sup>10</sup>, C(O)NR<sup>10</sup>SO<sub>2</sub>R<sup>10</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>10</sup>, SO<sub>2</sub>N(R<sup>10</sup>)<sub>2</sub>, C(O)H, C(O)OH, C(N)NH<sub>2</sub>, C(N)NHR<sup>10</sup>, C(N)N(R<sup>10</sup>)<sub>2</sub>, CNOH, CNOCH<sub>3</sub>, OH, (O), CN, N<sub>3</sub>, NO<sub>2</sub>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, OCF<sub>3</sub>, OCF<sub>2</sub>CF<sub>3</sub>, F, Cl, Br or I;</li><li>R<sup>10</sup> is R<sup>11</sup>,R<sup>12</sup>,R<sup>13</sup> or R<sup>14</sup>;</li><li>R<sup>11</sup> is phenyl which is unfused or fused with benzene, heteroarene or R<sup>11A</sup>; R<sup>11A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>12</sup> is heteroaryl which is unfused or fused with benzene, heteroarene or R<sup>12A</sup>; R<sup>12A</sup> is cycloalkane, cycloalkene, heterocycloalkane or hetaocycloalkene;</li><li>R<sup>13</sup> is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R<sup>13A</sup>; R<sup>13A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>14</sup> is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with one, two, three, four or five of independently selected R<sup>15</sup>, OR<sup>15</sup>, SR<sup>15</sup>, S(O)R<sup>15</sup>, SO<sub>2</sub>R<sup>15</sup>, CO(O)R<sup>15</sup>, OC(O)R<sup>15</sup>, OC(O)OR<sup>15</sup>, NH<sub>2</sub>, NHR<sup>15</sup>, N(R<sup>15</sup>)<sub>2</sub>, NHC(O)R<sup>15</sup>, NR<sup>15</sup>C(O)R<sup>15</sup>, NHS(O)<sub>2</sub>R<sup>15</sup>, NR<sup>15</sup>S(O)<sub>2</sub>R<sup>15</sup>, NHC(O)OR<sup>15</sup>, NR<sup>15</sup>C(O)R<sup>15</sup>, NHC(O)NH<sub>2</sub>, NHC(O)NHR<sup>15</sup>, NHC(O)N(R<sup>15</sup>)<sub>2</sub>, NR<sup>15</sup>C(O)NHR<sup>15</sup>, NR<sup>15</sup>C(O)N(R<sup>15</sup>)<sub>2</sub>, C(O)NH<sub>2</sub>, C(O)NHR<sup>15</sup>, C(O)N(R<sup>15</sup>)<sub>2</sub>, C(O)NHOH, C(O)NHOR<sup>15</sup>, C(O)NHSO<sub>2</sub>R<sup>15</sup>, C(O)NR<sup>15</sup>SO<sub>2</sub>R<sup>15</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>15</sup>, SO<sub>2</sub>N(R<sup>15</sup>)<sub>2</sub>, C(O)OH, C(N)NH<sub>2</sub>, C(N)NHR<sup>15</sup>, C(N)N(R<sup>15</sup>)<sub>2</sub>, CNOH, CNOCH<sub>3</sub>, OH, (O), CN, N<sub>3</sub>, NO<sub>2</sub>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, OCF<sub>3</sub>, OCF<sub>2</sub>CF<sub>3</sub>, F, Cl, Br or I;</li><li>R<sup>15</sup> is R<sup>16</sup> R<sup>17</sup>, R<sup>18</sup> or R<sup>19</sup>;<!-- EPO <DP n="9"> --></li><li>R<sup>16</sup> is phenyl which is unfused or fused with benzene, heteroarene or R<sup>16A</sup>; R<sup>16A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>17</sup> is heteroaryl which is unfused or fused with benzene, heteroarene or R<sup>17A</sup>; R<sup>17A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>18</sup> is cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl, each of which is unfused or fused with benzene, heteroarene or R<sup>18A</sup>; R<sup>18A</sup> is cycloalkane, cycloalkene, heterocycloalkane or heterocycloalkene;</li><li>R<sup>19</sup> is alkyl, alkenyl or alkenyl, each of which is unsubstituted or substituted with R<sup>20</sup>;</li><li>R<sup>20</sup> is phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heterocycloalkyl or heterocycloalkenyl;</li><li>wherein the moieties represented by R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>,R<sup>16</sup> , R<sup>17</sup>, R<sup>18</sup> and R<sup>20</sup> are independently unsubstituted or substituted with one or two or three of independently selected R<sup>21</sup>, OR<sup>21</sup>, SR<sup>21</sup>, S(O)R<sup>21</sup>, SO<sub>2</sub>R<sup>21</sup>, C(O)R<sup>21</sup>, CO(O)R<sup>21</sup>, OC(O)R<sup>21</sup>, OC(O)OR<sup>21</sup>, NH<sub>2</sub>, NHR<sup>21</sup>, N(R<sup>21</sup>)<sub>2</sub>, NHC(O)R<sup>21</sup>, NR<sup>21</sup>C(O)R<sup>21</sup>, NHS(O)<sub>2</sub>R<sup>21</sup>, NR<sup>21</sup>S(O)<sub>2</sub>R<sup>21</sup>, NHC(O)OR<sup>21</sup>, NR<sup>21</sup>C(O)OR<sup>21</sup>, NHC(O)NH<sub>2</sub>, NHC(O)NHR<sup>21</sup>, NHC(O)N(R<sup>21</sup>)<sub>2</sub>, NR<sup>21</sup>C(O)NHR<sup>21</sup>, NR<sup>21</sup>C(O)N(R<sup>21</sup>)<sub>2</sub>, C(O)NH<sub>2</sub>, C(O)NHR<sup>21</sup>, C(O)N(R<sup>21</sup>)<sub>2</sub>, C(O)NHOH, C(O)NHOR<sup>21</sup>, C(O)NHSO<sub>2</sub>R<sup>21</sup>, C(O)NR<sup>21</sup>SO<sub>2</sub>R<sup>21</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>21</sup>, SO<sub>2</sub>N(R<sup>21</sup>)<sub>2</sub>, C(O)H, C(O)OH, C(N)NH<sub>2</sub>, C(N)NHR<sup>21</sup>, C(N)N(R<sup>21</sup>)<sub>2</sub>, CNOH, CNOCH<sub>3</sub>, OH, (O), CN, N<sub>3</sub>, NO<sub>2</sub>, CF<sub>3</sub>, CF<sub>2</sub>CF<sub>3</sub>, OCF<sub>3</sub>, OCF<sub>2</sub>CF<sub>3</sub>, F, Cl, Br or I;</li><li>R<sup>21</sup> is alkyl, alkenyl or alkynyl, each of which is unsubstituted or substituted with one or two or three of independently selected R<sup>22</sup>, F, Cl, Br, I, OH, C(O)OH, NO<sub>2</sub> or NH<sub>2</sub>; and</li><li>R<sup>22</sup> is is phenyl, heteroaryl, cycloalkyl, cycloalkenyl or heterocycloalkyl,</li></ul>
with or without also administering radiotherapy thereto.<!-- EPO <DP n="10"> --></p><p id="p0009" num="0009">Methods of treating bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer and thyroid cancer in a mammal are also disclosed herein, the methods comprising administering thereto a therapeutically effective amount of a compound having Formula I, with or without also administering radiotherapy thereto.</p><p id="p0010" num="0010">Compositions comprising an excipient and a therapeutically effective amount of a compound having Formula I and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent, are also disclosed herein.</p><p id="p0011" num="0011">Methods of treating diseases involving overespression or unregulation of Aurora-kinases in a mammal are also disclosed herein, the methods comprising administering thereto a therapeutically effective amount of a compound having Formula I and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent with or without also administering radiotherapy thereto.</p><p id="p0012" num="0012">Methods of treating bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer and thyroid cancer in a mammal are also disclosed herein, the methods comprising administering thereto a therapeutically effective amount of a compound having Formula I and a therapeutically effective amount of one additional therapeutic agent or more than one additional therapeutic agent, with or without also administering radiotherapy thereto.</p><p id="p0013" num="0013">Still another embodiment pertains to compounds
<ul><li>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3 -amino-N-(3-(((((2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,<!-- EPO <DP n="11"> --></li><li>3-amino-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-methytphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-methoxyphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-methoxyphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3,5-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-((((cyclopentylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxam ide,</li><li>3-amino-N-(3-((((cyclohexylaminoxarbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-((((thien-2-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-((((thien-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3,5-dimethylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((2-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,<!-- EPO <DP n="12"> --></li><li>3-amino-N-(3-(((3-methylbenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-((benzoylamino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((phenylacetyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-(((thien-3-ylamino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((4-methylphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-methylphenyl)amino)carbonyl)atnino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((2,4-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3,5-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3,4-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-(benzoylamino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide,<!-- EPO <DP n="13"> --></li><li>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide,</li><li>3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-(2-hydroxyethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide,</li><li>3-amino-N-(4-((((3,4-dichlorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-methoxyphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((4-bromophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((4-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((4-chlorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((4-methoxyphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-(((benzylamino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-cyanophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-(methylthio)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((4-(methylthio)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-chloro-4-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,<!-- EPO <DP n="14"> --></li><li>3-amino-N-(3-(((((3-chlorophenyl)aminocarbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-(trifluoromethoxy)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carhoxamide,</li><li>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(1-((((3-fuorophenyl)amino)carbonyl)amino)ethyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(4-((anilinocarbonyl)amino)benzyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-fluoro-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,<!-- EPO <DP n="15"> --></li><li>3-amino-N-(3-(((((2-fluoro-5-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3,5-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-fluoro-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((-3-bromophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</li><li>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-7-(2-morpholin-4-ylethoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-7-methoxy-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-7-(3-hydroxypropoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="16"> --></li><li>3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-((((pyridin-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-7-methoxy-N-(3-((((pyridin-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chlorophenyl)aminocarbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-7-(2-(4-methylpiperazin-1-yl)ethoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,;</li><li>3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((2,4-dinuorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-7-methoxy-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((2,5-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-(difluoromethoxy)phenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-(((((-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-((((3-fluomphenyl)amino)carbonyl)amino)-3-methylphenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="17"> --></li><li>3-amino-N-(4-((((2-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-((((2-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-methy)-4-((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-7-methoxy-N-(3-methyl-4-((((4-{trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-fluoro-3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-(difluoromethoxy)phenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-fluoro-3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)-4-ftuorophenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-fluoro-3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-fluoro-3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(4-fluoro-3-(((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((2,5-difluorophenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((4-fluorobenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="18"> --></li><li>3-amino-N-(3-(((3-fluorobenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)-4-methylphenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(aminomethyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</li><li>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((3-fluoro-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((3-chloro-4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</li><li>3-amino-1-methyl-N-(3-(((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</li><li>3-amino-1-methyl-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((2-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</li><li>3-amino-N-(3-(((((4-isopropylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</li></ul>
and therapeutically acceptable salts, prodrugs, esters, amides, salts of prodrugs, salts of esters, and salts of amides thereof.</p><heading id="h0004">DETAILED DESCRIPTION OF THE INVENTION</heading><!-- EPO <DP n="19"> --><p id="p0014" num="0014">Variable moieties of compounds herein are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.</p><p id="p0015" num="0015">It is meant to be understood that proper valences are maintained for all moieties and combinations thereof, that monovalent moieties having more than one atom are attached through their left ends.</p><p id="p0016" num="0016">It is also meant to be understood that a specific embodiment of a variable moiety may be the same or different as another specific embodiment having the same identifier.</p><p id="p0017" num="0017">The term "cyclic moiety," as used herein, means benzene, cycloalkane, cycloalkyl, cycloalkene, cycloalkenyl, heteroarene, heteroaryl, heterocycloalkane, heterocycloalkyl, heterocycloalkene, heterocycloalkenyl and phenyl.</p><p id="p0018" num="0018">The term "cycloalkane," as used herein, means C<sub>3</sub>-cycloalkane, C<sub>4</sub>-cycloalkane, C<sub>5</sub>-cycloalkane and C<sub>6</sub>-cycloalkane.</p><p id="p0019" num="0019">The term "cycloalkyl," as used herein, means C<sub>3</sub>-cycloalkyl, C<sub>4</sub>-cycloalkyl, C<sub>5</sub>-cycloalkyl and C<sub>6</sub>-cycloalkyl.</p><p id="p0020" num="0020">The term "cycloalkene," as used herein, means C<sub>4</sub>-cycloalkene, C<sub>5</sub>-cycloalkene and C<sub>6</sub>-cycloalkene.</p><p id="p0021" num="0021">The term "cycloalkenyl," as used herein, means C<sub>4</sub>-cycloalkenyl, C<sub>5</sub>-cycloalkenyl and C<sub>6</sub>-cycloalkenyl.</p><p id="p0022" num="0022">The term "heteroarene," as used herein, means furan, imidazole, isothiazole, isoxazole, 1,2,3-oxadiazole, 1,2,5-oxadiazole, oxazole, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, thiazole, thiophene, triazine and 1,2,3-triazole.</p><p id="p0023" num="0023">The term "heteroaryl," as used herein, means furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thiophenyl, triazinyl and 1,2,3-triazolyl.<!-- EPO <DP n="20"> --></p><p id="p0024" num="0024">The term "heterocycloalkane," as used herein, means cycloalkane having one or two or three CH<sub>2</sub> moieties replaced with independently selected O, S, S(O), SO<sub>2</sub> or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkane having one or two or three CH<sub>2</sub> moieties unreplaced or replaced with independently selected O, S, S(O), SO<sub>2</sub> or NH and one or two CH moieties replaced with N.</p><p id="p0025" num="0025">The term "heterocycloalkyl," as used herein, means cycloalkyl having one or two or three CH<sub>2</sub> moieties replaced with independently selected O, S, S(O), SO<sub>2</sub> or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkyl having one or two or three CH<sub>2</sub> moieties unreplaced or replaced with independently selected O, S, S(O), SO<sub>2</sub> or NH and one or two CH moieties replaced with N.</p><p id="p0026" num="0026">The term "heterocycloalkene," as used herein, means cycloalkene having one or two or three CH<sub>2</sub> moieties replaced with independently selected O, S, S(O), SO<sub>2</sub> or NH and one or<!-- EPO <DP n="21"> --> two CH moieties unreplaced or replaced with N and also means cycloalkene having one or two or three CH<sub>2</sub> moieties unreplaced or replaced with independently selected O, S, S(O), SO<sub>2</sub> or NH and one or two CH moieties replaced with N.</p><p id="p0027" num="0027">The term "heterocycloalkenyl," as used herein, means cycloalkenyl having one or two or three CH<sub>2</sub> moieties replaced with independently selected O, S, S(O), SO<sub>2</sub> or NH and one or two CH moieties unreplaced or replaced with N and also means cycloalkenyl having one or two or three CH<sub>2</sub> moieties unreplaced or replaced with independently selected O, S, S(O), SO<sub>2</sub> or NH and one or two CH moieties replaced with N.</p><p id="p0028" num="0028">The term "alkenyl," as used herein, means C<sub>2</sub>-alkenyl, C<sub>3</sub>-alkenyl, C<sub>4</sub>-alkenyl, C<sub>5</sub>-alkenyl and C<sub>6</sub>-alkenyl.</p><p id="p0029" num="0029">The term "alkyl," as used herein, means C<sub>1</sub>-alkyl, C<sub>2</sub>-alkyl, C<sub>3</sub>-alkyl, C<sub>4</sub>-alkyl, C<sub>5</sub>-alkyl and C<sub>6</sub>-alkyl.</p><p id="p0030" num="0030">The term "alkynyl," as used herein, means C<sub>2</sub>-alkynyl, C<sub>3</sub>-alkynyl, C<sub>4</sub>-alkynyl, C<sub>5</sub>-alkynyl and C<sub>6</sub>-alkynyl.</p><p id="p0031" num="0031">Compounds of this invention may contain asymmetrically substituted carbon atoms in the R or S configuration, wherein the terms "R" and "S" are as defined in <nplcit id="ncit0001" npl-type="s"><text>Pure Appl. Chem. (1976) 45, 13-10</text></nplcit>. Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic at those atoms. Atoms having excess of one configuration over the other are assigned the configuration in excess, preferably an excess of about 85%-90%, more preferably an excess of about 95%-99%, and still more preferably an excess greater than about 99%. Accordingly, this invention is meant to embrace racemic mixtures and relative and absolute diastereoisomers of the compounds thereof.</p><p id="p0032" num="0032">Compounds of this invention may also contain carbon-carbon double bonds or carbon-nitrogen double bonds in the Z or E configuration, in which the term "Z" represents the larger two substituents on the same side of a carbon-carbon or carbon-nitrogen double<!-- EPO <DP n="22"> --> bond and the term "E" represents the larger two substituents on opposite sides of a carbon-carbon or carbon-nitrogen double bond. The compounds of this invention may also exist as a mixture of "Z" and "E" isomers.</p><p id="p0033" num="0033">Compounds of this invention may also exist as tautomers or equilibrium mixtures thereof wherein a proton of a compound shifts from one atom to another. Examples of tautomers include, but are not limited to, keto-enol, phenol-keto, oxime-nitroso, nitro-aci, imine-enamine and the like.</p><p id="p0034" num="0034">Compounds of this invention containing NH, C(O)OH, OH or SH moieties may have attached thereto prodrug-forming moieties. The prodrug-forming moieties are removed by metabolic processes and release the compounds having the freed NH, C(O)OH, OH or SH in vivo. Prodrugs are useful for adjusting such pharmacokinetic properties of the compounds as solubility and/or hydrophobicity, absorption in the gastrointestinal tract, bioavailability, tissue penetration, and rate of clearance.</p><p id="p0035" num="0035">Metabolites of compounds having Formula I produced by in vitro or in vivo metabolic processes, may also have utility for treating diseases associated with overexpression or unregulation of protein kinases.</p><p id="p0036" num="0036">Certain precursor compounds which may be metabolized in vitro or in vivo to form compounds having Formula I may also have utility for treating diseases associated with overexpression or unregulation of protein kinases.</p><p id="p0037" num="0037">Compounds having Formula I may exist as acid addition salts, basic addition salts or zwitterions. Salts of compounds having Formula I are prepared during their isolation or following their purification. Acid addition salts are those derived from the reaction of a compound having Formula I with acid. Accordingly, salts including the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate (besylate), bisulfate, butyrate, camphorate, camphorsufonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate,<!-- EPO <DP n="23"> --> nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetic, trifluoroacetic, para-toluenesulfonate and undecanoate salts of the compounds having Formula I are meant to be embraced by this invention. Basic addition salts of compounds are those derived from the reaction of the compounds having Formula I with the bicarbonate, carbonate, hydroxide or phosphate of cations such as lithium, sodium, potassium, calcium and magnesium.</p><p id="p0038" num="0038">Compounds having Formula I may be administered, for example, bucally, ophthalmically, orally, osmotically, parenterally (intramuscularly, intraperintoneally intrasternally, intravenously, subcutaneously), rectally, topically, transdermally, vaginally and intraarterially as well as by intraarticular injection, infusion, and placement in the body, such as, for example, the vasculature.</p><p id="p0039" num="0039">Therapeutically effective amounts of a compound having Formula I depend on recipient of treatment, disease treated and severity thereof, composition comprising it, time of administration, route of administration, duration of treatment, potency, rate of clearance and whether or not another drug is co-administered. The amount of a compound having Formula I used to make a composition to be administered daily to a patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg body weight. Single dose compositions contain these amounts or a combination of submultiples thereof.</p><p id="p0040" num="0040">Compounds having Formula I may be administered with or without an excipient. Excipients include, but are not limited to, encapsulators and additives such as absorption accelerators, antioxidants, binders, buffers, coating agents, coloring agents, diluents, disintegrating agents, emulsifiers, extenders, fillers, flavoring agents, humectants, lubricants, perfumes, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, solubilizers, wetting agents, mixtures thereof and the like.</p><p id="p0041" num="0041">Excipients for preparation of compositions comprising a compound having Formula I to be administered orally include, but are not limited to, agar, alginic acid, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butylene glycol, carbomers, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, cross-povidone,<!-- EPO <DP n="24"> --> diglycerides, ethanol, ethyl cellulose, ethyl laureate, ethyl oleate, fatty acid esters, gelatin, germ oil, glucose, glycerol, groundnut oil, hydroxypropylmethyl celluose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salts, potato starch, povidone, propylene glycol, Ringer's solution, safflower oil, sesame oil, sodium carboxymethyl cellulose, sodium phosphate salts, sodium lauryl sulfate, sodium sorbitol, soybean oil, stearic acids, stearyl fumarate, sucrose, surfactants, talc, tragacanth, tetrahydrofurfuryl alcohol, triglycerides, water, mixtures thereof and the like. Excipients for preparation of compositions comprising a compound having Formula I to be administered ophthalmically or orally include, but are not limited to, 1,3-butylene glycol, castor oil, corn oil, cottonseed oil, ethanol, fatty acid esters of sorbitan, germ oil, groundnut oil, glycerol, isopropanol, olive oil, polyethylene glycols, propylene glycol, sesame oil, water, mixtures thereof and the like. Excipients for preparation of compositions comprising a compound having Formula I to be administered osmotically include, but are not limited to, chlorofluorohydrocarbons, ethanol, water, mixtures thereof and the like. Excipients for preparation of compositions comprising a compound having Formula I to be administered parenterally include, but are not limited to, 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, germ oil, groundnut oil, liposomes, oleic acid, olive oil, peanut oil, Ringer's solution, safflower oil, sesame oil, soybean oil, U.S.P. or isotonic sodium chloride solution, water, mixtures thereof and the like. Excipients for preparation of compositions comprising a compound having Formula I to be administered rectally or vaginally include, but are not limited to, cocoa butter, polyethylene glycol, wax, mixtures thereof and the like.</p><p id="p0042" num="0042">Compounds having Formula I are also expected to be useful as chemotherapeutic agents in combination with actinomycins, alkylating agents, anthracyclines, antifolates, antiestrogen agents, anti-metabolites, anti-androgens, antimicrotubule agents, aromatase inhibitors, bleomycins, Ca<sup>2+</sup> adenosine triphosphate (ATP)ase inhibitors, cytosine analogs, deltoids/retinoids, dihydrofolate reductase inhibitors, deoxyribonucleic acid (DNA) topoisomerase inhibitors, dopaminergic neurotoxins, glucocorticoids, histone deacetylase inhibitors, hormonal therapies, immunotherapeutic agents, inosine monophosphate (IMP) dehydrogenase inhibitors, isoprenylation inhibitors, luteinizing hormone-releasing hormone agonists, mammalian target of rapamycin (mtor) inhibitors, multi-drug resistance (MDR)<!-- EPO <DP n="25"> --> inhibitors, mitomycins, photodyamic therapies, proteasome inhibitors, platinum containing compounds, radiation, receptor tyrosine kinase inhibitors, ribonuclotide reductase inhibitors, thrombospondin mimetics, uracil analogs, vinca alkaloids, and vitamin D3 analogs such as, but not limited to, γ-radiation or an additional chemotherapeutic agent or additional chemotherapeutic agents such as N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-Pro-NHCH<sub>2</sub>CH<sub>3</sub> or a salt thereof, actinomycin D, AG13736, 17-allylamino-17-demethoxygeldanamycin, 9-aminocamptothecin, N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea or a salt thereof, N-(4-(4-aminothieno(2,3-d)pyrimidin-5-yl)phenyl)-N'-(2-fluoro-5-(trifluoromethyl)phenyl)urea or a salt thereof, anastozole, AP-23573, asparaginase, azacitidine, bevacizumab, bicalutamide, bleomycin a2, bleomycin b2, bortezamib, busulfan, campathecins, carboplatin, carmustine (BCNU), CB1093, cetuximab, CHOP (C: Cytoxan® (cyclophosphamide); H: Adriamycin® (hydroxydoxorubicin); O: Vincristine (Oncovin®); P: prednisone), chlorambucil, CHIR258, cisplatin, CNF-101, CNF-1001, CNF-2024, CP547632, crisnatol, cytarabine, cyclophosphamide, cytosine arabinoside, daunorubicin, dacarbazine, dactinomycin, dasatinib, daunorubicin, deferoxamine, demethoxyhypocrellin A, depsipeptide, dexamethasone, 17-dimethylaminoethylamino-17-demethoxygeldanamycin, docetaxel, doxifluridine, doxorubicin, EB1089, epothilone D, epirubicin, 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR), erlotinib, etoposide, everolimus, 5-fluorouracil (5-FU), floxuridine, fludarabine, flutamide, gefitinib, geldanamycin, gemcitabine, goserelin, N-(2-(4-hydroxyanilino)-3-pyridinyl)-4-methoxybenzenesulfonamide or a salt thereof, hydroxyurea, idarubicin, ifosfamide, imatinab, interferon-α, interferon-γ, IPI-504, irinotecan, KH 1060, lapatanib, LAQ824, leuprolide acetate, letrozole, lomustine (CCNU), lovastatin, megestrol, melphalan, mercaptopurine, methotrexate, 1-methyl-4-phyenylpyridinium, MG132, mitomycin, mitoxantrone, MLN-518, MS-275, mycophenolic acid, mitomycin C, nitrosoureas, oxaliplatin, paclitaxel, PD98059, peplomycin, photosensitizer Pc4, phtalocyanine, pirarubicin, plicamycin, prednisone, procarbizine, PTK787, PU24FCl, PU3, radicicol, raloxifene, rapamycin, ratitrexed, retinoids such as pheuretinide, ribavirin, rituximab (Rituxin®), sorafenib, staurosporine, steroids such as dexamethasone and prednisone, suberoylanilide hydroxamic acid, sunitinib, tamoxifen, taxol, temozolamide, temsirolimus, teniposide, thapsigargin, thioguanine, thrombospondin-1, tiazofurin, topotecan, trapoxin, trastuzumab, treosulfan, trichostatin A, trimetrexate, trofosfamide, tumor necrosis<!-- EPO <DP n="26"> --> factor, valproic acid, VER49009, verapamil, vertoporfin, vinblastine, vincristine, vindesine, vinorelbine vitamin D3, VX-680, zactima, ZK-EPO, zorubicin or combinations thereof.</p><p id="p0043" num="0043">To determine activity of representative compounds of the invention, Active Aurora B enzyme (recombinant residues 1-344) and INCENP (recombinant GST fusion protein from Upstate) were incubated in wells of a 384 well plate with biotinylted histone H3 peptide residues 1-21 (Upstate), 1 mM ATP, and various concentrations of inhibitors in a Hepes buffer, pH 7.4 containing MgCl<sub>2</sub>, sodium othrovanadate, and Triton X-100. After I hour, the reaction was stopped with EDTA and anti-phospho-histone H3 Europium Cryptate (Cis-Bio) and SA-APC (Phycolink, Prozyme) were added to detect the phosphopeptide. The amount of phosphorylation was determined by the time-resolved fluorescence ratio of signals at 665 nm and 615 nm. The IC<sub>50</sub>'s were calculated by an exponential fit of the inhibition values with the inhibitor concentrations using Assay Explorer software.</p><p id="p0044" num="0044">The following table of data (nM) demonstrates the utility of compounds having Formula I as inhibitors of Aurora-kinase B.
<tables id="tabl0001" num="0001"><table frame="all"><tgroup cols="5"><colspec colnum="1" colname="col1" colwidth="14mm"/><colspec colnum="2" colname="col2" colwidth="14mm"/><colspec colnum="3" colname="col3" colwidth="14mm"/><colspec colnum="4" colname="col4" colwidth="16mm"/><colspec colnum="5" colname="col5" colwidth="16mm"/><tbody><row><entry align="center">2.2</entry><entry align="center">2.4</entry><entry align="center">2.6</entry><entry align="center">2.9</entry><entry align="center">3.0</entry></row><row><entry align="center">3.6</entry><entry align="center">3.8</entry><entry align="center">4.6</entry><entry align="center">6.4</entry><entry align="center">6.5</entry></row><row><entry align="center">6.7</entry><entry align="center">6.8</entry><entry align="center">7.4</entry><entry align="center">7.7</entry><entry align="center">8.1</entry></row><row><entry align="center">8.8</entry><entry align="center">9.0</entry><entry align="center">9.0</entry><entry align="center">10.4</entry><entry align="center">10.6</entry></row><row><entry align="center">10.9</entry><entry align="center">11.3</entry><entry align="center">12.1</entry><entry align="center">12.2</entry><entry align="center">12.2</entry></row><row><entry align="center">13.4</entry><entry align="center">14.6</entry><entry align="center">15.4</entry><entry align="center">15.7</entry><entry align="center">15.9</entry></row><row><entry align="center">16.2</entry><entry align="center">17.5</entry><entry align="center">17.9</entry><entry align="center">18.4</entry><entry align="center">18.5</entry></row><row><entry align="center">19.7</entry><entry align="center">21.0</entry><entry align="center">21.2</entry><entry align="center">21.5</entry><entry align="center">21.7</entry></row><row><entry align="center">24.0</entry><entry align="center">24.7</entry><entry align="center">27.6</entry><entry align="center">32.5</entry><entry align="center">33.6</entry></row><row><entry align="center">34.0</entry><entry align="center">38.3</entry><entry align="center">38.4</entry><entry align="center">39.0</entry><entry align="center">40.7</entry></row><row><entry align="center">40.9</entry><entry align="center">45.0</entry><entry align="center">47.1</entry><entry align="center">50.3</entry><entry align="center">51.1</entry></row><row><entry align="center">53.4</entry><entry align="center">55.1</entry><entry align="center">58.6</entry><entry align="center">60.2</entry><entry align="center">61.6</entry></row><row><entry align="center">65.3</entry><entry align="center">66.0</entry><entry align="center">70.4</entry><entry align="center">72.6</entry><entry align="center">72.7</entry></row><row><entry align="center">76.8</entry><entry align="center">80.0</entry><entry align="center">81.1</entry><entry align="center">82.4</entry><entry align="center">85.9</entry></row><row><entry align="center">86.6</entry><entry align="center">90.7</entry><entry align="center">95.4</entry><entry align="center">105.0</entry><entry align="center">111.0</entry></row><!-- EPO <DP n="27"> --><row><entry align="center">127.0</entry><entry align="center">129.0</entry><entry align="center">140.0</entry><entry align="center">143.0</entry><entry align="center">164.0</entry></row><row><entry align="center">173.0</entry><entry align="center">188.0</entry><entry align="center">194.0</entry><entry align="center">195.0</entry><entry align="center">197.0</entry></row><row><entry align="center">199.0</entry><entry align="center">205.0</entry><entry align="center">206.0</entry><entry align="center">211.0</entry><entry align="center">223.0</entry></row><row><entry align="center">237.0</entry><entry align="center">254.0</entry><entry align="center">288.0</entry><entry align="center">331.0</entry><entry align="center">353.0</entry></row><row><entry align="center">395.0</entry><entry align="center">397.0</entry><entry align="center">447.0</entry><entry align="center">450.0</entry><entry align="center">471.0</entry></row><row><entry align="center">481.0</entry><entry align="center">504.0</entry><entry align="center">525.0</entry><entry align="center">573.0</entry><entry align="center">636.0</entry></row><row><entry align="center">640.0</entry><entry align="center">693.0</entry><entry align="center">817.0</entry><entry align="center">843.0</entry><entry align="center">858.0</entry></row><row><entry align="center">887.0</entry><entry align="center">915.0</entry><entry align="center">939.0</entry><entry align="center">1080.0</entry><entry align="center">1250.0</entry></row><row><entry align="center">1740.0</entry><entry align="center">1830.0</entry><entry align="center">2500.0</entry><entry align="center">2570.0</entry><entry align="center">2590.0</entry></row><row><entry align="center">2700.0</entry><entry align="center">2800.0</entry><entry align="center">3440.0</entry><entry align="center">4890.0</entry><entry align="center">5560.0</entry></row><row><entry align="center">5650.0</entry><entry align="center">7670.0</entry><entry align="center">9800.0</entry><entry align="center">10900.0</entry><entry align="center">12100.0</entry></row></tbody></tgroup></table></tables></p><p id="p0045" num="0045">It is expected that, because compounds having Formula I inhibit the activity of Aurora-kinase B, they could also have utility as inhibitors of protein kinases having close structural homology thereto, such as, for example, Aurora-kinase A and Aurora-kinase C.</p><p id="p0046" num="0046">The structural homology between Protein Kinases A, B and C is reported in <nplcit id="ncit0002" npl-type="s"><text>Nature Reviews/Cancer, Vol. 4 December, 2004</text></nplcit>.</p><p id="p0047" num="0047">Accordingly, compounds having Formula I are expected to have utility in treatment of diseases during which protein kinases such as any or all Aurora-kinase family members are expressed.</p><p id="p0048" num="0048">Diseases involving overexpression or unregulation of Aurora-kinase family members include, but are not limited to, acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myleogeneous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and<!-- EPO <DP n="28"> --> metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor.</p><p id="p0049" num="0049">It is also expected that compounds having Formula I would inhibit the growth of cells derived from a cancer or neoplasm such as breast cancer (including estrogen-receptor positive breast cancer), colorectal cancer, endometrial cancer, lung cancer (including small cell lung cancer), lymphoma (including follicular or Diffuse Large B-cell), lymphoma (including non-Hodgkin's lymphoma), neuroblastoma, ovarian cancer, prostate cancer (including hormone-insensitive prostate cancer) and testicular cancer (including germ cell testicular cancer).</p><p id="p0050" num="0050">It is also expected that compounds having Formula I would inhibit the growth of cells derived from a pediatric cancer or neoplasm such as embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rhabdoid tumor<!-- EPO <DP n="29"> --> of the central nervous syatem, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer.</p><p id="p0051" num="0051">Involvement of Aurora Kinase in pancreatic carcinoma cells is reported in<nplcit id="ncit0003" npl-type="s"><text> Zhu, J., et al., AURKA amplification, chromosome instability, and centrosome abnormality in human pancreatic carcinoma cells. Cancer Genet. Cytogenet., 2005. 159(1): p. 10-17</text></nplcit>; and<br/>
<nplcit id="ncit0004" npl-type="s"><text>Li D, ZhuJ, Firozi PF, et al. Overexpression of oncogenic STK15/BTAK/aurora A kinase in human pancreatic cancer. Clin Cancer Res 2003; 9:991-7</text></nplcit>.</p><p id="p0052" num="0052">Involvement of Aurora Kinase in non-small cell lung carcinoma is reported in <nplcit id="ncit0005" npl-type="s"><text>Smith, S.L., et al., Overexpression of Aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability. Br. J. Cancer, 2005. 93(6): p. 719-729</text></nplcit>.</p><p id="p0053" num="0053">Involvement of Aurora Kinase in prostate cancer is reported in<nplcit id="ncit0006" npl-type="s"><text> Chieffi, P., et al., Aurora B expression directly correlates with prostate cancer malignancy. Prostate, 2006. 66(3): p. 326-33</text></nplcit>; and<br/>
<nplcit id="ncit0007" npl-type="s"><text>Chieffi P, Cozzolino L, KisslingerA, et al. Aurora B expression directly correlates with prostate cancer
malignancy and influence prostate cell proliferation. Prostate 2006; 66:326-33</text></nplcit>.</p><p id="p0054" num="0054">Involvement of Aurora Kinase in head and neck squamous cell carcinoma is reported in <nplcit id="ncit0008" npl-type="s"><text>Reiter, R., et al., Aurora kinase a messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res, 2006.12(17): p. 5136-41</text></nplcit>.<!-- EPO <DP n="30"> --></p><p id="p0055" num="0055">Involvement of Aurora Kinase in acute myeloid leukemia is reported in <nplcit id="ncit0009" npl-type="s"><text>Walsby E, Walsh V, Pepper C, Burnett A, Mills K. Haematologica. 2008 May; 93(5):662-9</text></nplcit>.</p><p id="p0056" num="0056">Involvement of Aurora Kinase in breast cancer is reported in <nplcit id="ncit0010" npl-type="s"><text>Tanaka T, Kimura M, Matsunaga K, Fukada D, Mori H, Okano Y. Centrosomal kinase AIKlis overexpressed in invasive ductal carcinoma of the breast. Cancer Res 1999; 59:2041-4</text></nplcit>;<br/>
<nplcit id="ncit0011" npl-type="s"><text>Miyoshi Y, Iwao K, Egawa C, Noguchi S. Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers. Int J Cancer 2001; 92:370-3</text></nplcit>;<br/>
<nplcit id="ncit0012" npl-type="s"><text>Hoque A, Carter J, Xia W, et al. Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast Cancer Epidemiol Biomarkers Prev 2003; 12:1518-22</text></nplcit>;<br/>
<nplcit id="ncit0013" npl-type="s"><text>Royce ME, Xia W, Sahin AA, et al. STK15/aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis. Cancer 2004; 100: 12-9</text></nplcit>;<br/>
<nplcit id="ncit0014" npl-type="s"><text>Bodvarsdottir SK, Hilmarsdottir H, Birgisdottir V, Steinarsdottir M, Jonasson JG, Eyfjord JE. Aurora-A amplification associated with BRCA2 mutation in breast tumours. Cancer Lett 2007;248:96-102</text></nplcit>;<br/>
<nplcit id="ncit0015" npl-type="s"><text>Sen S, Zhou H, White RA. A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines. Oncogene 1997;14:2195-200</text></nplcit>;<br/>
<nplcit id="ncit0016" npl-type="s"><text>Lo YL,Yu JC, Chen ST, et al. Breast cancer risk associated with genotypic polymorphism of the mitosisregulating gene aurora-A/STK15/BTAK. Int J Cancer 2005; 115:276-83</text></nplcit>;<br/>
<nplcit id="ncit0017" npl-type="s"><text>Vidarsdottir L, Bodvarsdottir SK, Hilmarsdottir H, Tryggvadottir L, Eyfjord JE. Breast cancer risk associated with AURKA 91T A polymorphismin relation to BRCA mutations. Cancer Lett 2007; 250:206-12</text></nplcit>;<br/>
<nplcit id="ncit0018" npl-type="s"><text>Cox DG, Hankinson SE, Hunter DJ. Polymorphisms of theAURKA (STK15/aurora kinase) gene and breast cancer risk (United States). Cancer Causes Control 2006; 17:81-3</text></nplcit>; and<br/>
<nplcit id="ncit0019" npl-type="s"><text>Tchatchou S, Wirtenberger M, Hemminki K, et al. Aurora kinases A and B and familial breast cancer risk. Cancer Lett 2007;247:266-72</text></nplcit>.</p><p id="p0057" num="0057">Involvement of Aurora Kinase in lung cancer is reported in <nplcit id="ncit0020" npl-type="s"><text>Smith SL, Bowers NL, Betticher DC, et al. Overexpression of aurora B kinase (AURKB) in primary nonsmall cell lung<!-- EPO <DP n="31"> --> carcinoma is frequent, generally driven fromone allele, and correlates with the level of genetic instability. BrJ Cancer 2005; 93:719-29</text></nplcit>;<br/>
<nplcit id="ncit0021" npl-type="s"><text>Xu HT, Ma L, Qi FJ, et al. Expression of serine threonine kinase 15 is associated with poor differentiation in lung squamous cell carcinoma and adenocarcinoma. Pathol Int 2006; 56:375-80</text></nplcit>;<br/>
<nplcit id="ncit0022" npl-type="s"><text>Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G. Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther 2006;5:2905-13</text></nplcit>; and<br/>
<nplcit id="ncit0023" npl-type="s"><text>Gu J,Gong Y,Huang M, Lu C, Spitz MR,Wu X.Polymorphisms of STK15 (aurora-A) gene and lung cancer risk in Caucasians. Carcinogenesis 2007; 28:350-5</text></nplcit>.</p><p id="p0058" num="0058">Involvement of Aurora Kinase in bladder cancer is reported in <nplcit id="ncit0024" npl-type="s"><text>Comperat E, Camparo P, Haus R, et al. Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms. Virchows Arch 2007;450:419-24</text></nplcit>;<br/>
<nplcit id="ncit0025" npl-type="s"><text>Fraizer GC, Diaz MF, Lee IL, Grossman HB, Sen S. Aurora-A/STK151BTAK enhances chromosomal instability in bladder cancer cells. Int J Oncol 2004; 25:1631-9</text></nplcit>; and<br/>
<nplcit id="ncit0026" npl-type="s"><text>Sen S, ZhouH, Zhang RD, et al. Amplification/overexpression of a mitotic kinase gene in human bladder
cancer. J Natl Cancer Inst 2002; 94:1320-9</text></nplcit>.</p><p id="p0059" num="0059">Involvement of Aurora Kinase in esophageal cancer is reported in <nplcit id="ncit0027" npl-type="s"><text>Tong T, Zhong Y, Kong J, et al. Overexpression of aurora-A contributes to malignant development of human esophageal squamous cell carcinoma. Clin Cancer Res 2004;10:7304-10</text></nplcit>;<br/>
<nplcit id="ncit0028" npl-type="s"><text>Yang SB, Zhou XB, Zhu HX, et al. Amplification and overexpression of aurora-A in esophageal squamous cell carcinoma. Oncol Rep 2007; 17:1083-8</text></nplcit>; and<br/>
<nplcit id="ncit0029" npl-type="s"><text>Kimura MT, Mori T, Conroy J, et al. Two functional coding single nucleotide polymorphisms in STK15 (aurora-A) coordinately increase esophageal cancer risk. Cancer Res 2005; 65:3548-54</text></nplcit>.<!-- EPO <DP n="32"> --></p><p id="p0060" num="0060">Involvement of Aurora Kinase in brain cancer is reported in<nplcit id="ncit0030" npl-type="s"><text> Araki K, Nozaki K, Ueba T,Tatsuka M, Hashimoto N. High expression of aurora-B/aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas. J Neurooncol 2004;67:53-64</text></nplcit>;<br/>
<nplcit id="ncit0031" npl-type="s"><text>Zeng WF, Navaratne K, Prayson RA,Weil RJ. Aurora B expression correlates with aggressive behaviour
in glioblastoma multiforme. J Clin Pathol 2007; 60:218-21</text></nplcit>;<br/>
<nplcit id="ncit0032" npl-type="s"><text>ReichardtW, Jung V, Brunner C, et al. The putative serine/threonine kinase gene STK15 on chromosome
20q13.2 is amplified in human gliomas. Oncol Rep 2003;10:1275-9</text></nplcit>;<br/>
<nplcit id="ncit0033" npl-type="s"><text>Klein A, Reichardt W, Jung V, Zang KD, Meese E, Urbschat S. Overexpression and amplification of STK15 inhuman gliomas. Int J Oncol 2004; 25:1789-94</text></nplcit>; and<br/>
<nplcit id="ncit0034" npl-type="s"><text>Neben K, KorshunovA, Benner A, et al.Microarraybased screening formolecularmarkers nmedulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 2004; 64:3103-11</text></nplcit>.</p><p id="p0061" num="0061">Involvement of Aurora Kinase in liver cancer is reported in <nplcit id="ncit0035" npl-type="s"><text>Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10:2065-71</text></nplcit>.</p><p id="p0062" num="0062">Involvement of Aurora Kinase in head and neck cancer is reported in <nplcit id="ncit0036" npl-type="s"><text>Zhao X, Li FC, Li YH, et al. [Mutation of p53 and overexpression of STK15 in laryngeal squamous-cell carcinoma]. Zhonghua Zhong Liu Za Zhi 2005; 27:134-7</text></nplcit>;<br/>
<nplcit id="ncit0037" npl-type="s"><text>Li FC, Li YH, Zhao X, et al. [Deletion of p15 and p16 genes and overexpression of STK15 gene in human laryngeal squamous cell carcinoma]. Zhonghua Yi Xue Za Zhi 2003; 83:316-9</text></nplcit>;<br/>
<nplcit id="ncit0038" npl-type="s"><text>Reiter R, Gais P, Jutting U, et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12:5136-41</text></nplcit>;<br/>
<nplcit id="ncit0039" npl-type="s"><text>Qi G, Ogawa I, KudoY, et al. Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch 2007; 450:297-302</text></nplcit>; and<br/>
<nplcit id="ncit0040" npl-type="s"><text>Tatsuka M, Sato S, Kitajima S, et al.Overexpression of aurora-A potentiates HRAS-mediated oncogenic<!-- EPO <DP n="33"> --> transformation and is implicated in oral carcinogenesis. Oncogene 2005; 4:1122-7</text></nplcit>.</p><p id="p0063" num="0063">Involvement of Aurora Kinase in thyroid cancer is reported in<nplcit id="ncit0041" npl-type="s"><text> Sorrentino R, Libertini S, Pallante PL, et al. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J Clin Endocrinol Metab 2005; 90:928-35</text></nplcit>.</p><p id="p0064" num="0064">Involvement of Aurora Kinase in ovarian cancer is reported in <nplcit id="ncit0042" npl-type="s"><text>Lassmann S, ShenY, Jutting U, et al. Predictive value of aurora-A/STK15 expression for late stage epithelial ovarian cancer patients treated by adjuvant chemotherapy. Clin Cancer Res 2007; 13:4083-91</text></nplcit>; and<br/>
<nplcit id="ncit0043" npl-type="s"><text>Landen CN, Jr., LinYG, Immaneni A, et al. Overexpression of the centrosomal protein aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 2007; 13:4098-104</text></nplcit>.</p><p id="p0065" num="0065">Involvement of Aurora Kinase in renal cancer is reported in <nplcit id="ncit0044" npl-type="s"><text>KurahashiT, Miyake H, Hara I, Fujisawa M. Significance of aurora-A expression in renal cell carcinoma. Urol Oncol 2007; 25:128-33</text></nplcit>.</p><p id="p0066" num="0066">Involvement of Aurora Kinase in endometrium cancer is reported in <nplcit id="ncit0045" npl-type="s"><text>Moreno-Bueno G, Sanchez-Estevez C, Cassia R, et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma:STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 2003; 63:5697-702</text></nplcit>.</p><p id="p0067" num="0067">Involvement of Aurora Kinase in gastric cancer is reported in <nplcit id="ncit0046" npl-type="s"><text>Ju H, Cho H, Kim YS, et al. Functional polymorphism 57Val&gt;Ile of aurora kinaseA associated with increased risk of gastric cancer progression. Cancer Lett 2006; 242:273-9</text></nplcit>.</p><p id="p0068" num="0068">Involvement of Aurora Kinase in colon cancer is reported in <nplcit id="ncit0047" npl-type="s"><text>Nishida N, Nagasaka T, Kashiwagi K, Boland CR, Goel A. High copy amplification of the Aurora-A gene is associated with chromosomal instability phenotype in human colorectal cancers. Cancer Biol Ther 2007; 6:525-33</text></nplcit>;<br/>
<!-- EPO <DP n="34"> --><nplcit id="ncit0048" npl-type="s"><text>Bischoff JR, Anderson L, ZhuY, et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17:3052-65</text></nplcit>; <nplcit id="ncit0049" npl-type="s"><text>Chen J, Sen S, Amos CI, et al. Association between aurora-A kinase polymorphisms and age of onset of
hereditary nonpolyposis colorectal cancer in a Caucasian population.Mol Carcinog 2007; 46:249-56</text></nplcit>;<br/>
HienonenT, Salovaara R, Mecklin JP, Jarvinen H, Karhu A, Aaltonen LA. Preferential amplification of<br/>
AURKA 91A (Ile31) in familial colorectal cancers. <nplcit id="ncit0050" npl-type="s"><text>Int JCancer 2006; 118:505-8</text></nplcit>; and<br/>
<nplcit id="ncit0051" npl-type="s"><text>Ewart-Toland A, Briassouli P, de Koning JP, et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat Genet 2003; 34:403-12</text></nplcit>.</p><p id="p0069" num="0069">Involvement of Aurora Kinase in cancer is reported in <nplcit id="ncit0052" npl-type="s"><text>Lin, Y.S., et al., Gene expression profiles of the aurora family kinases. Gene Expr, 2006.13(1): p. 15-26</text></nplcit>; and<br/>
<nplcit id="ncit0053" npl-type="s"><text>Ewart-Toland A, Dai Q, Gao YT, et al. Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis 2005; 26:1368-73</text></nplcit>.</p><p id="p0070" num="0070">Compounds having Formula I are expected to be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitotics, antiproliferatives, aurora kinase inhibitors, Bcl-2 family protein (for example, Bcl-xL, Bcl-2, Bcl-w, Bfl-1) inhibitors, Bcr-Abl kinase inhibitors, biologic response modifiers, cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2 inhibitors, leukemia viral oncogene homolog (ErbB2) receptor inhibitors, growth factor inhibitors, heat shock protein HSP-90 inhibitors, histone deacetylase (HDAC) inhibitors inhibitors, hormonal therapies, immunological, intercalating antibiotics, kinase inhibitors, mammalian target of rapomycin inhibitors, mitogen-activated extracellular signal-regulated kinase inhibitors, non-steroidal anti-inflammatory drugs (NSAID's), platinum chemotherapeutics, polo-like kinase inhibitors, proteasome inhibitors, purine analogs, pyrimidine analogs, receptor tyrosine kinase inhibitors, retinoids/deltoids plant alkaloids, topoisomerase inhibitors and the like.<!-- EPO <DP n="35"> --></p><p id="p0071" num="0071">Akylating agents include altretamine, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, Cloretazine™ (VNP 40101M), cyclophosphamide, decarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustine (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, nitrogen mustard N-oxide, ranimustine, temozolomide, thiotepa, treosulfan, trofosfamide and the like.</p><p id="p0072" num="0072">Angiogenesis inhibitors include endothelial-specific receptor tyrosine kinase (Tie-2) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, insulin growth factor-2 receptor (IGFR-2) inhibitors, matrix metalloproteinase-2 (MMP-2) inhibitors, matrix metalloproteinase-9 (MMP-9) inhibitors, platelet-derived growth factor receptor (PDGFR) inhibitors, thrombospondin analogs vascular endothelial growth factor receptor tyrosine kinase (VEGFR) inhibitors and the like.</p><p id="p0073" num="0073">Aurora kinase inhibitors include AZD-1152, MLN-8054, VX-680 and the like.</p><p id="p0074" num="0074">Bcl protein family member inhibitors include AT-101 ((-)gossypol), GENASENSE<sup>®</sup> (G3139 or oblimersen (Bcl-2-targeting antisense oglionucleotide)), IPI-194, IPI-565, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazin-1-yl)benzoyl)-4(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide (ABT-263), GX-070 (obatoclax) and the like.</p><p id="p0075" num="0075">Bcr-Abl kinase inhibitors include DASATINIB<sup>®</sup> (BMS-354825), GLEEVEC<sup>®</sup> (imatinib) and the like.</p><p id="p0076" num="0076">CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopyridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and the like.<!-- EPO <DP n="36"> --></p><p id="p0077" num="0077">COX-2 inhibitors include ABT-963, ARCOXIA<sup>®</sup> (etoricoxib), BEXTRA<sup>®</sup> (valdecoxib), BMS347070, CELEBREX™ (celecoxib), COX-189 (lumiracoxib), CT-3, DERAMAXX<sup>®</sup> (deracoxib), JTE-522,4-methyl-2-(3,4-dimethylphenyl)-1-(4-sulfamoylphenyl-1H-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX<sup>®</sup> (rofecoxib) and the like.</p><p id="p0078" num="0078">EGFR inhibitors include ABX-EGF, anti-EGFr immunoliposomes, EGF-vaccine, EMD-7200, ERBITUX<sup>®</sup> (cetuximab), HR3, IgA antibodies, IRESSA<sup>®</sup> (gefitinib), TARCEVA<sup>®</sup> (erlotinib or OSI-774), TP-38, EGFR fusion protein, TYKERB<sup>®</sup> (lapatinib) and the like.</p><p id="p0079" num="0079">ErbB2 receptor inhibitors include CP-724-714, CI-1033 (canertinib), Herceptin<sup>®</sup> (trastuzumab), TYKERB<sup>®</sup> (lapatinib), OMNITARG<sup>®</sup> (2C4, petuzumab), TAK-165, GW-572016 (ionafamib), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER-2 vaccine), anti-HER/2neu bispecific antibody, B7.her2IgG3, AS HER2 trifunctional bispecfic antibodies, mAB AR-209, mAB 2B-1 and the like.</p><p id="p0080" num="0080">Histone deacetylase inhibitors include depsipeptide, LAQ-824, MS-275, trapoxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproic acid and the like.</p><p id="p0081" num="0081">HSP-90 inhibitors include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB<sup>®</sup>, NCS-683664, PU24FCl, PU-3, radicicol, SNX-2112, STA-9090 VER49009 and the like.</p><p id="p0082" num="0082">MEK inhibitors include ARRY-142886, ARRY-438162 PD-325901, PD-98059 and the like.</p><p id="p0083" num="0083">mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus and the like.</p><p id="p0084" num="0084">Non-steroidal anti-inflammatory drugs include AMIGESIC<sup>®</sup> (salsalate), DOLOBID<sup>®</sup> (diflunisal), MOTRIN<sup>®</sup> (ibuprofen), ORUDIS<sup>®</sup> (ketoprofen), RELAFEN<sup>®</sup> (nabumetone),<!-- EPO <DP n="37"> --> FELDENE<sup>®</sup> (piroxicam) ibuprofin cream, ALEVE<sup>®</sup> and NAPROSYN<sup>®</sup> (naproxen), VOLTAREN<sup>®</sup> (diclofenac), INDOCIN<sup>®</sup> (indomethacin), CLINORIL<sup>®</sup> (sulindac), TOLECTIN<sup>®</sup> (tolmetin), LODINE<sup>®</sup> (etodolac), TORADOL<sup>®</sup> (ketorolac), DAYPRO<sup>®</sup> (oxaprozin) and the like.</p><p id="p0085" num="0085">PDGFR inhibitors include C-451, CP-673, CP-868596 and the like.</p><p id="p0086" num="0086">Platinum chemotherapeutics include cisplatin, ELOXATIN<sup>®</sup> (oxaliplatin) eptaplatin, lobaplatin, nedaplatin, PARAPLATIN<sup>®</sup> (carboplatin), satraplatin and the like.</p><p id="p0087" num="0087">Polo-like kinase inhibitors include BI-2536 and the like.</p><p id="p0088" num="0088">Thrombospondin analogs include ABT-510, ABT-567, ABT-898, TSP-1 and the like.</p><p id="p0089" num="0089">VEGFR inhibitors include AVASTIN<sup>®</sup> (bevacizumab), ABT-869, AEE-788, ANGIOZYME™, axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, Macugen (pegaptamib), NEXAVAR<sup>®</sup> (sorafenib, BAY43-9006), pazopanib (GW-786034), (PTK-787, ZK-222584), SUTENT<sup>®</sup> (sunitinib, SU-11248), VEGF trap, vatalanib, ZACTIMA™ (vandetanib, ZD-6474) and the like.</p><p id="p0090" num="0090">Antimetabolites include ALIMTA<sup>®</sup> (premetrexed disodium, LY231514, MTA), 5-azacitidine, XELODA<sup>®</sup> (capecitabine), carmofur, LEUSTAT<sup>®</sup> (cladribine), clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflomithine, EICAR, enocitabine, ethnylcytidine, fludarabine, hydroxyurea, 5-fluorouracil (5-FU) alone or in combination with leucovorin, GEMZAR<sup>®</sup> (gemcitabine), hydroxyurea, ALKERAN<sup>®</sup>(melphalan), mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolic acid, nelarabine, nolatrexed, ocfosate, pelitrexol, pentostatin, raltitrexed, Ribavirin, triapine, trimetrexate, S-1, tiazofurin, tegafur, TS-1, vidarabine, UFT and the like.</p><p id="p0091" num="0091">Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE<sup>®</sup> (bleomycin), daunorubicin, CAELYX<sup>®</sup> or<!-- EPO <DP n="38"> --> MYOCET<sup>®</sup> (doxorubicin), elsamitrucin, epirbucin, glarbuicin, ZAVEDOS<sup>®</sup> (idarubicin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimalamer, streptozocin, VALSTAR<sup>®</sup> (valrubicin), zinostatin and the like.</p><p id="p0092" num="0092">Topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, becatecarin, belotecan, BN-80915, CAMPTOSAR<sup>®</sup> (irinotecan hydrochloride), camptothecin, CARDIOXANE<sup>®</sup> (dexrazoxine), diflomotecan, edotecarin, ELLENCE<sup>®</sup> or PHARMORUBICIN<sup>®</sup> (epirubicin), etoposide, exatecan, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, orathecin, pirarbucin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluposide, topotecan and the like.</p><p id="p0093" num="0093">Antibodies include AVASTIN<sup>®</sup> (bevacizumab), CD40-specific antibodies, chTNT-1/B, denosumab, ERBITUX<sup>®</sup> (cetuximab), HUMAX-CD4<sup>®</sup> (zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX<sup>®</sup> (edrecolomab), RENCAREX<sup>®</sup> (WX G250), RITUXAN<sup>®</sup> (rituximab), ticilimumab, trastuzimab and and the like.</p><p id="p0094" num="0094">Hormonal therapies include ARMIDEX<sup>®</sup> (anastrozole), AROMASIN<sup>®</sup> (exemestane), arzoxifene, CASODEX<sup>®</sup> (bicalutamide), CETROTIDE<sup>®</sup> (cetrorelix), degarelix, deslorelin, DESOPAN<sup>®</sup> (trilostane), dexamethasone, DROGENIL<sup>®</sup>, (flutamide), EVISTA<sup>®</sup> (raloxifene), fadrozole, FARESTON<sup>®</sup> (toremifene), FASLODEX<sup>®</sup> (fulvestrant),FEMARA<sup>®</sup>, (letrozole), formestane, glucocorticoids, HECTOROL<sup>®</sup> or RENAGEL<sup>®</sup> (doxercalciferol), lasofoxifene, leuprolide acetate, MEGACE<sup>®</sup> (megesterol), MIFEPREX<sup>®</sup> (mifepristone), NILANDRON<sup>™</sup> (nilutamide), NOLVADEX<sup>®</sup> (tamoxifen citrate), PLENAXIS™ (abarelix), predisone, PROPECIA<sup>®</sup> (finasteride), rilostane, SUPREFACT<sup>®</sup> (buserelin), TRELSTAR<sup>®</sup> (luteinizing hormone releasing hormone (LHRH)), vantas, VETORYL<sup>®</sup>, (trilostane or modrastane), ZOLADEX<sup>®</sup> (fosrelin, goserelin) and the like.</p><p id="p0095" num="0095">Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexacalcitrol (KH1060), fenretinide, PANRETIN<sup>®</sup> (aliretinoin), ATRAGEN<sup>®</sup> (liposomal tretinoin), TARGRETIN<sup>®</sup>(bexarotene), LGD-1550 and the like.<!-- EPO <DP n="39"> --></p><p id="p0096" num="0096">Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine and the like.</p><p id="p0097" num="0097">Proteasome inhibitors include VELCADE<sup>®</sup> (bortezomib), MG132, NPI-0052, PR-171 and the like.</p><p id="p0098" num="0098">Examples of immunologicals include interferons and other immune-enhancing agents. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-1a, ACTIMMUNE<sup>®</sup> (interferon gamma-Ib), interferon gamma-nl, combinations thereof and the like. Other agents include ALFAFERONE<sup>®</sup>, BAM-002, BEROMUN<sup>®</sup> (tasonermin), BEXXAR<sup>®</sup> (tositumomab), CamPath<sup>®</sup> (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), decarbazine, denileukin, epratuzumab, GRANOCYTE<sup>®</sup> (lenograstim), lentinan, leukocyte alpha interferon, imiquimod, MDX-010, melanoma vaccine, mitumomab, molgramostim, MYLOTARG™ (gemtuzumab ozogamicin), NEUPOGEN<sup>®</sup> (filgrastim), OncoVAC-CL, OvaRex<sup>®</sup> (oregovomab), pemtumomab (Y-muHMFGI), PROVENGE<sup>®</sup>, sargaramostim, sizofilan, teceleukin, TheraCys<sup>®</sup>, ubenimex, VIRULIZIN<sup>®</sup>, Z-100, WF-10, PROLEUKIN<sup>®</sup> (aldesleukin), ZADAXIN<sup>®</sup> (thymalfasin), ZENAPAX<sup>®</sup> (daclizumab), ZEVALIN<sup>®</sup> (90Y-Ibritumomab tiuxetan) and the like.</p><p id="p0099" num="0099">Biological response modifiers are agents that modify defense mechanisms of living organisms or biological responses, such as survival, growth or differentiation of tissue cells to direct them to have anti-tumor activity and include include krestin, lentinan, sizofiran, picibanil PF-3512676 (CpG-8954), ubenimex and the like.</p><p id="p0100" num="0100">Pyrimidine analogs include cymrabine (ara C or Arabinoside C), cytosine arabinoside, doxifluridine, FLUDARA<sup>®</sup> (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR<sup>®</sup> (gemcitabine), TOMUDEX<sup>®</sup> (ratitrexed), TROXATYL™ (triacetyluridine troxacitabine) and the like.</p><p id="p0101" num="0101">Purine analogs include LANVIS<sup>®</sup> (thioguanine) and PURI-NETHOL<sup>®</sup> (mercaptopurine).<!-- EPO <DP n="40"> --></p><p id="p0102" num="0102">Antimitotic agents include batabulin, epothilone D (KOS-862), N-(2-((4-hydroxyphenyl)amino)pyridin-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE<sup>®</sup> (docetaxel), PNU100940 (109881), patupilone, XRP-9881, vinflunine, ZK-EPO and the like.</p><p id="p0103" num="0103">Compounds of the present invention are also intended to be used as a radiosensitizer that enhances the efficacy of radiotherapy. Examples of radiotherapy include, but are not limited to, external beam radiotherapy, teletherapy, brachtherapy and sealed and unsealed source radiotherapy.</p><p id="p0104" num="0104">Additionally, compounds having Formula I may be combined with other chemptherapeutic agents such as ABRAXANE™ (ABI-007), ABT-100 (farnesyl transferase inhibitor), ADVEXIN<sup>®</sup>, ALTOCOR<sup>®</sup> or MEVACOR<sup>®</sup> (lovastatin), AMPLIGEN<sup>®</sup> (poly I:poly C12U, a synthetic RNA), APTOSYN™ (exisulind), AREDIA<sup>®</sup> (pamidronic acid), arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE<sup>®</sup> (tazarotne), AVE-8062, BEC2 (mitumomab), cachectin or cachexin (tumor necrosis factor), canvaxin (vaccine), CeaVac™ (cancer vaccine), CELEUK<sup>®</sup> (celmoleukin), CEPLENE<sup>®</sup> (histamine dihydrochloride), CERVARIX™ (human papillomavirus vaccine), CHOP<sup>®</sup> (C: CYTOXAN<sup>®</sup> (cyclophosphamide); H: ADRIAMYCIN<sup>®</sup> (hydroxydoxorubicin); O: Vincristine (ONCOVIN<sup>®</sup>); P: prednisone), CyPat™, combrestatin A4P, DAB(389)EGF or TransMID-107R™ (diphtheria toxins), dacarbazine, dactinomycin, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), eniluracil, EVIZON™ (squalamine lactate), DIMERICINE<sup>®</sup> (T4N5 liposome lotion), discodermolide, DX-8951f (exatecan mesylate), enzastaurin, EP0906, GARDASIL<sup>®</sup> (quadrivalent human papillomavirus (Types 6, 11, 16, 18) recombinant vaccine), gastrimmune, genasense, GMK (ganglioside conjugate vaccine), GVAX<sup>®</sup> (prostate cancer vaccine), halofuginone, histerelin, hydroxycarbamide, ibandronic acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-pseudomonas exotoxin, interferon-α, interferon-γ, JUNOVAN™ or MEPACT™ (mifamurtide), lonafarnib, 5,10-methylenetetrahydrofolate, miltefosine (hexadecylphosphocholine), NEOVASTAT<sup>®</sup>(AE-941), NEUTREXIN<sup>®</sup> (trimetrexate glucuronate), NIPENT<sup>®</sup> (pentostatin), ONCONASE<sup>®</sup> (a ribonuclease enzyme), ONCOPHAGE<sup>®</sup> (melanoma vaccine treatment), OncoVAX (IL-2 Vaccine), ORATHECIN™ (rubitecan), OSIDEM<sup>®</sup> (antibody-based cell drug), OvaRex<sup>®</sup><!-- EPO <DP n="41"> --> MAb ( murine monoclonal antibody), paditaxel, PANDIMEX™ (aglycone saponins from ginseng comprising 20(S)protopanaxadiol (aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab, PANVAC<sup>®</sup>-VF (investigational cancer vaccine), pegaspargase, PEG Interferon A, phenoxodiol, procarbazine, rebimastat, REMOVAB<sup>®</sup> (catumaxomab), REVLIMID<sup>®</sup> (lenalidomide), RSR13 (efaproxiral), SOMATULINE<sup>®</sup> LA (lanreotide), SORIATANE<sup>®</sup> (acitretin), staurosporine (Streptomyces staurospores), talabostat (PT100), TARGRETIN<sup>®</sup> (bexarotene), Taxoprexin<sup>®</sup> (DHA-paclitaxel), TELCYTA™ (TLK286), temilifene, TEMODAR<sup>®</sup> (temozolomide), tesmilifene, thalidomide, THERATOPE<sup>®</sup> (STn-KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline dihydrochloride), TNFerade™ (adenovector: DNA carrier containing the gene for tumor necrosis factor-α), TRACLEER<sup>®</sup> or ZAVESCA<sup>®</sup> (bosentan), tretinoin (Retin-A), tetrandrine, TRISENOX<sup>®</sup> (arsenic trioxide), VIRULIZIN<sup>®</sup>, ukrain (derivative of alkaloids from the greater celandine plant), vitaxin (anti-alphavbeta3 antibody), XCYTRIN<sup>®</sup> (motexafin gadolinium), XINLAY™ (atrasentan), XYOTAX™ (paclitaxel poliglumex), YONDELIS™ (trabectedin), ZD-6126, ZINECARD<sup>®</sup> (dexrazoxane), zometa (zolendronic acid), zorubicin and the like.</p><p id="p0105" num="0105">It is also expected that compounds having Formula I would inhibit growth of cells derived from a pediatric cancer or neoplasm including embryonal rhabdomyosarcoma, pediatric acute lymphoblastic leukemia, pediatric acute myelogenous leukemia, pediatric alveolar rhabdomyosarcoma, pediatric anaplastic ependymoma, pediatric anaplastic large cell lymphoma, pediatric anaplastic medulloblastoma, pediatric atypical teratoid/rhabdoid tumor of the central nervous syatem, pediatric biphenotypic acute leukemia, pediatric Burkitts lymphoma, pediatric cancers of Ewing's family of tumors such as primitive neuroectodermal rumors, pediatric diffuse anaplastic Wilm's tumor, pediatric favorable histology Wilm's tumor, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, pediatric neuroblastoma-derived myelocytomatosis, pediatric pre-B-cell cancers (such as leukemia), pediatric psteosarcoma, pediatric rhabdoid kidney tumor, pediatric rhabdomyosarcoma, and pediatric T-cell cancers such as lymphoma and skin cancer and the like (commonly-owned United States Application Serial No. 10/988,338), Cancer Res., 2000,60,6101-10); and autoimmune disorders include, acquired immunodeficiency disease syndrome, autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, thrombocytopenia<!-- EPO <DP n="42"> --> and the like (<nplcit id="ncit0054" npl-type="s"><text>Current Allergy and Asthma Reports 2003, 3:378-384</text></nplcit>; <nplcit id="ncit0055" npl-type="s"><text>Br. J. Haematol. 2000 Sep; 110(3): 584-90</text></nplcit>;<nplcit id="ncit0056" npl-type="s"><text> Blood 2000 Feb 15;95(4):1283-92</text></nplcit>; and <nplcit id="ncit0057" npl-type="s"><text>New England Journal of Medicine 2004 Sep; 351(14): 1409-1418</text></nplcit>).</p><p id="p0106" num="0106">For example, involvement of Aurora-kinases in bladder cancer, breast cancer, cervical cancer, colon cancer, endometrial cancer, esophageal cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, skin cancer, stomach cancer and thyroid cancer is reported in <nplcit id="ncit0058" npl-type="s"><text>Nature Reviews/Cancer, Vol. 4 december, 2004</text></nplcit>.</p><p id="p0107" num="0107">Compounds having Formula I may be made by synthetic chemical processes, examples of which are shown herein. It is meant to be understood that the order of the steps in the processes may be varied, that reagents, solvents and reaction conditions may be substituted for those specifically mentioned, and that vulnerable moieties may be protected and deprotected, as necessary.</p><p id="p0108" num="0108">Protecting groups for C(O)OH moieties include, but are not limited to, acetoxymethyl, allyl, benzoylmethyl, benzyl, benzyloxymethyl, tert-butyl, tert-butyldiphenylsilyl, diphenylmethyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclopropyl, diphenylmethylsilyl, ethyl, para-methoxybenzyl, methoxymethyl, methoxyethoxymethyl, methyl, methylthiomethyl, naphthyl, para-nitrobenzyl, phenyl, n-propyl, 2,2,2-trichloroethyl, triethylsilyl, 2-(trimethylsilyl)ethyl, 2-(trimethylsilyl)ethoxymethyl, triphenylmethyl and the like.</p><p id="p0109" num="0109">Protecting groups for C(O) and C(O)H moieties include, but are not limited to, 1,3-dioxylketal, diethylketal, dimethylketal, 1,3-dithianylketal, O-methyloxime, O-phenyloxime and the like.</p><p id="p0110" num="0110">Protecting groups for NH moieties include, but are not limited to, acetyl, alanyl, benzoyl, benzyl (phenylmethyl), benzylidene, benzyloxycarbonyl (Cbz), tert-butoxycarbonyl (Boc), 3,4-dimethoxybenzyloxycarbonyl, diphenyhnethyl, diphenylphosphoryl, formyl, methanesulfonyl, para-methoxybenzyloxycarbonyl, phenylacetyl, phthaloyl, succinyl, trichloroethoxycarbonyl, triethylsilyl, trifluoroacetyl, trimethylsilyl, triphenylmethyl, triphenylsilyl, para-toluenesulfonyl and the like.<!-- EPO <DP n="43"> --></p><p id="p0111" num="0111">Protecting groups for OH and SH moieties include, but are not limited to, acetyl, allyl, allyloxycarbonyl, benzyloxycarbonyl (Cbz), benzoyl, benzyl, tert-butyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, 3,4-dimethoxybenzyl, 3,4-dimethoxybenzyloxycarbonyl, 1,1-dimethyl-2-propenyl, diphenylmethyl, formyl, methanesulfonyl, methoxyacetyl, 4-methoxybenzyloxycarbonyl, para-methoxybenzyl, methoxycarbonyl, methyl, para-toluenesulfonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-trichloroethyl, triethylsilyl, trifluoroacetyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-trimethylsilylethyl, triphenylmethyl, 2-(triphenylphosphonio)ethoxycarbonyl and the like.</p><p id="p0112" num="0112">The following abbreviations have the meanings indicated. ADDP means 1,1'-(azodicarbonyl)dipiperidine; AD-mix-β means a mixture of (DHQD)<sub>2</sub>PHAL, K<sub>3</sub>Fe(CN)<sub>6</sub>, K<sub>2</sub>CO<sub>3</sub> and K<sub>2</sub>SO<sub>4</sub>); AIBN means 2,2'-azobis(2-methylpropionitrile); 9-BBN means 9-borabicyclo(3.3.1)nonane; Cp means cyclopentadiene; (DHQD)<sub>2</sub>PHAL means hydroquinidine 1,4-phthalazinediyl diethyl ether, DBU means 1,8-diazabicyclo(5.4.0)undec-7-ene; DIBAL means diisobutylaluminum hydride; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DME means 1,2-dimethoxyethane; DMF means N,N-dimethylformamide; dmpe means 1,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppa means diphenylphosphoryl azide; dppb means 1,4-bis(diphenylphosphino)butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1'-bis(diphenylphosphino)ferrocene; dppm means 1,1-bis(diphenylphosphino)methane; EDAC means 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; Fmoc means fluorenylmethoxycarbonyl; HATU means O-(7-azabenzotriazol-1-yl)-N,N'N'N'-tetramethyluronium hexafluorophosphate; HMPA means hexamethylphosphoramide; HOAT means 1-hydroxy-7-azabenzotriazole; IPA means isopropyl alcohol; LDA means lithium diisopropylamide; LHMDS means lithium bis(hexamethyldisilylamide); MP-BH<sub>3</sub> means macroporus triethylammonium methylpolystyrene cyanoborohydride; LAH means lithium aluminum hydride; NCS means N-chlorosuccinimide; PyBOP means benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate; TBTU means O-benzotriazol-1-yl-N,N,N',N'-tetramethyluronium tetrafluoroborate; TDA-1 means tris(2-(2-methoxyethoxy)ethyl)amine; TEA means triethylamine; TFA means trifluoroacetic acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide;<!-- EPO <DP n="44"> --> NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh<sub>3</sub> means triphenylphosphine.</p><p id="p0113" num="0113">The following schemes and examples are presented to provide what is believed to be the most useful and readily understood description of procedures and conceptual aspects of this invention.
<chemistry id="chem0003" num="0003"><img id="ib0003" file="imgb0003.tif" wi="82" he="36" img-content="chem" img-format="tif"/></chemistry></p><p id="p0114" num="0114">As shown in SCHEME 1, compounds having Formula (1) can be converted to compounds having Formula (2) by reacting the former, N-hydroxyacetamide and potassium tert-butoxide. The reaction is typically conducted at ambient temperature in a solvent such as DMF, DME, NMP or a mixture thereof.
<chemistry id="chem0004" num="0004"><img id="ib0004" file="imgb0004.tif" wi="78" he="36" img-content="chem" img-format="tif"/></chemistry></p><p id="p0115" num="0115">As shown in SCHEME 2, compounds having Formula (1) can be converted to compounds having Formula (3) by reacting the former and hydrazine. The reaction is typically conducted in refluxing ethanol.<!-- EPO <DP n="45"> -->
<chemistry id="chem0005" num="0005"><img id="ib0005" file="imgb0005.tif" wi="82" he="36" img-content="chem" img-format="tif"/></chemistry></p><p id="p0116" num="0116">As shown in SCHEME 3, compounds having Formula (1) can be converted to compounds having Formula (4) by reacting the former, phenylmethanethiol and potassium tert-butoxide and reacting the product thereform with sulfuryl chloride and then ammonia. The reactions are typically conducted at ambient temperature in a solvent such as THF, dichloromethane, methanol or a mixture thereof.
<chemistry id="chem0006" num="0006"><img id="ib0006" file="imgb0006.tif" wi="74" he="38" img-content="chem" img-format="tif"/></chemistry></p><p id="p0117" num="0117">As shown in SCHEME 4, compounds having Formula (4A) can be converted to compounds having Formula (5) by reacting the former, carbon monoxide, a palladium catalyst, and a base, followed by hydrolysis of the ester. Examples of palladium catalysts include (1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II), bis(triphenylphosphine)palladium(II) dichloride and the like. Examples of bases include TEA and potassium carbonate. The reaction is typically conducted at elevated temperatures in a solvent such as methanol or ethanol. Hydrolysis of the ester is typically performed using a aqueous base such as but not limited to LiOH in a solvent such as but not limited to methanol, THF and the like or mixtures thereof.<!-- EPO <DP n="46"> -->
<chemistry id="chem0007" num="0007"><img id="ib0007" file="imgb0007.tif" wi="146" he="35" img-content="chem" img-format="tif"/></chemistry></p><p id="p0118" num="0118">As shown in SCHEME 5, compounds having Formula (5) can be converted to compounds having formula (7) by reacting the former, compounds having Formula (6), a coupling agent and a base, with or without a coupling auxiliary. Examples of coupling agents include DCC, EDCI, HATU, TBTU and the like. Examples of bases include DIEA, TEA, NMM and the like. Examples of coupling auxiliaries include DMAP, HOAT, HOBT and the like. The reaction is typically conducted between about 25°C and about 45°C, over about 1 to about 24 hours, in a solvent such as THF, DMF, dichloromethane, ethyl acetate or a mixture thereof.<!-- EPO <DP n="47"> -->
<chemistry id="chem0008" num="0008"><img id="ib0008" file="imgb0008.tif" wi="145" he="156" img-content="chem" img-format="tif"/></chemistry></p><p id="p0119" num="0119">As shown in SCHEME 6, compounds having Formula (5) can be converted to compounds having formula (9) by reacting the former and compounds having Formula (8) as described for the conversion of compounds having Formula (5) to compounds having Formula (7) in in SCHEME 5.</p><p id="p0120" num="0120">Compounds having Formula (9) can be converted to compounds having Formula (10) by reacting the former and an acid. Examples of acids include TFA or HCl. The reaction is typically conducted at ambient temperature in a solvent such as dichloromethane, dioxane, ethyl acetate or a mixture thereof.<!-- EPO <DP n="48"> --></p><p id="p0121" num="0121">Compounds having Formula (10) can be converted to compounds having Formula (11) by reacting the former and compounds having formula R<sup>30</sup>NCO, with or without a base. Examples of bases include TEA, DIEA and the like. The reaction is typically initially conducted below room temperature and then warmed to room temperature.</p><p id="p0122" num="0122">Alternatively, compounds having Formula (10) can be converted to compounds having Formula (12) by reacting the former and compounds having formula R<sup>30</sup>COH as described for the conversion of compounds having Formula (5) to compounds having Formula (7) in in SCHEME 5.</p><heading id="h0005">EXAMPLE 1</heading><heading id="h0006">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0007">EXAMPLE 1A</heading><p id="p0123" num="0123">A mixture of N-hydroxyacetamide (7.37 g) in DMF (100 mL) was treated with potassium tert-butoxide (11 g),stirred at room temperature for 30 minutes, treated with 2-fluoro-6-iodobenzonitrile (12.1 g), stirred at room temperature for 8 hours, diluted with water and filtered.</p><heading id="h0008">EXAMPLE 1B</heading><p id="p0124" num="0124">A mixture of EXAMPLE 1A (8.5 g),(1,1'-bis(diphenylphosphino)ferrocene)dichloropalladium(II) (940 mg) and TEA (6.2 mL) in methanol (100 mL) under 60 psi carbon monoxide was heated at 100°C for 2 hours, cooled to room temperature and concentrated. The concentrate was dissolved in methanol (50 mL) and THF (100 mL), treated with 2M lithium hydroxide (50 mL), stirred at room temperature for 2 hours, diluted with water and washed with diethyl ether. The aqueous layer was neutralized to pH 4-5 with 3N HCl and filtered.</p><heading id="h0009">EXAMPLE 1C</heading><p id="p0125" num="0125">A mixture of 3-(aminomethyl)aniline (1.12 g) in dichloromethane (40 mL) at --30°C was treated with 1-fluoro-3-isocyanatobenzene (1.03 mL), warmed to room temperature, stirred for 30 minutes and filtered. The solid was suspended in 100 mL of 4N HCl, stirred at<!-- EPO <DP n="49"> --> room temperature for 30 minutes and filtered. The filtrate was neutralized with 10% aqueous NaOH and filtered.</p><heading id="h0010">EXAMPLE 1D</heading><heading id="h0011">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0126" num="0126">A mixture of EXAMPLE 1B (0.036 g), EXAMPLE 1C (0.052 g), HATU (0.077 g) and TEA (0.078 mL) in DMF (2 mL) was stirred at room temperature for 24 hours, diluted with water and extracted with ethyl acetate. The extract was washed (brine) and dried (MgSO<sub>4</sub>), filtered and concentrated. The concentrate was flash chromatographed on silica gel with 0-5 % methanol in dichloromethane. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.76 Hz, 2H) 6.32 (s, 2H) 6.63-6.82 (m, 2H) 7.08 (dd, J=17.97, 8.48 Hz, 2H) 7.17-7.54 (m, 3H) 7.58-7.86 (m, 5H) 8.83 (s, 1H) 10.79 (s, 1H).</p><heading id="h0012">EXAMPLE 2</heading><heading id="h0013">3-amino-N-(3-(((((2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0127" num="0127">The title compound was prepared by substituting 1-fluoro-2-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene in EXAMPLES 1C-D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.34 (d, J=6.10 Hz, 2H) 6.31 (s, 2H) 6.83-6.98 (m, 1H) 6.99-7.25 (m, 4H) 7.36 (t, J=7.80 Hz, 1H) 7.59-7.81 (m, 5H) 8.01-8.26 (m, 1H) 8.39 (d, J=2.37 Hz, 1H) 10.78 (s, 1H).</p><heading id="h0014">EXAMPLE 3</heading><heading id="h0015">3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0128" num="0128">The title compound was prepared by substituting isocyanatobenzene for 1-fluoro-3-isocyanatobenzene in EXAMPLES 1C-D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=6.10 Hz, 2H) 6.31 (s, 2H) 6.63 (t, J=5.93 Hz, 1H) 6.89 (t, J=7.29 Hz, 1H) 7.11 (d, J=7.80 Hz, 1H) 7.15-7.29 (m, 2H) 7.28-7.49 (m, 3H) 7.55-7.85 (m, 5H) 8.55 (s, 1H) 10.78 (s, 1H).</p><heading id="h0016">EXAMPLE 4</heading><heading id="h0017">3-amino-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0129" num="0129">The title compound was prepared by substituting 1-isocyanato-4-trifluoromethylbenzene for 1-fluoro-3-isocyanatobenzene in EXAMPLES 1C-D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.34 (d, J=5.95 Hz, 2H) 6.32 (s, 2H) 6.81 (t, J=5.95 Hz, 1H) 7.12 (d, J=7.93 Hz, 1H) 7.36 (t, J=7.93 Hz, 1H) 7.48-7.87 (m, 9H) 9.03 (s, 1H) 10.78 (s, 1H).<!-- EPO <DP n="50"> --></p><heading id="h0018">EXAMPLE 5</heading><heading id="h0019">3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0020">EXAMPLE 5A</heading><p id="p0130" num="0130">A mixture of EXAMPLE 1B (1.0 g), tert-butyl 3-aminobenzylcarbamate (1.373 g), HATU (2.348 g) and TEA (2.347 mL) in DMF (30 mL) was stirred at room temperature for 24 hours, then diluted with water and extracted with ethyl acetate. The ethyl acetate phase was washed (brine), dried (MgSO<sub>4</sub>) and filtered. The filtrate was evaporated to dryness to leave an oil which was triturated with water. The resulting precipitate was filtered and dried.</p><heading id="h0021">EXAMPLE 5B</heading><p id="p0131" num="0131">A mixture of EXAMPLE 5A (1.6 g) in dichloromethane (10 mL) was treated with trifluoroacetic acid (5 mL), stirred at room temperature for 2 hours and concentrated.</p><heading id="h0022">EXAMPLE 5C</heading><heading id="h0023">3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0132" num="0132">A mixture of EXAMPLE 5B (51 mg) in DMF (2 mL) was treated with TEA (27.9 µL), cooled to -20°C, treated with 1-isocyanato-4-methylbenzene (13.3 mg), stirred for 30 minutes, then at room temperature for 30 minutes, treated with water and filtered. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.21 (s, 3H) 4.31 (d, J=6.10 Hz, 2H) 6.32 (s, 2H) 6.58 (t, J=5.93 Hz, 1H) 6.91-7.21 (m, 3H) 7.21-7.42 (m, 3H) 7.53-7.84 (m, 5H) 8.44 (s, 1H) 10.79 (s, 1H).</p><heading id="h0024">EXAMPLE 6</heading><heading id="h0025">3-amino-N-(3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0133" num="0133">The title compound was prepared by substituting 1-fluoro-2-isocyanato-4-methylbenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.23 (s, 3H) 4.33 (d, J=5.76 Hz, 2H) 6.32 (s, 2H) 6.52-6.81 (m, 1H) 6.91-7.21 (m, 3H) 7.36 (t, J=7.80 Hz, 1H) 7.56-7.85 (m, 5H) 7.98 (dd, J=7.97, 1.86 Hz, 1H) 8.32 (d, J=2.37 Hz, 1H) 10.80 (s, 1H).</p><heading id="h0026">EXAMPLE 7</heading><heading id="h0027">3-amino-N-(3-(((((3-methoxyphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><!-- EPO <DP n="51"> --><p id="p0134" num="0134">The title compound was prepared by substituting 1-isocyanato-3-methoxylbenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 3.70 (s, 3H) 4.32 (d, J=5.95 Hz, 2H) 6.31 (s, 2H) 6.47 (dd, J=7.73, 2.18 Hz, 1H) 6.63 (t, J=5.95 Hz, 1H) 6.79-7.01 (m, 1H) 7.03-7.23 (m, 3H) 7.35 (t, J=7.93 Hz, 1H) 7.55-7.87 (m, 5H) 8.58 (s, 1H) 10.79 (s, 1H).</p><heading id="h0028">EXAMPLE 8</heading><heading id="h0029">3-amino-N-(3-(((((4-methoxyphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0135" num="0135">The title compound was prepared by substituting 1-isocyanato-4-methoxylbenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 3.69 (s, 3H) 4.31 (d, J=5.95 Hz, 2H) 6.32 (s, 2H) 6.53 (t, J=5.95 Hz, 1H) 6.81 (d, J=9.12 Hz, 2H) 7.10 (d, J=7.54 Hz, 1H) 7.21-7.49 (m, 3H) 7.54-7.86 (m, 5H) 8.35 (s, 1H) 10.78 (s, 1H).</p><heading id="h0030">EXAMPLE 9</heading><heading id="h0031">3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0136" num="0136">The title compound was prepared by substituting 1,2-difluoro-4-isocyanatobenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.76 Hz, 2H) 6.32 (s, 2H) 6.74 (t, J=5.93 Hz, 1H) 6.94-7.17 (m, 2H) 7.17-7.46 (m, 2H) 7.51-7.88 (m, 6H) 8.83 (s, 1H) 10.78 (s, 1H).</p><heading id="h0032">EXAMPLE 10</heading><heading id="h0033">3-amino-N-(3-(((((3,5-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0137" num="0137">The title compound was prepared by substituting 1,3-difluoro-5-isocyanatobenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) 8 4.32 (d, J=5.95 Hz, 2H) 6.31 (s, 2H) 6.69 (s, 1H) 6.86 (s, 1H) 7.01-7.24 (m, 3H) 7.35 (t, J=7.93 Hz, 1H) 7.57-7.86 (m, 5H) 9.04 (s, 1H) 10.78 (s, 1H).</p><heading id="h0034">EXAMPLE 11</heading><heading id="h0035">3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0138" num="0138">The title compound was prepared by substituting 1-fluoro-4-isocyanatobenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d,<!-- EPO <DP n="52"> --> J=6.10 Hz, 2H) 6.32 (s, 2H) 6.63 (t, J=5.93 Hz, 1H) 6.97-7.16 (m, 3H) 7.30-7.51 (m, 3H) 7.58-7.84 (m, 5H) 8.60 (s, 1H) 10.78 (s, 1H).</p><heading id="h0036">EXAMPLE 12</heading><heading id="h0037">3-amino-N-(3-((((cyclopentylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0139" num="0139">The title compound was prepared by substituting isocyanatocyclopentane for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 1.22-1.40 (m, 2H) 1.42-1.67 (m, 4H) 1.70-1.90 (m, 2H) 3.70-4.03 (m, 1H) 4.22 (d, J=5.76 Hz, 2H) 5.92 (d, J=7.46 Hz, 1H) 6.17 (t, J=5.93 Hz, 1H) 6.32 (s, 2H) 7.05 (d, J=7.46 Hz, 1H) 7.33 (t, J=7.80 Hz, 1H) 7.52-7.90 (m, 5H) 10.76 (s, 1H).</p><heading id="h0038">EXAMPLE 13</heading><heading id="h0039">3-amino-N-(3-((((cyclohexylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0140" num="0140">The title compound was prepared by substituting isocyanatocyclohexane for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 0.82-1.37 (m, 6H) 1.40-1.87 (m, 5H) 4.21 (d, J=5.76 Hz, 2H) 5.83 (d, J=8.14 Hz, 1H) 6.20 (t, J=5.93 Hz, 1H) 6.33 (s, 2H) 7.04 (d, J=7.80 Hz, 1H) 7.32 (t, J=7.80 Hz, 1H) 7.52-7.87 (m, 5H) 10.76 (s, 1H).</p><heading id="h0040">EXAMPLE 14</heading><heading id="h0041">3-amino-N-(3-((((thien-2-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0141" num="0141">The title compound was prepared by substituting 2-isocyanatothiophene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C.<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.33 (d, J=6.10 Hz, 2H) 6.31 (s, 2H) 6.44 (dd, J=3.22, 1.86 Hz, 1H) 6.65-6.78 (m, 3H) 7.10 (d, J=7.46 Hz, 1H) 7.35 (t, J=7.80 Hz, 1H) 7.59-7.80 (m, 5H) 9.55 (s, 1H) 10.78 (s, 1H).</p><heading id="h0042">EXAMPLE 15</heading><heading id="h0043">3-amino-N-(3-((((thien-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0142" num="0142">The title compound was prepared by substituting 3-isocyanatothiophene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C.<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.31 (d, J=5.95 Hz, 2H) 6.31 (s, 2H) 6.60 (s, 1H) 6.98 (d, J=5.16 Hz, 1H) 7.10 (d, J=7.54 Hz, 1H) 7.17 (d, J=1.98 Hz, 1H) 7.25-7.43 (m, 2H) 7.55-7.84 (m, 5H) 8.84 (s, 1H) 10.78 (s, 1H).<!-- EPO <DP n="53"> --></p><heading id="h0044">EXAMPLE 16</heading><heading id="h0045">3-amino-N-(3-(((((3-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0143" num="0143">The title compound was prepared by substituting 1-isocyanato-3-methylbenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C.<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.24 (s, 3H) 4.31 (d, J=5.43 Hz, 2H) 6.31 (s, 2H) 6.53-6.79 (m, 2H) 7.02-7.44 (m, 5H) 7.57-7.90 (m, 5H) 8.47 (s, 1H) 10.78 (s, 1H).</p><heading id="h0046">EXAMPLE 17</heading><heading id="h0047">3-amino-N-(3-(((((3,5-dimethylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0144" num="0144">The title compound was prepared by substituting 1,3-dimethyl-5-isocyanatobenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.19 (s, 6H) 4.30 (d, J=5.55 Hz, 2H) 6.32 (s, 2H) 6.48-6.76 (m, 2H) 7.03 (s, 2H) 7.10 (d, J=7.93 Hz, 1H) 7.35 (t, J=7.73 Hz, 1H) 7.53-7.85 (m, 5H) 8.39 (s, 1H) 10.78 (s, 1H).</p><heading id="h0048">EXAMPLE 18</heading><heading id="h0049">3-amino-N-(3-(((((3-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0145" num="0145">The title compound was prepared by substituting 1-chloro-3-isocyanatobenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C.<sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.95 Hz, 2H) 6.32 (s, 2H) 6.75 (t, J=5.95 Hz, 1H) 6.85-6.99 (m, 1H) 7.11 (d, J=7.93 Hz, 1H) 7.16-7.28 (m, 2H) 7.35 (t, J=7.73 Hz, 1H) 7.54-7.88 (m, 6H) 8.81 (s, 1H) 10.78 (s, 1H).</p><heading id="h0050">EXAMPLE 19</heading><heading id="h0051">3-amino-N-(3-(((((2-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0146" num="0146">The title compound was prepared by substituting 1-isocyanato-2-trifluoromethylbenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.34 (d, J=5.76 Hz, 2H) 6.31 (s, 2H) 7.04-7.26 (m, 2H) 7.38 (t, J=7.80 Hz, 1H) 7.45-7.83 (m, 8H) 7.87 (s, 1H) 8.00 (d, J=8.14 Hz, 1H) 10.79 (s, 1H).</p><heading id="h0052">EXAMPLE 20</heading><heading id="h0053">3-amino-N-(3-(((3-methylbenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0147" num="0147">The title compound was prepared by substituting EXAMPLE 5B and 3-methylbenzoic acid for EXAMPLES 1C and 1B, respectively, in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz,<!-- EPO <DP n="54"> --> DMSO-d<sub>6</sub>) δ 2.36 (s, 3H) 4.49 (d, J=6.10 Hz, 2H) 6.31 (s, 2H) 7.13 (d, J=7.80 Hz, 1H) 7.25-7.49 (m, 3H) 7.54-7.91 (m, 7H) 9.02 (t, J=5.93 Hz, 1H) 10.78 (s, 1H).</p><heading id="h0054">EXAMPLE 21</heading><heading id="h0055">3-amino-N-(3-((benzoylamino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0148" num="0148">The title compound was prepared by substituting EXAMPLE 5B and benzoic acid for EXAMPLES 1C and 1B, respectively, in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.51 (d, J=6.10 Hz, 2H) 6.31 (s, 2H) 7.13 (d, J=7.80 Hz, 1H) 7.35 (t, J=7.97 Hz, 1H) 7.41-7.60 (m, 3H) 7.60-7.83 (m, 5H) 7.82-8.00 (m, 2H) 9.07 (t, J=5.93 Hz, 1H) 10.77 (s, 1H).</p><heading id="h0056">EXAMPLE 22</heading><heading id="h0057">3-amino-N-(3-(((phenylacetyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0149" num="0149">The title compound was prepared by substituting EXAMPLE 5B and 2-phenylacetic acid for EXAMPLES 1C and 1B, respectively, in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 3.49 (s, 2H) 4.29 (d, J=5.76 Hz, 2H) 6.33 (s, 2H) 7.04 (d, J=8.14 Hz, 1H) 7.12-7.42 (m, 6H) 7.53-7.85 (m, 5H) 8.58 (t, J=5.76 Hz, 1H) 10.76 (s, 1H).</p><heading id="h0058">EXAMPLE 23</heading><heading id="h0059">3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0060">EXAMPLE 23A</heading><p id="p0150" num="0150">A mixture of (4-aminophenyl)carbamic acid tert-butyl ester (1.04 g) in dichloromethane (20 mL) at 0°C was treated with 1-fluoro-3-isocyanatobenzene (0.56 mL), stirred at ambient temperature for 4 hours and filtered. The filtrate was suspended in dichloromethane (20 mL), cooled in an ice bath, treated with trifluoroacetic acid (5 mL), stirred for 15 minutes at 0°C, then at ambient temperature for 3 hours, and concentrated. The concentrate was reconcentrated twice from methanol and toluene and dried.</p><heading id="h0061">EXAMPLE 23B</heading><heading id="h0062">3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0151" num="0151">A mixture of EXAMPLE 1B (35.6 mg), EXAMPLE 23A (72 mg), HATU (84 mg) and TEA (83 ul) in DMF (20 mL) at room temperature was stirred for 20 hours, poured into water (30 mL) and filtered. The flitrate was dried and suspended in refluxing diethyl ether. The mixture was cooled to room temperature, filtered and dried. <sup>1</sup>H NMR (300 MHz,<!-- EPO <DP n="55"> --> DMSO-d<sub>6</sub>) S 6.36 (s, 2H) 6.78 (t, J=8.31 Hz, 1H) 7.12 (d, J=7.80 Hz, 1H) 7.31 (q, J=7.80 Hz, 1H) 7.49 (t, J=8.48 Hz, 3H) 7.61-7.85 (m, 5H) 8.76 (s, 1H) 8.88 (s, 1H) 10.69 (s, 1H).</p><heading id="h0063">EXAMPLE 24</heading><heading id="h0064">3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0152" num="0152">The title compound was prepared by substituting isocyanatobenzene for 1-fluoro-3-isocyanatobenzene in EXAMPLES 23A-B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 6.36 (s, 2H) 6.97 (t, J=7.29 Hz, 1H) 7.28 (t, J=7.80 Hz, 2H) 7.46 (dd, J=8.14, 4.41 Hz, 4H) 7.58-7.84 (m, 5H) 8.64 (s, 1H) 8.69 (s, 1H) 10.69 (s, 1H).</p><heading id="h0065">EXAMPLE 25</heading><heading id="h0066">3-amino-N-(4-((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0153" num="0153">The title compound was prepared by substituting isocyanato-3-trifluoromethylbenzene for 1-fluoro-3-isocyanatobenzene in EXAMPLES 23A-B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 6.36 (s, 2H) 7.31 (d, J=7.12 Hz, 1H) 7.43-7.61 (m, 4H) 7.63-7.81 (m, 5H) 8.03 (s, 1H) 8.83 (s, 1H) 9.04 (s, 1H) 10.70 (s, 1H).</p><heading id="h0067">EXAMPLE 26</heading><heading id="h0068">3-amino-N-(4-(((thien-3-ylamino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0154" num="0154">The title compound was prepared by substituting 3-isocyanatothiophene for 1-fluoro-3-isocyanatobenzene, in EXAMPLES 23A-B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 6.35 (s, 2H) 7.05 (dd, J=5.26, 1.53 Hz, 1H) 7.28 (dd, J=3.05, 1.36 Hz, 1H) 7.35-7.48 (m, 3H) 7.60-7.83 (m, 5H) 8.64 (s, 1H) 8.90 (s, 1H) 10.67 (s, 1H).</p><heading id="h0069">EXAMPLE 27</heading><heading id="h0070">3-amino-N-(4-((((4-methylphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0155" num="0155">The title compound was prepared by substituting 1-isocyanato-4-methylbenzene for 1-fluoro-3-isocyanatobenzene, in EXAMPLES 23A-B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.07 (s, 3H) 6.35 (s, 2H) 7.08 (d, J=8.48 Hz, 2H) 7.34 (d, J=8.48 Hz, 2H) 7.46 (d, J=8.82 Hz, 2H) 7.55-7.99 (m, 6H) 8.52 (s, 1H) 8.63 (s, 1H).</p><heading id="h0071">EXAMPLE 28</heading><heading id="h0072">3-amino-N-(4-((((3-methylphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><!-- EPO <DP n="56"> --><p id="p0156" num="0156">The title compound was prepared by substituting 1-isocyanato-3-methylbenzene for 1-fluoro-3-isocyanatobenzene in EXAMPLES 23A-B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.28 (s, 3H) 6.35 (s, 2H) 7.11-7.26 (m, 2H) 7.30 (s, 1H) 7.47 (d, J=9.16 Hz, 2H) 7.59-7.86 (m, 6H) 8.55 (s, 1H) 8.66 (s, 1H) 10.67 (s, 1H).</p><heading id="h0073">EXAMPLE 29</heading><heading id="h0074">3-amino-N-(4-((((2,4-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0157" num="0157">The title compound was prepared by substituting 2,4-difluoro-1-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene, in EXAMPLES 23A-B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 6.35 (s, 2H) 6.91-7.13 (m, 1H) 7.21-7.39 (m, 1H) 7.40-7.54 (m, 2H) 7.57-7.86 (m, 5H) 7.97-8.21 (m, 1H) 8.48 (d, J=2.03 Hz, 1H) 9.04 (s, 1H) 10.69 (s, 1H).</p><heading id="h0075">EXAMPLE 30</heading><heading id="h0076">3-amino-N-(4-((((3,5-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0158" num="0158">The title compound was prepared by substituting 1,3-difluoro-5-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene, in EXAMPLES 23A-B. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub> and D<sub>2</sub>O) δ 6.71-6.84 (m, 1H) 7.14-7.23 (m, 2H) 7.43-7.52 (m, 2H) 7.66-7.73 (m, 3H) 7.73-7.78 (m, 2H).</p><heading id="h0077">EXAMPLE 31</heading><heading id="h0078">3-amino-N-(4-((((3,4-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0159" num="0159">The title compound was prepared by substituting 1,2-difluoro-4-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene, in EXAMPLES 23A-B. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub> and D<sub>2</sub>O) δ 7.06-7.21 (m, 1H) 7.27-7.41 (m, 1H) 7.43-7.53 (m, 2H) 7.59-7.79 (m, 6H).</p><heading id="h0079">EXAMPLE 32 (COMPARATIVE)</heading><heading id="h0080">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methyl-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0081">EXAMPLE 32A</heading><p id="p0160" num="0160">3-Amino-7-methylbenzo(d)isoxazole-4-carboxylic acid was prepared by substituting 4-iodo-7-methylbenzo(d)isoxazol-3-amine (prepared as in PCT application <patcit id="pcit0005" dnum="US2004016166W"><text>PCT/US2004/016166</text></patcit>, published as <patcit id="pcit0006" dnum="WO2004113304A"><text>W02004/113304</text></patcit>) for EXAMPLE 1A in EXAMPLE 1B.</p><heading id="h0082">EXAMPLE 32B</heading><!-- EPO <DP n="57"> --><heading id="h0083">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methyl-1,2-benzisoxazole-4-carboxamide</heading><p id="p0161" num="0161">The title compound was prepared by substituting EXAMPLE 32A for EXAMPLE 1B in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.50 (d, J=2.03 Hz, 3H) 4.32 (d, J=5.76 Hz, 2H) 6.36 (s, 2H) 6.58-6.86 (m, 2H) 7.07 (dd, J=14.92, 8.48 Hz, 2H) 7.15-7.41 (m, 2H) 7.41-7.55 (m, 2H) 7.57-7.78 (m, 3H) 8.82 (s, 1H) 10.69 (s, 1H).</p><heading id="h0084">EXAMPLE 33 (COMPARATIVE)</heading><heading id="h0085">3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-methyl-1,2-benzisoxazole-4-carboxamide</heading><p id="p0162" num="0162">The title compound was prepared by substituting isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 32A for EXAMPLE 1B in EXAMPLES 1C and EXAMPLE 1D, respectively. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.50 (dd, J=3.57, 1.59 Hz, 3H) 4.32 (d, J=5.95 Hz, 2H) 6.36 (s, 2H) 6.63 (t, J=5.95 Hz, 1H) 6.89 (t, J=7.34 Hz, 1H) 7.10 (d, J=7.93 Hz, 1H) 7.16-7.27 (m, 2H) 7.29-7.44 (m, 3H) 7.49 (d, J=8.33 Hz, 1H) 7.59-7.79 (m, 3H) 8.55 (s, 1H) 10.70 (s, 1H).</p><heading id="h0086">EXAMPLE 34 (COMPARATIVE)</heading><heading id="h0087">3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-7-methyl-1,2-benzisoxazole-4-carboxamide</heading><p id="p0163" num="0163">The title compound was prepared by substituting EXAMPLE 32A for EXAMPLE 1B in EXAMPLE 23B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.34-2.56 (m, 3H) 6.41 (s, 2H) 6.64-6.87 (m, 1H) 7.12 (d, J=9.15 Hz, 1H) 7.21-7.37 (m, 1H) 7.41-7.57 (m, 4H) 7.60-7.86 (m, 3H) 8.76 (s, 1H) 8.89 (s, 1H) 10.61 (s, 1H).</p><heading id="h0088">EXAMPLE 35 (COMPARATIVE)</heading><heading id="h0089">3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-7-methyl-1,2-benzisoxazole-4-carboxamide</heading><p id="p0164" num="0164">The title compound was prepared by substituting isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 32A for EXAMPLE 1B in EXAMPLES 23A and EXAMPLE 23B, respectively. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.33-2.55 (m, 3H) 6.41 (s, 2H) 6.97 (t, J=7.46 Hz, 1H) 7.28 (t, J=7.97 Hz, 2H) 7.38-7.53 (m, 5H) 7.60-7.81 (m, 3H) 8.64 (s, 1H) 8.68 (s, 1H) 10.60 (s, 1H).</p><heading id="h0090">EXAMPLE 36</heading><heading id="h0091">3-amino-N-(4-(benzoylamino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><!-- EPO <DP n="58"> --><p id="p0165" num="0165">The title compound was prepared by substituting N-(4-aminophenyl)benzamide for 23A in EXAMPLE 23B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 6.36 (s, 2H) 7.42-8.06 (m, 12H) 10.29 (s, 1H) 10.77 (s, 1H).</p><heading id="h0092">EXAMPLE 37</heading><heading id="h0093">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide</heading><heading id="h0094">EXAMPLE 37A</heading><p id="p0166" num="0166">The title compound was prepared by substituting 4-iodobenzo(d)isothiazol-3-amine (prepared as in PCT application <patcit id="pcit0007" dnum="US2004016166W"><text>PCT/US2004/016166</text></patcit>, published as <patcit id="pcit0008" dnum="WO2004113304A"><text>W02004/113304</text></patcit>) for EXAMPLE 1A in EXAMPLE 1B.</p><heading id="h0095">EXAMPLE 37B</heading><heading id="h0096">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide</heading><p id="p0167" num="0167">The title compound was prepared by substituting EXAMPLE 37A for EXAMPLE 1B in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 432 (none, 1H) 6.48 (s, 2H) 6.61-6.79 (m, 2H) 6.96-7.15 (m, 2H) 7.17-7.28 (m, 1H) 7.35 (t, J=7.80 Hz, 1H) 7.41-7.53 (m, 1H) 7.58-7.71 (m, 3H) 7.74 (s, 1H) 8.17 (dd, J=7.63, 1.53 Hz, 1H) 8.82 (s, 1H) 10.86 (s, 1H).</p><heading id="h0097">EXAMPLE 38</heading><heading id="h0098">3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide</heading><p id="p0168" num="0168">The title compound was prepared by substituting isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 37A for EXAMPLE 1B in EXAMPLES 1C and 1D, respectively. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=6.10 Hz, 2H) 6.48 (s, 2H) 6.63 (t, J=5.93 Hz, 1H) 6.89 (t, J=7.46 Hz, 1H) 7.05-7.29 (m, 3H) 7.29-7.49 (m, 3H) 7.53-7.83 (m, 4H) 8.17 (dd, J=7.63, 1.53 Hz, 1H) 8.55 (s, 1H) 10.86 (s, 1H).</p><heading id="h0099">EXAMPLE 39</heading><heading id="h0100">3-amino-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide</heading><p id="p0169" num="0169">The title compound was prepared by substituting 1-isocyanato-4-trifluoromethylbenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 37A for EXAMPLE 1B in EXAMPLES 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 4.34 (d, J=5.80 Hz, 2H) 6.49 (s, 2H) 6.83 (t, J=5.95 Hz, 1H) 7.12 (d, J=7.93 Hz, 1H) 7.36 (t,<!-- EPO <DP n="59"> --> J=7.93 Hz, 1H) 7.50-7.71 (m, 7H) 7.76 (s, 1H) 8.17 (d, J=7.93 Hz, 1H) 9.04 (s, 1H) 10.87 (s, 1H).</p><heading id="h0101">EXAMPLE 40</heading><heading id="h0102">3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide</heading><p id="p0170" num="0170">The title compound was prepared by substituting EXAMPLE 37A for EXAMPLE 1B in EXAMPLE 23B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 6.53 (s, 2H) 6.68-6.91 (m, 1H) 7.12 (d, J=8.14 Hz, 1H) 7.20-7.39 (m, 1H) 7.42-7.57 (m, 3H) 7.56-7.76 (m, 4H) 8.17 (dd, J=7.63, 1.53 Hz, 1H) 8.77 (s, 1H) 8.89 (s, 1H) 10.76 (s, 1H).</p><heading id="h0103">EXAMPLE 41</heading><heading id="h0104">3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide</heading><p id="p0171" num="0171">The title compound was prepared by substituting isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 37A for EXAMPLE 1B in EXAMPLES 23A and EXAMPLE 23B, respectively. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 6.53 (s, 2H) 6.97 (t, J=7.29 Hz, 1H) 7.28 (t, J=7.80 Hz, 2H) 7.46 (dd, J=8.14, 5.43 Hz, 4H) 7.58-7.78 (m, 4H) 8.17 (dd, J=7.63, 1.53 Hz, 1H) 8.64 (s, 1H) 8.69 (s, 1H) 10.75 (s, 1H).</p><heading id="h0105">EXAMPLE 42</heading><heading id="h0106">3-amino-N-(4-((((3-(2-hydroxyethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide</heading><p id="p0172" num="0172">The title compound was prepared by substituting EXAMPLE 37A and 1-(4-aminophenyl)-3-(3-(2-hydroxyethyl)phenyl)urea for EXAMPLE 1B and EXAMPLE 1C, respectively, in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.69 (t, J=7.14 Hz, 2H) 3.50-3.67 (m, 2H) 4.63 (t, J=5.16 Hz, 1H) 6.54 (s, 2H) 6.83 (d, J=7.54 Hz, 1H) 7.07-7.36 (m, 3H) 7.47 (d, J=8.72 Hz, 2H) 7.54-7.82 (m, 4H) 8.06-8.33 (m, 1H) 8.59 (s, 1H) 8.67 (s, 1H) 10.75 (s, 1H).</p><p id="p0173" num="0173">EXAMPLES 43-53 were prepared by substituting the appropriate isocyanate (X) for 1-fluoro-3-isocyanatobenzene in EXAMPLE 23A, and then substituting the product for EXAMPLE 23A in EXAMPLE 23B.</p><heading id="h0107">EXAMPLE 43</heading><heading id="h0108">3-amino-N-(4-((((3,4-dichlorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><!-- EPO <DP n="60"> --><p id="p0174" num="0174">X=1,2-dichloro-4-isocyanatobenzene. <sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 7.34 (dd, J=8.70, 2.59 Hz, 1H) 7.45-7.50 (m, 2H) 7.53 (d, J=8.54 Hz, 1H) 7.66-7.77 (m, 5H) 7.88 (d, J=2.44 Hz, 1H).</p><heading id="h0109">EXAMPLE 44</heading><heading id="h0110">3-amino-N-(4-((((3-methoxyphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0175" num="0175">X= 1-isocyanato-3-methoxybenzene. <sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ3.74 (s, 3H) 6.58 (dd, J=8.24, 1.83 Hz, 1H) 6.82-7.02 (m, 1H) 7.10-7.27 (m, 2H) 7.40-7.51 (m, 2H) 7.60-7.83 (m, 5H).</p><heading id="h0111">EXAMPLE 45</heading><heading id="h0112">3-amino-N-(4-((((4-bromophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0176" num="0176">X= 1-bromo-4-isocyanatobenzene.<sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 7.36-7.50 (m, 6H) 7.63-7.79 (m, 5H).</p><heading id="h0113">EXAMPLE 46</heading><heading id="h0114">3-amino-N-(4-((((4-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0177" num="0177">X= 1-fluoro-4-isocyanatobenzene.<sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 7.09-7.18 (m, 2H) 7.41-7.51 (m, 4H) 7.64-7.78 (m, 5H).</p><heading id="h0115">EXAMPLE 47</heading><heading id="h0116">3-amino-N-(4-((((4-chlorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0178" num="0178">X= 1-chloro-4-isocyanatobenzene.<sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 7.31-7.36 (m, 2H) 7.44-7.52 (m, 4H) 7.63-7.78 (m, 5H).</p><heading id="h0117">EXAMPLE 48</heading><heading id="h0118">3-amino-N-(4-((((4-methoxyphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0179" num="0179">X= 1-isocyanato-4-methoxybenzene.<sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 3.72-3.78 (m, 3H) 6.82-6.92 (m, 2H) 7.32-7.40 (m, 2H) 7.42-7.50 (m, 2H) 7.63-7.77.</p><heading id="h0119">EXAMPLE 49</heading><heading id="h0120">3-amino-N-(4-(((benzylamino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><!-- EPO <DP n="61"> --><p id="p0180" num="0180">X= (isocyanatomethyl)benzene. <sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 4.31 (s, 2H) 7.23-7.38 (m, 5H) 7.38-7.48 (m, 2H) 7.57-7.65 (m, 2H) 7.68-7.80 (m, 3H).</p><heading id="h0121">EXAMPLE 50</heading><heading id="h0122">3-amino-N-(4-((((3-cyanophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0181" num="0181">X = 3-isocyanatobenzonitrile. <sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 7.33-7.57 (m, 4H) 7.61-7.86 (m, 6H) 7.98 (t, J=1.83 Hz, 1H).</p><heading id="h0123">EXAMPLE 51</heading><heading id="h0124">3-amino-N-(4-((((3-(methylthio)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0182" num="0182">X= (3-isocyanatophenyl)(methyl)sulfane. <sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 2.46 (s, 3H) 6.89 (d, J=7.63 Hz, 1H) 7.16 (dd, J=7.93, 1.22 Hz, 1H) 7.19-7.36 (m, 1H) 7.40-7.58 (m, 4H) 7.64-7.80 (m, 5H).</p><heading id="h0125">EXAMPLE 52</heading><heading id="h0126">3-amino-N-(4-((((4-(methylthio)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0183" num="0183">X= (4-isocyanatophenyl)(methyl)sulfane. <sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 2.38 (s, 3H) 7.49 (d, J=8.85 Hz, 2H) 7.59-7.93 (m, 9H).</p><heading id="h0127">EXAMPLE 53</heading><heading id="h0128">3-amino-N-(4-((((3-chloro-4-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0184" num="0184">X= 2-chloro-1-fluoro-4-isocyanatobenzene. <sup>1</sup>H NMR (500 MHz, DMSO-D<sub>2</sub>O) δ 7.28-7.37 (m, 2H) 7.44-7.50 (m, 2H) 7.66-7.77 (m, 5H) 7.79 (dd, J=6.87, 2.29 Hz, 1H).</p><heading id="h0129">EXAMPLE 54</heading><heading id="h0130">3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><heading id="h0131">EXAMPLE 54A</heading><p id="p0185" num="0185">The title compound was prepared by substituting 4-iodo-<sup>1</sup>H-indazol-3-amine (prepared as described in PCT application <patcit id="pcit0009" dnum="US2004016166W"><text>PCT/US2004/016166</text></patcit>, published as <patcit id="pcit0010" dnum="WO2004113304A"><text>WO2004/113304</text></patcit>) for EXAMPLE 1A in EXAMPLE 1B.</p><heading id="h0132">EXAMPLE 54B</heading><!-- EPO <DP n="62"> --><p id="p0186" num="0186">The title compound was prepared by substituting EXAMPLE 54A for EXAMPLE 1B in EXAMPLES 5A-B.</p><heading id="h0133">EXAMPLE 54C</heading><heading id="h0134">3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><p id="p0187" num="0187">The title compound was prepared by substituting EXAMPLE 54B and 1-fluoro-4-isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.49 Hz, 2H) 6.66 (t, J=5.95 Hz, 1H) 7.02-7.11 (m, 3H) 7.34 (t, J=7.78 Hz, 1H) 7.39-7.47 (m, 3H) 7.52 (d, J=7.02 Hz, 1H) 7.59 (d, J=8.24 Hz, 1H) 7.67 (d, J=7.93 Hz, 1H) 7.75 (s, 1H) 8.64 (s, 1H) 10.68 (s, 1H).</p><heading id="h0135">EXAMPLE 55</heading><heading id="h0136">3-amino-N-(3-(((((3-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><p id="p0188" num="0188">The title compound was prepared by substituting EXAMPLE 54B and 1-chloro-3-isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.76 Hz, 2H) 6.75 (t, J=5.93 Hz, 1H) 6.91-6.96 (m, 1H) 7.08 (d, J=8.14 Hz, 1H) 7.20-7.25 (m, 2H) 7.30-7.35 (m, 1H) 7.42 (d, J=8.14 Hz, 1H) 7.45-7.51 (m, 1H) 7.56 (d, J=8.14 Hz, 1H) 7.65-7.72 (m, 2H) 7.75 (s, 1 H) 8.81 (s, 1H) 10.65 (s, 1H).</p><heading id="h0137">EXAMPLE 56</heading><heading id="h0138">3-amino-N-(3-(((((4-(trifluoromethoxy)phenyl)amino)carbonyl)amino)methyl)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><p id="p0189" num="0189">The title compound was prepared by substituting EXAMPLE 54B and 1-isocyanato-4-trifluoromethoxybenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.95 Hz, 2H) 6.72 (t, J=5.95 Hz, 1H) 7.08 (d, J=7.93 Hz, 1H) 7.22 (d, J=8.33 Hz, 2H) 7.34 (t, J=7.73 Hz, 1H) 7.40 (d, J=7.93 Hz, 1H) 7.42-7.47 (m, 1H) 7.48-7.55 (m, 3H) 7.66 (d, J=9.12 Hz, 1H) 7.76 (s, 1H) 8.81 (s, 1H) 10.64 (s, 1H).</p><heading id="h0139">EXAMPLE 57</heading><heading id="h0140">3-amino-N-(3-(((((3-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><!-- EPO <DP n="63"> --><p id="p0190" num="0190">The title compound was prepared by substituting EXAMPLE 54B and 1-isocyanato-3-methylbenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.24 (s, 3H) 4.31 (d, J=5.76 Hz, 2H) 6.62 (t, J=5.93 Hz, 1H) 6.71 (d, J=6.78 Hz, 1H) 7.05-7.13 (m, 2H) 7.15-7.22 (m, 1H) 7.25 (s, 1H) 7.34 (t, J=7.80 Hz, 1H) 7.38-7.46 (m, 1H) 7.47-7.52 (m, 1H) 7.57 (d, J=8.48 Hz, 1H) 7.67 (d, J=8.81 Hz, 1H) 7.75 (s, 1H) 8.48 (s, 1H) 10.67 (s, 1H).</p><heading id="h0141">EXAMPLE 58</heading><heading id="h0142">3-amino-N-(3-(((((4-(trinuoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><p id="p0191" num="0191">The title compound was prepared by substituting EXAMPLE 54B and 1-isocyanato-4-trifluoromethylbenzene for EXAMPLE 5B and 1-isocyanato-4-methyibenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.34 (d, J=5.95 Hz, 2H) 6.82 (t, J=5.95 Hz, 1H) 7.09 (d, J=7.54 Hz, 1H) 7.34 (t, J=7.73 Hz, 1H) 7.38-7.45 (m, 1H) 7.46-7.52 (m, 1H) 7.53-7.70 (m, 6H) 7.76 (s, 1H) 9.04 (s, 1H) 10.66 (s, 1H).</p><heading id="h0143">EXAMPLE 59</heading><heading id="h0144">3-amino-N-(3-(((((3-(trifluoromethyl)phenyl)ammo)carbonyl)ammo)methyl)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><p id="p0192" num="0192">The title compound was prepared by substituting EXAMPLE 54B and 1-isocyanato-3-trifluoromethylbenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.33 (d, J=5.55 Hz, 2H) 6.81 (t, J=5.95 Hz, 1H) 7.09 (d, J=7.93 Hz, 1H) 7.23 (d, J-7.54 Hz, 1H) 7.31-7.35 (m, 1H) 7.36-7.59 (m, 5H) 7.68 (d, J=9.12 Hz, 1H) 7.75 (s, 1H) 8.00 (s, 1H) 8.99 (s, 1H) 10.66 (s, 1H)</p><heading id="h0145">EXAMPLE 60</heading><heading id="h0146">3-ammo-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)metbyl)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><p id="p0193" num="0193">The title compound was prepared by substituting EXAMPLE 54B and 1-fluoro-3-isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.95 Hz, 2H) 6.65-6.77 (m, 2H) 7.02-7.11 (m, 2H) 7.19-7.29 (m, 1H) 7.34 (1, J=7.93 Hz, 1H) 7.38-7.52 (m, 3H) 7.57 (d, J=8.33 Hz, 1H) 7.67 (d, J=7.93 Hz, 1H) 7.75 (s, 1H) 8.84 (s, 1H) 10.66 (s, 1H).</p><heading id="h0147">EXAMPLE 61</heading><heading id="h0148">3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><!-- EPO <DP n="64"> --><p id="p0194" num="0194">The title compound was prepared by substituting EXAMPLE 54B and isocyanatobenzene for EXAMPLE 1B and 1-fluoro-3-isocyanatobenzene, respectively, in EXAMPLE 23A and EXAMPLE 23B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 5.35 (s, 2H) 6.96 (t, J=7.29 Hz, 1H) 7.24-7.37 (m, 4H) 7.42-7.49 (m, 5H) 7.70 (d, J=8.82 Hz, 2H) 8.62 (s, 1H) 8.64 (s, 1H) 10.51 (s, 1H) 11.81 (s, 1H).</p><heading id="h0149">EXAMPLE 62</heading><heading id="h0150">3-amino-N-(4-((((3-fluoropbenyl)amino)carbonyl)ammo)phenyl)-<sup>1</sup>H-indazole-4-carboxamide</heading><p id="p0195" num="0195">The title compound was prepared by substituting EXAMPLE 54B for EXAMPLE 1B in EXAMPLE 23B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 5.35 (s, 2H) 6.73-6.82 (m, 1H) 7.12 (d, J=9.16 Hz, 1H) 7.25-7.39 (m, 3H) 7.42-7.53 (m, 4H) 7.71 (d, J=9.16 Hz, 2H) 8.72 (s, 1H) 8.86 (s, 1H) 10.52 (s, 1H) 11.82 (s, 1H).</p><heading id="h0151">EXAMPLE 63</heading><heading id="h0152">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0153">EXAMPLE 63A</heading><p id="p0196" num="0196">A mixture of 2-fluoro-3-hydroxy-6-iodobenzonitrile (650 mg), (prepared as described in J. Med. Chem 2007, 50,1584), 3-iodopropan-1-ol (26 µL) and Cs<sub>2</sub>CO<sub>3</sub> (886 mg) in DMF (10 mL) at 60 °C was stirred for 4 hours, cooled to room temperature, poured into water and extracted with ethyl acetate. The extract was dried, filtered and concentrated, and the concentrate was flash chromatographed on silica gel with 0-4% medianot/dichlaromedme. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 1.77-1.95 (m, 2H) 3.54 (q, J=6.10 Hz, 2H) 4.17 (t, J=6.44 Hz, 2H) 4.59 (t, J=5.26 Hz, 1H) 7.37 (t, J=8.81 Hz, 1H) 7.77 (dd, J=8.81, 1.36 Hz, 1H).</p><heading id="h0154">EXAMPLE 63B</heading><p id="p0197" num="0197">A mixture of N-hydroxyacetamide (421 mg) and potassium tert-butoxide (0.63 g) in DMF (15 mL) at room temperature was stirred for 30 minutes, treated with EXAMPLE 63A (0.6 g), stirred overnight, diluted with water and extracted with ethyl acetate. The extract was dried, filtered and concentrated, and the concentrate was flash chromatographed on silica gel with 0-5% metbanol/ dichloromethane.</p><heading id="h0155">EXAMPLE 63C</heading><p id="p0198" num="0198">The title compound was prepared by substituting EXAMPLE 63B for EXAMPLE 1A in EXAMPLE 1B.</p><heading id="h0156">EXAMPLE 63 D</heading><!-- EPO <DP n="65"> --><heading id="h0157">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0199" num="0199">The title compound was prepared by substituting EXAMPLE 63C for EXAMPLE 1 B in EXAMPLE 1D. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 1.77-2.09 (m, 2H) 3.60 (q, J=5.73 Hz, 2H) 4.31 (t, J=5.37 Hz, 4H) 6.43 (s, 2H) 6.58-6.82 (m, 2H) 6.96-7.14 (m, 2H) 7.14-7.38 (m, 3H) 7.38-7.54 (m, 1H) 7.56-7.84 (m, 3H) 8.81 (s, 1H) 10.59 (s, 1H).</p><heading id="h0158">EXAMPLE 64</heading><heading id="h0159">3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0200" num="0200">The title compound was prepared by substituting isocyanatobenzene for I -fluoro-3-isocyanatobenzene and EXAMPLE 63C for EXAMPLE 1B in EXAMPLE 1C and EXAMPLE 1D, respectively. <sup>1</sup>HNMR (400 MHz, DMSO-d<sub>6</sub>) δ 1.77-2.03 (m, 2H) 3.47-3.68 (m, 2H) 4.20-4.40 (m, 4H) 4.60 (t, J=5.06 Hz, 1H) 6.44 (s, 2H) 6.61 (t, J=5.98 Hz, 1H) 6.89 (t, J=7.36 Hz, 1H) 7.09 (d, J=7.67 Hz, 1H) 7.16-7.28 (m, 3H) 7.28-7.48 (m, 3H) 7.57-7.91 (m, 3H) 8.54 (s, 1H) 10.59 (s, 1H).</p><heading id="h0160">EXAMPLE 65</heading><heading id="h0161">3-amino-N-(3-(1-((((3-fluorophenyl)amino)carbonyl)amino)ethyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0201" num="0201">The title compound was prepared by substituting tert-butyl 3-(1-aminoethyl)phenylcarbamate and 1-fluoro-3-isocyanatobenzene for tert-butyl 3-aminobenzylcarbamate and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLES 5A-C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 1.40 (1H) 1.42 (d, J=6.74 Hz, 3H) 2.08 (none, 1H) 4.81 (q, J=7.14 Hz, 1H) 6.32 (s, 2H) 6.58-6.78 (m, 2H) 6.99 (d, J=8.33 Hz, 1H) 7.11-7.29 (m, 2H) 7.31-7.49 (m, 2H) 7.56-7.89 (m, 5H) 8.63 (s, 1H) 10.78 (s, 1H).</p><heading id="h0162">EXAMPLE 66</heading><heading id="h0163">3-amino-N-(4-((anilinocarbonyl)amino)benzyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0202" num="0202">The title compound was prepared by substituting 1-(4-(aminomethyl)phenyl)-3-phenylurea for EXAMPLE 1C in EXAMPLE 1D. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) δ 4.51 (d, J=6.10 Hz, 2H) 6.22-6.75 (m, 2H) 6.96 (t, J=7.48 Hz, 2H) 7.15-7.33 (m, 3H) 7.32-7.54 (m, 4H) 7.54-7.77 (m, 3H) 8.62 (s, 1H) 8.70 (s, 1H) 9.55 (t, J=5.95 Hz, 1H).</p><heading id="h0164">EXAMPLE 67</heading><heading id="h0165">3-amino-N-(3-(((anilinocarbonyl)anino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><!-- EPO <DP n="66"> --><p id="p0203" num="0203">The title compound was prepared by substituting EXAMPLE 54B and isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.55 Hz, 2H) 6.63 (t, J=5.95 Hz, 1H) 6.89 (t, J=7.34 Hz, 1H) 7.08 (d, J=7.93 Hz, 1H) 7.17-7.27 (m, 2H) 7.29-7.48 (m, 5H) 7.53 (d, J=8.33 Hz, 1H) 7.67 (d, J=7.93 Hz, 1H) 7.76 (s, 1H) 8.56 (s, 1H) 10.65 (s, 1H).</p><heading id="h0166">EXAMPLE 68</heading><heading id="h0167">3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0204" num="0204">The title compound was prepared by substituting EXAMPLE 54B and 1-chloro-isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.76 Hz, 2H) 6.69 (t, J=5.76 Hz, 1H) 7.08 (d, J=7.80 Hz, 1H) 7.22-7.29 (m, 2H) 7.34 (t, J=7.97 Hz, 1H) 7.37-7.51 (m, 4H) 7.56 (d, J=8.14 Hz, 1H) 7.67 (d, J=7.80 Hz, 1H) 7.75 (s. 1H) 8.73 (s, 1H) 10.65 (s, 1H).</p><heading id="h0168">EXAMPLE 69</heading><heading id="h0169">3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyi)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0205" num="0205">The title compound was prepared by substituting EXAMPLE 54B and 1-chloro-3-fluoro-4-isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.34 (d, J=5.95 Hz, 2H) 7.05-7.21 (m, 3H) 7.32-7.48 (m, 3H) 7.49-7.55 (m, 1H) 7.59 (d, J=7.93 Hz, 1H) 7.68 (d, J=9.12 Hz, 1H) 7.75 (s, 2H) 8.18 (t, J=8.92 Hz, 1H) 8.52 (d, J=2.38 Hz, 1H) 10.68 (s, 1H).</p><heading id="h0170">EXAMPLE 70</heading><heading id="h0171">3-amino-N-(3-(((((3-fluoro-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)1H-indazole-4-carboxamide</heading><p id="p0206" num="0206">The title compound was prepared by substituting EXAMPLE 54B and 2-fluoro-4-isocyanato-1-methylbenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.13 (d, J=1.36 Hz, 3H) 4.31 (d, J=5.76 Hz, 2H) 6.67 (t, J=5.93 Hz, 1H) 6.95 (dd, J=8.14, 2.03 Hz, 1H) 7.09 (t, J=8.65 Hz, 2H) 7.30-7.45 (m, 4H) 7.52 (d, J=8.14 Hz, 1H) 7.66 (d, J=8.14 Hz, 1H) 7.75 (s, 1H) 8.68 (s, 1H) 10.63 (s, 1H).</p><heading id="h0172">EXAMPLE 71</heading><!-- EPO <DP n="67"> --><heading id="h0173">3-amino-N-(3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0207" num="0207">The title compound was prepared by substituting EXAMPLE 54B and 1-fluoro-2-isocyanato-4-methylbenzene for EXAMPLE 5B and 1-isocyanato-4-methytbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.23 (s, 3H) 4.33 (d, J=5.76 Hz, 2H) 6.67-6.76 (m, 1H) 6.99-7.14 (m, 3H) 7.35 (t, J=7.80 Hz, 1H) 7.39-7.47 (m, 1H) 7.48-7.53 (m, 1H) 7.57 (d, J=8.48 Hz, 1H) 7.68 (d, J=7.80 Hz, 1H) 7.75 (s, 1H) 7.98 (dd, J=7.80,2.03 Hz, 1H) 8.31 (d, J=2.71 Hz, 1H) 10.67 (s, 1H).</p><heading id="h0174">EXAMPLE 72</heading><heading id="h0175">3-amino-N-(3-(((((2-fluoro-5-(trifluommethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1 H-indazole-4-carboxamide</heading><p id="p0208" num="0208">The title compound was prepared by substituting EXAMPLE 54B and 1-fluoro-2-isocyanato-4-(trifluoromethyl)benzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.35 (d, J=5.76 Hz, 2H) 7.09 (d, J-7.46 Hz, 1H) 7.24 (t, J=5.93 Hz, 1H) 7.27-7.53 (m, 6H) 7.69 (d, J=8.14 Hz, 1H) 7.77 (s, 1H) 8.63 (dd, J=7.46,2.03 Hz, 1H) 8.77 (d, J=2.71 Hz, 1H) 10.63 (s, 1H).</p><heading id="h0176">EXAMPLE 73</heading><heading id="h0177">3-amino-N-(3-(((((3,5-difluomphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0209" num="0209">The title compound was prepared by substituting EXAMPLE 54B and 1,3-difluoro-5-isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.76 Hz, 2H) 6.69 (tt, J=9.32, 2.37 Hz, 1H) 6.87 (t, J=5.93 Hz, 1H) 7.05-7.18 (m, 3H) 7.30-7.50 (m, 3H) 7.55 (d, J=7.80 Hz, 1H) 7.67 (d, J=9.15 Hz, 1H) 7.75 (s, 1H) 9.05 (s, 1H) 10.66 (s, 1H).</p><heading id="h0178">EXAMPLE 74</heading><heading id="h0179">3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0210" num="0210">The title compound was prepared by substituting EXAMPLE 54B and 1,2-difluoro-4-isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively, in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.31 (d, J=5.76 Hz, 2H) 6.75 (t, J=5.93 Hz, 1H) 7.01-7.10 (m, 2H) 7.22-7.50 (m, 4H) 7.55 (d, J=8.14 Hz, 1H) 7.60-7.70 (m, 2H) 7.75 (s, 1H) 8.84 (s, 1H) 10.65 (s, 1H).<!-- EPO <DP n="68"> --></p><heading id="h0180">EXAMPLE 75</heading><heading id="h0181">3-amino-N-(3-(((((3-fluoro-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0211" num="0211">The title compound was prepared by substituting 2-fluoro-4-isocyanato-1-methylbenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 2.13 (s, 3H) 4.31 (d, J=5.95 Hz, 2H) 6.32 (s, 2H) 6.67 (t, J=5.95 Hz, 1H) 6.95 (dd, J=8.33, 1.98 Hz, 1H) 7.00-7.21 (m, 2H) 7.25-7.50 (m, 2H) 7.54-7.87 (m, 5H) 8.68 (s, 1H) 10.78 (s, 1H).</p><heading id="h0182">EXAMPLE 76</heading><heading id="h0183">3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0212" num="0212">The title compound was prepared by substituting 1-chloro-4-isocyanatobenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) 8 4.32 (d, J=5.76 Hz, 2H) 6.31 (s, 2H) 6.69 (t, J-5.93 Hz, 1H) 7.11 (d, J=7.80 Hz, 1H) 7.21-7.53 (m, 5H) 7.57-7.89 (m, 5H) 8.72 (s, 1H) 10.78 (s, 1H).</p><heading id="h0184">EXAMPLE 77</heading><heading id="h0185">3-amino-N-(3-(((((3-bromophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0213" num="0213">The title compound was prepared by substituting 1-bmmo-3-isocyanatobenzene for 1-isocyanato-4-methylbenzene in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) δ 4.32 (d, J=5.83 Hz, 2H) 6.33 (s, 2H) 6.74 (t, J=5.83 Hz, 1H) 6.96-7.45 (m, 5H) 7.55-7.79 (m, 5H) 7.84 (t, J=1.99 Hz, 1H) 8.79 (s, 1H) 10.77 (s, 1H).</p><heading id="h0186">EXAMPLE 78</heading><heading id="h0187">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0188">EXAMPLE 78A</heading><heading id="h0189">3-amino-7-(2-morpholinoethoxy)benzo(d)isoxazole-4-carboxylic acid</heading><p id="p0214" num="0214">The title compound was prepared by substituting 4-iodo-7-(2-morpholinoethoxy)benzo(d)isoxazol-3-amine (J. Med. Chem. 2008, 1, 1231-1241) for EXAMPLE 1A in EXAMPLE 1B. MS(ESI(+)) m/e 308 (M+H)<sup>+</sup>.</p><heading id="h0190">EXAMPLE 78B</heading><!-- EPO <DP n="69"> --><heading id="h0191">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methy1)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0215" num="0215">The title compound was prepared by substituting EXAMPLE 78A for EXAMPLE 1B in EXAMPLE 1D. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.51 (s, 4 H) 2.79 (t, <i>J</i>=5.49 Hz, 2 H) 3.54 - 3.63 (m, 4 H) 4.32 (d, <i>J</i>=5.80 Hz, 2 H) 4.36 (t, <i>J</i>=5.49 Hz, 2 H) 6.45 (s, 2H) 6.64 - 6.77 (m, 2 H) 7.05 (d, <i>J</i>=8.24 Hz, 1 H) 7.09 (d, <i>J</i>=7.32 Hz, 1H) 7.20 - 7.28 (m, 2 H) 7.34 (t, <i>J</i>=7.78 Hz, 1H) 7.47 (d, <i>J</i>=12.51 Hz, 1H) 7.63 (d, <i>J</i>=7.93 Hz, 1 H) 7.70 (s, 1 H) 7.75 (d, <i>J</i>=8.24 Hz, 1H) 8.84 (s, 1H) 10.62 (s, 1H). MS(ESI(+)) m/e 549(M+H)<sup>+</sup></p><heading id="h0192">EXAMPLE 79</heading><heading id="h0193">3-amino-N-(3-(((anitinocarbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ytethoxy)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0216" num="0216">The title compound was prepared by substituting isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 78A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.51 (d, <i>J</i>=1.53 Hz, 4 H) 2.79 (t, <i>J</i>=5.49 Hz, 2 H) 3.51- 3.63 (m, 4 H) 4.32 (d, <i>J</i>=5.80 Hz, 2 H) 4.37 (t, <i>J</i>=5.65 Hz, 2 H) 6.46 (s, 2 H) 6.63 (t, <i>J</i>=5.95 Hz, 1H) 6.89 (t, <i>J</i>=7.32 Hz, I H) 7.09 (d, <i>J</i>=7.63 Hz, 1H) 7.17 - 7.27 (m, 3 H) 7.34 (t, <i>J</i>=7.93 Hz, 1 H) 7.41 (d, <i>J</i>=7.63 Hz, 2 H) 7.63 (d, <i>J</i>=7.93 Hz, 1H) 7.71 (s, 1 H) 7.76 (d, <i>J</i>=8.24 Hz, 1H) 8.56 (s, 1 H) 10.62 (s, 1H). MS(ESI(+)) m/e 531(M+H)<sup>+</sup>.</p><heading id="h0194">EXAMPLE 80</heading><heading id="h0195">3-amino-7-(2-morpholin-4-ylethoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0217" num="0217">The title compound was prepared by substituting 1-isocyaaato-4-(trifluoromethyl)benzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 78A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.50 (s, 4 H) 2.79 (s, 2 H) 3.59 (s, 4 H) 4.29 - 4.43 (m, 4 H) 6.46 (s, 2 H) 6.82 (t, <i>J</i>=5.65 Hz, 1H) 7.10 (d, <i>J</i>=7.32 Hz, 1H) 7.26 (d, <i>J</i>=8.24 Hz, 1 H) 7.34 (t, <i>J</i>=7.78 Hz, 1H) 7.51 - 7.66 (m, 5 H) 7.72 (s, 1H) 7.76 (d, <i>J</i>=8.24 Hz, 1 H) 9.04 (s, 1 H) 10.62 (s, 1 H). MS(ESI(+)) m/e 599(M+H)<sup>+</sup>.</p><heading id="h0196">EXAMPLE 81</heading><heading id="h0197">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazote-4-carboxamide</heading><!-- EPO <DP n="70"> --><heading id="h0198">EXAMPLE 81A</heading><heading id="h0199">3-amino-7-methoxybenzo(d)isoxazole-4-carboxylic acid</heading><p id="p0218" num="0218">The title compound was prepared by substituting 4-iodo-7-methoxybenzo(d)isoxazol-3-amine (<nplcit id="ncit0059" npl-type="s"><text>J. Med. Chem. 2008, 51, 1231-1241</text></nplcit>) for EXAMPLE 1A in EXAMPLE 1B. MS(ESI(+)) m/e 209 (M+H)<sup>+</sup>.</p><heading id="h0200">EXAMPLE 81B</heading><heading id="h0201">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0219" num="0219">The title compound was prepared by substituting EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1D. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) □ ppm 4.02 (s, 3 H) 4.32 (d, <i>J</i>=6.14 Hz, 2 H) 6.43 (s, 2 H) 6.62 - 6.78 (m, 2 H) 7.07 (dd, <i>J</i>=16.11,8.44 Hz, 2 H) 7.18 - 7.27 (m, 2 H) 7.34 (t, <i>J</i>=7.83 Hz, 1 H) 7.42 - 7.51 (m, 1 H) 7.63 (d, <i>J</i>=8.29 Hz, 1 H) 7.70 (s, 1 H) 7.77 (d, <i>J</i>=8.29 Hz, 1 H) 8.82 (s, 1 H) 10.60 (s, 1 H). MS(ESI(+)) m/e 450(M+H)<sup>+</sup>.</p><heading id="h0202">EXAMPLE 82</heading><heading id="h0203">3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0220" num="0220">The title compound was prepared by substituting isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 4.01 (s, 3 H) 4.32 (d, <i>J</i>=5.80 Hz, 2 H) 6.29 - 6.57 (m, 2 H) 6.63 (t, <i>J</i>=5.95 Hz, 1 H) 6.89 (t, <i>J</i>=7.32 Hz, 1 H) 7.09 (d, <i>J</i>=7.63 Hz, 1 H) 7.22 (t, <i>J</i>=7.78 Hz, 3 H) 7.34 (t, <i>J</i>=7.78 Hz, 1 H) 7.41 (d, <i>J</i>=7.63 Hz, 2 H) 7.63 (d, J=7.93 Hz, 1 H) 7.71 (s, 1 H) 7.77 (d, <i>J</i>=8.24 Hz, 1 H) 8.56 (s, 1 H) 10.62 (s, 1 H). MS(ESI(+)) m/e 432(M+H)<sup>+</sup>.</p><heading id="h0204">EXAMPLE 83</heading><heading id="h0205">3-amino-7-methoxy-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0221" num="0221">The title compound was prepared by substituting 1-isocyanato-4-(trifluoromethyl)benzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 4.01 (s, 3 H) 4.34 (d, <i>J</i>=5.80 Hz, 2 H) 6.30 - 6.60 (m, 2 H) 6.82 (t, <i>J</i>=5.95 Hz, 1 H) 7.10 (d, <i>J</i>=7.93 Hz, 1 H) 7.23 (d, <i>J</i>=8.24 Hz, 1 H) 7.34 (t, <i>J</i>=7.78 Hz, 1 H) 7.52 - 7.67 (m, 5 H)<!-- EPO <DP n="71"> --> 7.72 (s, 1 H) 7.77 (d, J=8.24 Hz, 1 H) 9.04 (s, 1 H) 10.63 (s, 1 H). MS(ESI(+)) m/c 500 (M+H)<sup>+</sup>.</p><heading id="h0206">EXAMPLE 84</heading><heading id="h0207">3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0222" num="0222">The title compound was prepared by substituting 4-chloro-2-fluoro-1-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene in EXAMPLES 1C -1D. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) D ppm 4.34 (d, <i>J</i>=5.76 Hz, 2 H) 6.31 (s, 2 H) 6.99 - 7.25 (m, 3 H) 7.28 - 7.50 (m, 2 H) 7.56 - 7.84 (m, 5 H) 8.17 (t, <i>J</i>=8.82 Hz, 1 H) 8.51 (d, <i>J</i>=2.7 Hz, 1 H) 10.78 (s, 1 H). MS(ESI(+)) m/e 454 (M+H)<sup>+</sup>.</p><heading id="h0208">EXAMPLE 85</heading><heading id="h0209">3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methy)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0223" num="0223">The title compound was prepared by substituting 4-chloro-2-fluoro-1-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) C ppm 4.02 (s, 3 H) 4.33 (d, <i>J</i>=5.55 Hz, 2 H) 6.45 (s, 2 H) 7.01 - 7.26 (m, 4 H) 7.29 - 7.46 (m, 2 H) 7.64 (d, <i>J</i>-8.33 Hz, 1 H) 7.71 (s, 1 H) 7.77 (d, <i>J</i>=8.33 Hz, 1 H) 8.18 (t, <i>J</i>=8.92 Hz, 1 H) 8.51 (d, <i>J</i>=2.38 Hz, 1 H) 10.62 (s, 1 H)<br/>
MS(ESI(+)) m/e 484 (M+H)<sup>+</sup>.</p><heading id="h0210">EXAMPLE 86</heading><heading id="h0211">3-amino-7-(3-hydroxypropoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0224" num="0224">The title compound was prepared by substituting 1-isocyanato-4-(trifluoromethyl)benzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 63C for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR(500 MHz, DMSO-d<sub>6</sub>) □ ppm 1.76 - 2.06 (m, 2 H) 3.60 (t, <i>J</i>=6.10 Hz, 2 H) 4.22 - 4.40 (m, 4 H) 4.59 (s, 1 H) 6.45 (s, 2 H) 6.80 (t, <i>J</i>=5.93 Hz, 1 H) 7.03 - 7.14 (m, 1 H) 7.23 (d, <i>J</i>=8.48 Hz, 1 H) 7.34 (t, <i>J</i>=7.80 Hz, 1 H) 7.52 - 7.68 (m, 5 H) 7.68 - 7.83 (m, 2 H) 9.02 (s, 1 H) 10.60 (s, 1 H). MS(ESI(+)) m/e 544 (M+H)<sup>+</sup>.</p><heading id="h0212">EXAMPLE 87</heading><!-- EPO <DP n="72"> --><heading id="h0213">3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-metboxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0225" num="0225">The title compound was prepared by substituting 1,2-difluoro-4-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 4.02 (s, 3 H) 4.31 (d, <i>J</i>=5.76 Hz, 2 H) 6.44 (s, 2 H) 6.74 (t, <i>J</i>=5.93 Hz, 1 H) 6.96 - 7.14 (m, 2 H) 7.17 - 7.41 (m, 3 H) 7.55 - 7.72 (m, 3 H) 7.77 (d, <i>J</i>=8.14 Hz, 1 H) 8.82 (s, 1 H) 10.60 (s, 1 H). MS(ESI(+)) mle 468 (M+H)<sup>+</sup>.</p><heading id="h0214">EXAMPLE 88</heading><heading id="h0215">3-amino-N-(3 -((((pyndin-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0226" num="0226">The title compound was prepared by substituting 3-isocyanatopyridine for 1-fluoro-3-isocyanatobenzene in EXAMPLES 1C -1D. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 4.34 (d, <i>J</i>=5.76 Hz, 2 H) 6.32 (s, 2 H) 6.88 (t, <i>J</i>=5.93 Hz, 1 H) 7.12 (d, <i>J</i>=7.12 Hz, 1 H) 7.27 - 7.45 (m, 2 H) 7.55 - 7.84 (m, 5 H) 7.97 (d, <i>J</i>=9.16 Hz, 1 H) 8.17 (d. <i>J</i>=4.07 Hz, 1 H) 8.64 (s, 1 H) 8.91 (s, 1 H) 10.78 (s, 1 H). MS(ESI(+)) m/e 403 (M+H)<sup>+</sup>.</p><heading id="h0216">EXAMPLE 89</heading><heading id="h0217">3-amino-7-methoxy-N-(3-((((pyridin-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0227" num="0227">The title compound was prepared by substituting 3-isocyanatopyridine for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 4.01 (s, 3 H) 4.34 (d, <i>J</i>=5.76 Hz, 2 H) 6.44 (s, 2 H) 6.88 (t, <i>J</i>=5.76 H, 1 H) 7.10 (d, <i>J</i>=7.46 Hz, 1 H) 7.22 (d, <i>J</i>=8.14 Hz, 1 H) 7.28 - 7.44 (m, 2 H) 7.62 (d, <i>J</i>=8.14 Hz, 1 H) 7.67 - 7.82 (m, 2 H) 7.97 (d, <i>J</i>=8.82 Hz, 1 H) 8.18 (d, <i>J</i>=4.07 Hz, 1 H) 8.66 (s, 1 H) 8.92 (s, 1 H) 10.61 (s, I H). MS(ESI(+)) m/e 433 (M+H)<sup>+</sup>.</p><heading id="h0218">EXAMPLE 90</heading><heading id="h0219">3-amino-N-(3-(((((4-chiorophenyl)amino)carbonyl)amino)methyl)phenyl)7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0228" num="0228">The title compound was prepared by substituting 1-chloro-4-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 78A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 3.64 (d, <i>J</i>=15.47 Hz, 10 H) 4.32 (d, <i>J</i>=5.95 Hz, 2 H) 4.62 (s, 2 H) 6.48 (s, 2 H) 6.75 (t, <i>J</i>=6.15 Hz, 1 H) 7.09 (d, <i>J</i>=7.54 Hz, 1 H)<!-- EPO <DP n="73"> --> 7.21 - 7.49 (m, 6 H) 7.64 (d, J=7.93 Hz, 1 H) 7.69 (s, 1 H) 7.80 (d, <i>J</i>=8.33 Hz, 1 H) 8.78 (s, I H) 10.64 (s, 1 H). MS(ESI(+)) m/e 565(M+H)<sup>+</sup>.</p><heading id="h0220">EXAMPLE 91</heading><heading id="h0221">3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-7-(2-morpholin-4-ytethoxy)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0229" num="0229">The title compound was prepared by substituting 1-(4-aminophenyl)-3-phenylurea for EXAMPLE 1C and EXAMPLE 78A for EXAMPLE 1B in EXAMPLE 1D. <sup>1</sup>H NMR (500 MHz, DMS4-d<sub>6</sub>) □ ppm 3.46 - 4.21 (m, 10 H) 4.62 (s, 2 H) 6.52 (s, 2 H) 6.97 (t, <i>J</i>=7.29 Hz, 1 H) 7.21 - 7.36 (m, 3 H) 7.40 - 7.53 (m, 4 H) 7.65 (d, <i>J</i>=9.16 Hz, 2 H) 7.80 (d, <i>J</i>=8.14 Hz, 1 H) 8.68 (s, 1 H) 8.71 (s, 1 H) 10.53 (s, 1 H)MS(ESI(+)) m/e 517(M+H)<sup>+</sup>.</p><heading id="h0222">EXAMPLE 92</heading><heading id="h0223">3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0224">EXAMPLE 92A</heading><heading id="h0225">3-amino-7-(2-(4-methylpiperazin-1-yl)ethoxy)benzo(d)isoxazole-4-carboxylic acid</heading><p id="p0230" num="0230">The title compound was prepared by substituting 4-iodo-7-(2-(4-methylpiperazin-1-yl)ethoxy)benzo(d)isoxazol-3-amine (<nplcit id="ncit0060" npl-type="s"><text>J. Med. Chem. 2008, 51, 1231-1241</text></nplcit>) for EXAMPLE 1A in EXAMPLE 1B. MS(ESI(+)) m/e 321 (M+H)<sup>+</sup>.</p><heading id="h0226">EXAMPLE 92B</heading><heading id="h0227">3-amino-N-(3-(((((4-cMorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazole-4-arboxamide</heading><p id="p0231" num="0231">The title compound was prepared by substituting 1-chloro-4-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 92A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.65 (s, 3 H) 2.69 - 3.15 (m, 10 H) 4.31 (d, <i>J</i>=5.95 Hz, 2 H) 4.37 (t, <i>J</i>=5.16 Hz, 2 H) 6.46 (s, 2 H) 6.70 (t, <i>J</i>=5.95 Hz, 1 H) 7.09 (d, <i>J</i>=7.54 Hz, 1 H) 7.19 - 7.48 (m, 6 H) 7.63 (d, <i>J</i>=7.93 Hz, 1 H) 7.69 (s, 1 H) 7.76 (d, <i>J</i>=8.33 Hz, 1 H) 8.74 (s, 1 H) 10.60 (s, 1 H). MS(ESI(+)) m/e 578 (M+H)<sup>+</sup>.</p><heading id="h0228">EXAMPLE 93</heading><heading id="h0229">3-amino-7-(2-(4-methylpiperazin-1-yl)ethoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)mino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><!-- EPO <DP n="74"> --><p id="p0232" num="0232">The title compound was prepared by substituting 1-isocyanato-4-(trifluoromethyl)benzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 92A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.77 (s, 3 H) 2.83 - 3.24 (m, 10 H) 4.33 (d, <i>J</i>=5.95 Hz, 2 H) 4.40 (s, 2 H) 6.46 (s, 2 H) 6.85 (t, <i>J</i>=5.95 Hz, 1 H) 7.10 (d, <i>J</i>=7.93 Hz, 1 H) 7.25 (d, <i>J</i>=8.33 Hz, 1 H) 7.34 (t, <i>J</i>=7.73 Hz, 1 H) 7.53 - 7.69 (m, 5 H) 7.71 (s, 1 H) 7.77 (d, <i>J</i>=8.33 Hz, 1 H) 9.10 (s, 1 H) 10.62 (s, 1 H). MS(ESI(+)) m/e 612 (M+H)<sup>+</sup>.</p><heading id="h0230">EXAMPLE 94</heading><heading id="h0231">3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0233" num="0233">The title compound was prepared by substituting 1-isocyanato-4-methylbenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 92A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.21 (s, 3 H) 2.66 (s, 3 H) 2.70 - 3.17 (m, 10 H) 4.30 (d, <i>J</i>=5.76 Hz, 2 H) 4.37 (t, <i>J</i>=5.09 Hz, 2 H) 6.46 (s, 2 H) 6.57 (t, <i>J</i>=5.93 Hz, 1 H) 6.97 - 7.14 (m, 3 H) 7.21 - 7.42 (m, 4 H) 7.63 (d, <i>J</i>=8.48 Hz, 1 H) 7.69 (s, 1 H) 7.77 (d, <i>J</i>=8.14 Hz, 1 H) 8.43 (s, 1 H) 10.60 (s, 1 H). MS(ESI(+)) m/e 558 (M+H)<sup>+</sup>.</p><heading id="h0232">EXAMPLE 95</heading><heading id="h0233">3-amino-N-(3-(((((2,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0234" num="0234">The title compound was prepared by substituting 2,4-difluoro-1-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 4.02 (s, 3 H) 4.33 (d, <i>J</i>=6.10 Hz, 2 H) 6.44 (s, 2 H) 6.92 - 7.12 (m, 3 H) 7.15 - 7.29 (m, 2 H) 7.34 (1, <i>J</i>=7.80 Hz, 1 H) 7.64 (d, <i>J</i>=8.14 Hz, 1 H) 7.71 (s, 1 H) 7.77 (d, <i>J</i>=8.48 Hz, 1 H) 7.94 - 8.17 (m, 1 H) 8.36 (d, <i>J</i>=2.03 Hz, 1 H) 10.61 (s, 1 H). MS(ESI(+)) m/e 468 (M+H)<sup>+</sup>.</p><heading id="h0234">EXAMPLE 96</heading><heading id="h0235">3-amino-N-(3-(((((4-chlomphenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0235" num="0235">The title compound was prepared by substituting 1-chloro-4-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 4.01 (s, 3 H) 4.31 (d, <i>J</i>=6.10 Hz, 2 H) 6.44 (s, 2 H) 6.68 (t, <i>J</i>=5.93 Hz, 1 H) 7.08 (d, <i>J</i>=7.46 Hz, 1 H) 7.17 - 7.38 (m, 4 H) 7.39-7.48<!-- EPO <DP n="75"> --> (m, 2 H) 7.63 (d. J<i>=</i>8.14 Hz, I H) 7.70 (s, 1 H) 7.77 (d, <i>J</i>=8.14 Hz, 1 H) 8.72 (s, 1 H) 10.60 (s, 1 H). MS(ESI(+)) m/e 433 (M+H)<sup>+</sup>.</p><heading id="h0236">EXAMPLE 97</heading><heading id="h0237">3-amino-7-methoxy-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole4-carboxamide</heading><p id="p0236" num="0236">The title compound was prepared by substituting 1-isocyanato-4-methylbenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81 A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.21 (s, 3 H) 4.01 (s, 3 H) 4.30 (d, <i>J</i>=5.76 Hz, 2 H) 6.44 (s, 1 H) 6.56 (t, <i>J=</i>5.93 Hz, 2 H) 6.99 - 7.12 (m, 3 H) 7.18 - 7.38 (m, 4 H) 7.63 (d, <i>J</i>=8.14 Hz, 1 H) 7.70 (s, I H) 7.77 (d, <i>J</i>=8.14 Hz, 1 H) 8.42 (s, 1 H) 10.61 (s, 1 H). MS(ESI(+)) m/e 433 (M+H)<sup>+</sup>.</p><heading id="h0238">EXAMPLE 98</heading><heading id="h0239">3-amino-N-(3-(((((2,5-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0237" num="0237">The title compound was prepared by substituting 1,4-difluoro-2-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.02 (s, 3 H) 4.34 (d, <i>J</i>=5.55 Hz, 2 H) 6.46 (s, 2 H) 6.60 - 6.84 (m, 1 H) 7.09 (d, <i>J</i>=7.54 Hz, 1 H) 7.16 - 7.28 (m, 3 H) 7.35 (t, <i>J</i>=7.93 Hz, 1 H) 7.65 (d, <i>J</i>=7.93 Hz, 1 H) 7.70 (s, 1 H) 7.78 (d, <i>J</i>=8.33 Hz, 1 H) 7.91 - 8.17 (m, I H) 8.65 (s, I H) 10.64 (s, I H). MS(ESI(+)) m/e 468 (M+H)<sup>+</sup>.</p><heading id="h0240">EXAMPLE 99</heading><heading id="h0241">3-amino-N-3-(((((4-(difluoromethoxy)phenyl)mino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0238" num="0238">The title compound was prepared by substituting 1-(difluoromethoxy)-4-isocyanatobenzene for 1-fluoro-3-isocyanatobenzene and EXAMPLE 81A for EXAMPLE 1B in EXAMPLE 1C and 1D, respectively. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 4.01 (s, 3 H) 4.31 (d, <i>J</i>=5.55 Hz, 2 H) 6.46 (s, 2 H) 6.66 (t, <i>J</i>=5.95 Hz, 1 H) 6.99 - 7.15 (m, 4 H) 7.23 (d, <i>J</i>=8.33 Hz, 1 H) 7.34 (t, <i>J</i>=7.73 Hz, 1 H) 7.44 (d, <i>J</i>=9.12 Hz, 2 H) 7.63 (d, <i>J</i>=7.93 Hz, 1 H) 7.71 (s, 1 H) 7.77 (d, <i>J</i>=8.33 Hz, 1 H) 8.67 (s, 1 H) 10.63 (s, 1 H). MS(ESI(+)) m/e 498 (M+H)<sup>+</sup>.</p><heading id="h0242">EXAMPLE 100</heading><!-- EPO <DP n="76"> --><heading id="h0243">3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0244">EXAMPLE 100A</heading><heading id="h0245">1-(3-fluorophenyl)-3-(2-methyt-4-nitrophenyl)urea</heading><p id="p0239" num="0239">The title compound was prepared by substituting 1-isocyanato-2-methyl-4-nitrobenzene and 3-fluoroaniline for 1-fluoro-3-isocyanatobenzene and 3-(aminomethyl)aniline in EXAMPLE 1C. MS(ESI(+)) m/e 290 (M+H)<sup>+</sup>.</p><heading id="h0246">EXAMPLE 100B</heading><heading id="h0247">1-(4-amino-2-methylphenyl)-3-(3-fluorophenyl)urea</heading><p id="p0240" num="0240">A solution of EXAMPLE 100A (1.28 g, 4.43 mmol) in 12 mL of N, N-dimethylformamide was degassed and hydrogenated under an atmosphere of hydrogen (balloon) in the presence of catalytic amount of 10% Pd on carbon for 24 hours. The mixture was filtered and the filtrate was extracted with ethyl acetate. The organic extract was washed with brine, dried with MgSO<sub>4</sub> and concentrated to provide EXAMPLE 100B. MS(ESI(+)) m/e 260 {M+H)<sup>+</sup>.</p><heading id="h0248">EXAMPLE 100C</heading><heading id="h0249">3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0241" num="0241">The title compound was prepared by substituting EXAMPLE 100B for EXAMPLE 1C in EXAMPLE 1D. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.27 (s, 3 H) 6.35 (s, 2 H) 6.62 - 6.89 (m, 1 H) 7.11 (d, <i>J</i>=8.14 Hz, 1 H) 7.22 - 7.41 (m, 1 H) 7.42 - 7.59 (m, 2 H) 7.59-7.84 (m, 5 H) 8.02 (s, 1 H) 9.18 (s, 1 H) 10.65 (s, 1 H). MS(ESI(+)) m/e 420 (M+H)<sup>+</sup>.</p><heading id="h0250">EXAMPLE 101</heading><heading id="h0251">3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide</heading><p id="p0242" num="0242">The title compound was prepared by substituting EXAMPLE 100B and EXAMPLE 81A for EXAMPLES 1C and 1B, respectively in EXAMPLE 1D. <sup>1</sup>H NMR (500 MHz, DMSO-d<sub>6</sub>) □ ppm 2.26 (s, 3 H) 4.02 (s, 3 H) 6.48 (s, 2 H) 6.64 - 6.87 (m, 1 H) 7.10 (d, <i>J</i>=9.12 Hz, 1 H) 7.17 - 7.39 (m, 2 H) 7.43 - 7.58 (m, 2 H) 7.61 (d, <i>J</i>=1.98 Hz, 1 H) 7.76 (dd, <i>J</i>=8.53, 6.15 Hz, 2 H) 8.00 (s, 1 H) 9.17 (s, 1 H) 10.48 (s, 1 H). MS(ESI(+)) m/e 450 (M+H)<sup>+</sup>.</p><heading id="h0252">EXAMPLE 102</heading><!-- EPO <DP n="77"> --><heading id="h0253">3-amino-N-(4-((((2-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0243" num="0243">The title compound was prepared by substituting 2-fluomaniline for 3-fluoroaniline in EXAMPLE 100A then following procedures of EXAMPLES 100B-C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.28 (s, 3 H) 6.36 (s, 2 H) 6.90 - 7.04 (m, 1 H) 7.14 (t, <i>J</i>=7.14 Hz, 1 H) 7.19 - 7.33 (m, 1 H) 7.46 - 7.87 (m, 6 H) 8.10 - 8.27 (m, 1 H) 8.38 (s, 1 H) 8.93 (d, <i>J</i>=2.38 Hz, 1 H) 10.65 (s, 1 H). MS(ESI(+)) m/e 420 (M+H)<sup>+</sup>.</p><heading id="h0254">EXAMPLE 103</heading><heading id="h0255">3-amino-N-(4-(((2-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-7-methoxy-1,2-benzisoxazole-4-carboxami de</heading><p id="p0244" num="0244">The title compound was prepared by substituting 2-fluoroaniline for 3-fluoroaniline in EXAMPLE 100A-B then coupling the product with EXAMPLE 81A as described in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.28 (s. 3 H) 4.02 (s, 3 H) 6.49 (s, 2 H) 6.91 - 7.05 (m, 1 H) 7.14 (t, <i>J</i>=7.63 Hz, 1 H) 7.18 - 7.33 (m, 2 H) 7.50 (dd, <i>J</i>=8.81, 2.37 Hz, 1 H) 7.60 (d, <i>J</i>=2.03 Hz, 1 H) 7.79 (dd, <i>J</i>=11.36, 8.65 Hz, 2 H) 8.07 - 8.29 (m, 1 H) 8.37 (s, 1 H) 8.92 (d, <i>J</i>=2.71 Hz, 1 H) 10.48 (s, 1 H). MS(ESI(+)) m/e 450 (M+H)<sup>+</sup>.</p><heading id="h0256">EXAMPLE 104</heading><heading id="h0257">3-amino-N-(3-methyl-4-((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0245" num="0245">The title compound was prepared by substituting 4-trifluomethylaniline for 3-fluoroaniline in EXAMPLE 100A then following procedures of EXAMPLES 100B-C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.28 (s, 3 H) 6.36 (d, <i>J</i>=1.59 Hz, 2 H) 7.38 - 7.88 (m, 10 H) 8.08 (s, 1 H) 9.37 (s, 1 H) 10.66 (s, 1 H). MS(ESI(+)) m/e 470 (M+H)<sup>+</sup>.</p><heading id="h0258">EXAMPLE 105</heading><heading id="h0259">3-amino-7-methoxy-N-(3-methyl-4-((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0246" num="0246">The title compound was prepared by substituting 4-trifluoromethylaniline for 3-fluoroaniline in EXAMPLE 100A-B then coupling the product with EXAMPLE 81A as described in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.27 (s, 3 H) 4.02 (s, 3 H) 6.48 (s, 2 H) 7.23 (d, <i>J</i>=8.33 Hz, 1 H) 7.45 - 7.91 (m, 8 H) 8.07 (s, 1 H) 9.36 (s, 1 H) 10.49 (s, 1 H). MS(ESI(+)) m/e 500(M+H)<sup>+</sup>.</p><heading id="h0260">EXAMPLE 106</heading><!-- EPO <DP n="78"> --><heading id="h0261">3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide</heading><heading id="h0262">EXAMPLE 106A</heading><heading id="h0263">3-amino-N-(3-(aminomethyl)-4-fluorophenyl)benzo(d)isoxazole-4-carboxamide</heading><p id="p0247" num="0247">The title compound was prepared following the procedures of EXAMPLE 5A and EXAMPLE 5B, substituting tert-butyl 5-amino-2-fluorobenzylcarbamate for tert-butyl 3-aminobenzylcarbamate in EXAMPLE 5A. MS(ESI(+)) m/e 301 (M+H)<sup>+</sup>.</p><heading id="h0264">EXAMPLE 106B</heading><p id="p0248" num="0248">The title compound was prepared by substituting 1-chloro4-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.36 (d, <i>J</i>=5.76 Hz, 2 H) 6.32 (s, 2 H) 6.71 (t, <i>J</i>=5.93 Hz, I H) 7.08 - 7.33 (m, 3 H) 7.34 - 7.48 (m, 2 H) 7.57 - 7.96 (m, 5 H) 8.79 (s, 1 H) 10.83 (s, 1 H). MS(ESI(+)) m/e 454(M+H)<sup>+</sup>.</p><heading id="h0265">EXAMPLE 107</heading><heading id="h0266">3-amino-N-(4-fluoro-3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0249" num="0249">The title compound was prepared by substituting EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.20 (s, 3 H) 4.35 (d, <i>J</i>=5.76 Hz, 2 H) 6.32 (s, 2 H) 6.59 (s, 1 H) 7.02 (d, <i>J</i>=8.14 Hz, 2 H) 7.12 - 7.37 (m, 3 H) 7.52 - 7.85 (m, 5 H) 8.49 (s, 1 H) 10.84 (s, 1 H). MS(ESI(+)) m/e 434(M+H)<sup>+</sup>.</p><heading id="h0267">EXAMPLE 108</heading><heading id="h0268">3-amino-N-(3-(((((4-(difluoromethoxy)phenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0250" num="0250">The title compound was prepared by substituting 1-(difluoromethoxy)-4-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.36 (d, <i>J</i>=5.76 Hz, 2 H) 6.32 (s, 2 H) 6.66 (t, <i>J</i>=6.10 Hz, 2 H) 6.99 - 7.12 (m, 2 H) 7.14 - 7.28 (m, 1 H) 7.37 - 7.51 (m, 2 H) 7.58 - 8.03 (m, 5 H) 8.71 (s, 1 H) 10.83 (s, 1 H). MS(ESI(+)) m/e 486(M+H)<sup>+</sup>.</p><heading id="h0269">EXAMPLE 109</heading><heading id="h0270">3-amino-N-(4-fluoro-3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><!-- EPO <DP n="79"> --><p id="p0251" num="0251">The title compound was prepared by substituting 1-fluoro-2-isocyanato-4-methylbenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.22 (s, 3 H) 4.37 (d, <i>J</i>=5.76 Hz, 2 H) 6.31 (s, 2 H) 6.59 - 6.79 (m, 1 H) 6.92 - 7.37 (m, 3 H) 7.57 - 7.86 (m, 5 H) 7.97 (dd, <i>J</i>=7.97, 1.86 Hz, 1 H) 8.36 (d, <i>J</i>=2.37 Hz, 1 H) 10.83 (s, 1 H). MS(ESI(+)) m/e 452(M+H)<sup>+</sup>.</p><heading id="h0271">EXAMPLE 110</heading><heading id="h0272">3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0252" num="0252">The title compound was prepared by substituting 4-chloro-2-fluoro-1-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.38 (d, <i>J</i>=5.55 Hz, 2 H) 6.32 (s, 2 H) 7.03 - 7.30 (m, 3 H) 7.40 (dd, <i>J</i>=11.10, 2.38 Hz, 1 H) 7.60 - 7.93 (m, 5 H) 8.16 (t, <i>J</i>=8.92 Hz, 1 H) 8.56 (d, <i>J</i>=2.78 Hz, 1 H) 10.83 (s, 1 H). MS(ESI(+)) m/e 472(M+H)<sup>+</sup>.</p><heading id="h0273">EXAMPLE 111</heading><heading id="h0274">3-amino-N-(4-fluoro-3-(((((4-(thfluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0253" num="0253">The title compound was prepared by substituting 1-isocyanato-4-(trifluoromethyl)benzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.40 (d, <i>J</i>=5.76 Hz, 2 H) 6.28 (s, 2 H) 6.77 (t, <i>J</i>=5.93 Hz, 1 H) 7.01 - 7.27 (m, 1 H) 7.37 - 7.91 (m, 9 H) 8.99 (s, 1 H) 10.77 (s, 1 H). MS(ESI(+)) m/e 488(M+H)<sup>+</sup>.</p><heading id="h0275">EXAMPLE 112</heading><heading id="h0276">3-amino-N-(3-(((anilinocarbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0254" num="0254">The title compound was prepared by substituting isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.36 (d, <i>J</i>=5.95 Hz, 2 H) 6.31 (s, 2 H) 6.65 (t, <i>J</i>=5.95 Hz, 1 H) 6.89 (t, <i>J</i>=7.34 Hz, 1 H) 7.12 - 7.33 (m, 3 H) 7.34 - 7.52 (m, 2 H) 7.59 - 7.86 (m, 5 H) 8.61 (s, 1 H) 10.83 (s, 1 H). MS(ESI(+)) m/e 420(M+H)<sup>+</sup>.</p><heading id="h0277">EXAMPLE 113</heading><heading id="h0278">3-amino-N-(4-fluoro-3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)henyl)-1,2-benzisoxazole-4-carboxamide</heading><!-- EPO <DP n="80"> --><p id="p0255" num="0255">The title compound was prepared by substituting 1-fluoro-4-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-(<sub>6</sub>) □ ppm 4.36 (d, <i>J</i>=5.76 Hz, 2 H) 6.31 (s, 2 H) 6.64 (t, <i>J</i>=5.93 Hz, 1 H) 6.95 - 7.95 (m, 10 H) 8.65 (s, 1 H) 10.82 (s, 1 H). MS(ESI(+)) m/e 438(M+H)<sup>+</sup>.</p><heading id="h0279">EXAMPLE 114</heading><heading id="h0280">3-amino-N-(4-fluoro-3-(((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0256" num="0256">The title compound was prepared by substituting 1-isocyanato-3-(trifluoromethyl)benzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.38 (d, <i>J</i>=5.95 Hz, 2 H) 6.31 (s, 2 H) 6.81 (t, <i>J</i>=5.95 Hz, 1 H) 7.02 - 7.36 (m, 2 H) 7.36 - 7.57 (m, 2 H) 7.59 - 7.89 (m, 5 H) 7.99 (s, 1 H) 9.04 (s, 1 H) 10.83 (s, 1 H) MS(ESI(+)) m/e 488(M+H)<sup>+</sup>.</p><heading id="h0281">EXAMPLE 115</heading><heading id="h0282">3-amino-N-(3-((((2,5-difluorophenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0257" num="0257">The title compound was prepared by substituting 2,4-difluoro-1-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 106A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.38 (d, <i>J</i>=5.95 Hz, 2 H) 6.31 (s, 2 H) 6.60 - 6.84 (m, 1 H) 7.14 - 7.38 (m, 3 H) 7.55 - 7.86 (m, 5 H) 7.90 - 8.16 (m, 1 H) 8.68 (s, I H) 10.83 (s, 1 H). MS(ESI(+)) m/e 456(M+H)<sup>+</sup>.</p><heading id="h0283">EXAMPLE 116</heading><heading id="h0284">3-amino-N-3-(((4-fluorobenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0258" num="0258">The title compound was prepared by substituting EXAMPLE 5B for EXAMPLE 1C and 4-fluorobenzoic acid for EXAMPLE 1B in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.50 (d, <i>J</i>=5.95 Hz, 2 H) 6.31 (s, 2 H) 7.13 (d, <i>J</i>=7.54 Hz, 1 H) 7.22 - 7.50 (m, 3 H) 7.56 - 7.83 (m, 5 H) 7.85 - 8.14 (m, 2 H) 9.11 (t, <i>J</i>=5.95 Hz, 1 H) 10.77 (s, 1 H) MS(ESI(+)) m/e 405 (M+H)<sup>+</sup>.</p><heading id="h0285">EXAMPLE 117</heading><heading id="h0286">3-amino-N-(3-(((3-fluorobenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0259" num="0259">The title compound was prepared by substituting EXAMPLE 5B for EXAMPLE 1C and 3-fluorobenzoic acid for EXAMPLE 1B in EXAMPLE 1D. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.51 (d, <i>J</i>=5.95 Hz, 2 H) 6.31 (s, 2 H) 7.13 (d, <i>J</i>=7.54 Hz, 1 H) 7.28 - 7.46 (m, 2<!-- EPO <DP n="81"> --> H) 7.47 - 7.62 (m, 1 H) 7.62 - 7.85 (m, 7 H) 9.18 (t, <i>J</i>=5.95 Hz, I H) 10.77 (s, I H). MS(ESI(+)) m/e 405 (M+H)<sup>+</sup>.</p><heading id="h0287">EXAMPLE 118</heading><heading id="h0288">3-amino-N-(3-(((anilinocarbonyl)amino)methyl)-4-methylphenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0260" num="0260">The title compound was prepared by substituting aniline for 3-fluoroaniline in EXAMPLE 100A then following procedures of EXAMPLES 100B-C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.49 (s, 3 H) 4.49 (d, <i>J</i>=5.55 Hz, 2 H) 6.52 (s, 2 H) 6.72 (t, <i>J</i>=5.75 Hz, 1 H) 7.08 (t, <i>J</i>=7.34 Hz, 1 H) 7.27 - 7.47 (m, 3 H) 7.59 (d, <i>J</i>=7.54 Hz, 2 H) 7.71 - 8.03 (m, 5 H) 8.71 (s, 1 H) 10.92 (s, 1 H). MS(ESI(+)) m/e 416 (M+H)<sup>+</sup>.</p><heading id="h0289">EXAMPLE 119</heading><heading id="h0290">3-amino-N-(3-(aminomethyl)phenyl)-1,2-benzisoxazole-4-carboxamide</heading><p id="p0261" num="0261">The title compound was prepared as described in EXAMPLE 5B. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.07 (q, <i>J</i>=5.76 Hz, 2 H) 6.33 (s, 2 H) 7.27 (d, <i>J</i>=8.14 Hz, 1 H) 7.46 (t, <i>J</i>=7.80 Hz, 1 H) 7.56 - 7.89 (m, 4 H) 8.03 (s, 1 H) 8.21 (s, 2 H) 10.91 (s, 1 H). MS(ESI(+)) m/e 283 (M+H)<sup>+</sup>.</p><heading id="h0291">EXAMPLE 120</heading><heading id="h0292">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><heading id="h0293">EXAMPLE 120A</heading><heading id="h0294">3-amino-N-(3-(aminomethyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><p id="p0262" num="0262">The title compound was prepared following the procedures of EXAMPLES 5A and EXAMPLE 5B, except substituting 4-iodo-1-methyl-1H-indazol-3-amine ((<nplcit id="ncit0061" npl-type="s"><text>J. Med. Chem. 2007,50,1584-1597</text></nplcit>) for EXAMPLE 1B in EXAMPLE 5A. MS(ESI(+)) m/e 296 (M+H)<sup>+</sup>.</p><heading id="h0295">EXAMPLE 120B</heading><heading id="h0296">3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><p id="p0263" num="0263">The title compound was prepared by substituting 1-fluoro-3-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ 3.80 (s, 3 H) 4.32 (d, <i>J</i>=5.95 Hz, 2 H) 5.38 (s, 2 H) 6.65 - 6.75 (m, 2 H) 7.06 (t, <i>J</i>=8.33 Hz, 2 H) 7.18 - 7.43 (m, 4 H) 7.47 (dt, <i>J</i>=1229, 2.38 Hz, 1 H)<!-- EPO <DP n="82"> --> 7.60 (dd, <i>J</i>=7.14, 2.38 Hz, 1 H) 7.65 (d, <i>J</i>=7.14 Hz, 1 H) 7.76 (s, 1 H) 8.82 (s, 1 H) 10.63 (s, 1 H); MS (ESI) m/z 433 (M+H)<sup>+</sup>.</p><heading id="h0297">EXAMPLE 121</heading><heading id="h0298">3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><p id="p0264" num="0264">The title compound was prepared by substituting 4-chloro-2-fluoro-1-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) n ppm 3.80 (s, 3 H) 4.33 (d, <i>J</i>=5.55 Hz, 2 H) 5.38 (s, 2 H) 7.01 - 7.23 (m, 3 H) 7.28 - 7.47 (m, 4 H) 7.56 - 7.82 (m, 3 H) 8.18 (t, <i>J</i>=8.92 Hz, 1 H) 8.51 (d, <i>J</i>=2.38 Hz, 1 H) 10.64 (s, 1 H); MS (ESI) m/z 467 (M+H)<sup>+</sup>.</p><heading id="h0299">EXAMPLE 122</heading><heading id="h0300">3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><p id="p0265" num="0265">The title compound was prepared by substituting 4-chloro-1-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 3.85 (s, 3 H) 4.31 (d, <i>J</i>=5.76 Hz, 2 H) 6.69 (t, <i>J</i>=6.10 Hz, 1 H) 7.08 (d, <i>J</i>=7.80 Hz, 1 H) 7.22 - 7.29 (m, 2 H) 7.33 (t, <i>J</i>=7.80 Hz, 1 H) 7.39 - 7.48 (m, 4 H) 7.66 (dd, <i>J</i>=7.12, 2.37 Hz, 2 H) 7.75 (s, 1 H) 8.73 (s, 1 H) 10.65 (s, 1 H); MS (ESI) m/z 449 (M+H)+.</p><heading id="h0301">EXAMPLE 123</heading><heading id="h0302">3-amino-N-(3-(((((3-fluoro4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><p id="p0266" num="0266">The title compound was prepared by substituting 2-fluoro-4-isocyanato-1-methylbenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.10 (d, <i>J</i>=16.28 Hz, 3 H) 3.82 (s, 3 H) 4.31 (d, <i>J</i>=5.76 Hz, 2 H) 6.66 (t, <i>J</i>=5.93 Hz, 1 H) 6.95 (dd, <i>J</i>=8.14,2.03 Hz, 1 H) 7.09 (t, <i>J</i>=8.82 Hz, 2 H) 7.26 - 7.45 (m, 4 H) 7.56 - 7.69 (m, 2 H) 7.75 (s, 1 H) 8.67 (s, 1 H) 10.64 (s, 1 H); MS (ESI) m/z 447 (M+H)<sup>+</sup>.</p><heading id="h0303">EXAMPLE 124</heading><heading id="h0304">3-amino-N-(3-(((((3-chloro-4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><!-- EPO <DP n="83"> --><p id="p0267" num="0267">The title compound was prepared by substituting 2-chloro-1-fluoro-4-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) n ppm 3.80 (s, 3 H) 4.31 (d, <i>J</i>=5.55 Hz, 2 H) 5.38 (s, 2 H) 6.76 (t, <i>J</i>=5.95 Hz, 1 H) 7.07 (d, <i>J</i>=7.93 Hz, 1 H) 7.21 - 7.43 (m, 5 H) 7.60 (dd, <i>J</i>=7.14, 1.98 Hz, 1 H) 7.65 (d, <i>J</i>=9.12 Hz, 1 H) 7.73 - 7.82 (m, 2 H) 8.81 (s, 1 H) 10.63 (s, 1 H). MS (ESI) m/z 467 (M+H)<sup>+</sup>.</p><heading id="h0305">EXAMPLE 125</heading><heading id="h0306">3-amino-1-methyl-N-(3-(((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0268" num="0268">The title compound was prepared by substituting 1-isocyanato-3-(trifluoromethyl)benzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 3.83 (s, 3 H) 4.33 (d, <i>J</i>=5.55 Hz, 2 H) 6.80 (t, <i>J</i>=5.95 Hz, 1 H) 7.09 (d, <i>J</i>=7.93 Hz, 1 H) 7.22 (d, <i>J</i>=7.54 Hz, 1 H) 7.30 - 7.56 (m, 5 H) 7.59 - 7.70 (m, 2 H) 7.75 (s, 1 H) 8.00 (s, 1 H) 8.98 (s, 1 H) 10.64 (s, 1 H); MS (ESI) m/z 483 (M+H)<sup>+</sup>.</p><heading id="h0307">EXAMPLE 126</heading><heading id="h0308">3-amino-1-methyl-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0269" num="0269">The title compound was prepared by substituting 1-isocyanato-4-(trifluoromethyl)benzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 3.84 (s, 3 H) 4.33 (d, <i>J</i>=5.55 Hz, 2 H) 6.81 (t, <i>J</i>=5.95 Hz, 1 H) 7.09 (d, <i>J</i>=7.54 Hz, 1 H) 7.39 - 7.46 (m, 2 H) 7.53 - 7.70 (m, 6 H) 7.76 (s, 1 H) 9.03 (s, 1 H) 10.65 (s, 1 H); MS (ESI) m/z 483 (M+H)+.</p><heading id="h0309">EXAMPLE 127</heading><heading id="h0310">3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><p id="p0270" num="0270">The title compound was prepared by substituting 1-fluoro-4-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) C ppm 3.85 (s, 3 H) 4.31 (d, <i>J</i>=5.76 Hz, 2 H) 6.63 (t, <i>J</i>=5.76 Hz, 1 H) 7.01 - 7.12 (m, 3 H) 7.33 (t, <i>J</i>=7.80 Hz, 1 H) 7.37 - 7.48 (m, 4 H) 7.59 - 7.70 (m, 2 H) 7.75 (s, 1 H) 8.60 (s, 1 H) 10.65 (s, 1 H); MS (ESI) m/z 433 (M+H)+.</p><heading id="h0311">EXAMPLE 128</heading><!-- EPO <DP n="84"> --><heading id="h0312">3-amino-N-(3-(((((2-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide</heading><p id="p0271" num="0271">The title compound was prepared by substituting 1-chloro-2-isocyanatobenzene for 1-isocyanato-4-methylbenzene and EXAMPLE 120A for EXAMPLE 5B in EXAMPLE 5C. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 3.81 (s, 3H) 4.33 (d, <i>J</i>=5.76 Hz, 2 H) 6.90 - 6.99 (m, 1 H) 7.09 (d, <i>J</i>=7.80 Hz, 1 H) 7.24 (td, 1 H) 7.31 - 7.43 (m, 4 H) 7.51 (t, <i>J</i>=5.76 Hz, 1 H) 7.58 - 7.65 (m, 1 H) 7.67 (d, <i>J</i>=9.16 Hz, 1 H) 7.78 (s, 1 H) 8.11 (s, 1 H) 8.18 (dd, <i>J</i>=8.31, 1.53 Hz, 1 H) 10.65 (s, 1 H); MS (ESI) m/z 449 (M+H)+.</p><heading id="h0313">EXAMPLE 129</heading><heading id="h0314">3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0272" num="0272">The title compound was prepared by substituting EXAMPLE 54B for EXAMPLE 5B in EXAMPLE 5C and purified by preparative HPLC on a Waters Symmetry C8 column (25mm x 100mm, 7µm particle size) using a gradient of 10% to 100% acetonitrile/0.1% aqueous TFA over 8 minutes (10 minute run time) at a flow rate of 40 mL/min. and was isolated as the TFA salt. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 2.21 (s, 3 H) 4.31 (d, <i>J</i>=5.43 Hz, 2 H) 6.57 (t, <i>J</i>=5.93 Hz, 1 H) 7.02 (d, <i>J</i>=8.14 Hz, 2 H) 7.08 (d, <i>J</i>=7.80 Hz, 1 H) 7.25 - 7.51 (m, 5 H) 7.56 (d, <i>J</i>=8.14 Hz, 1 H) 7.67 (d, <i>J</i>=7.80 Hz, 1 H) 7.75 (s, 1 H) 8.43 (s, 1 H) 10.65 (s, 1 H); MS (ESI) m/z = 415 (M+H)+,</p><heading id="h0315">EXAMPLE 130</heading><heading id="h0316">3-amino-N-(3-(((((2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0273" num="0273">The title compound was prepared by substituting EXAMPLE 54B and 1-fluoro-2-isocyanatobenzene for EXAMPLE 5B and 1-isocyanato-4-methylbenzene, respectively in EXAMPLE 5C and purified by preparative HPLC on a Waters Symmetry C8 column (25mm x 104mm, 7µm particle size) using a gradient of 10% to 100% acetonitrile/0.1% aqueous TFA over 8 minutes (10 minute run time) at a flow rate of 40 mL/min. and was isolated as the TFA salt. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 4.34 (d, <i>J</i>=5.76 Hz, 2 H) 6.87 - 6.98 (m, 1 H) 7.03 - 7.23 (m, 4 H) 7.36 (t, <i>J</i>=7.80 Hz, 1 H) 7.40 - 7.48 (m, 1 H) 7.49 - 7.56 (m, 1 H) 7.59 (d, <i>J</i>=8.14 Hz, 1 H) 7.69 (d, <i>J</i>=8.14 Hz, 1 H) 7.75 (s, 1 H) 8.15 (td, <i>J</i>=8.31. 1.70 Hz, 1 H) 8.39 (d, <i>J</i>=2.37 Hz, 1 H) 10.68 (s, 1 H); MS (ESI) m/z = 419 (M+H)+.</p><heading id="h0317">EXAMPLE 131</heading><!-- EPO <DP n="85"> --><heading id="h0318">3-amino-N-(3-(((((4-isopropylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide</heading><p id="p0274" num="0274">The title compound was prepared by substituting EXAMPLE 54B and 1-isocyanato-4-isopropylbenzene for EXAMPLE 58 and 1-isocyanato-4-methylbenzene, respectively in EXAMPLE 5C and purified by preparative HPLC on a Waters Symmetry C8 column (25mm x 100mm, 7µm particle size) using a gradient of 10% to 100% acetonitrile/0.1% aqueous TFA over 8 minutes (10 minute run time) at a flow rate of 40 mL/min. and was isolated as the TFA salt. <sup>1</sup>H NMR (300 MHz, DMSO-d<sub>6</sub>) □ ppm 1.16 (d, <i>J</i>=6.78 Hz, 6 H) 2.71 - 2.88 (m, 1 H) 4.31 (d, <i>J</i>=5.76 Hz, 2 H) 6.57 (t, <i>J</i>=5.93 Hz, 1 H) 7.04 - 7.12 (m, 3 H) 7.27 - 7.47 (m, 5 H) 7.53 (d, <i>J</i>=7.80 Hz, 1 H) 7.66 (d, <i>J</i>=7.80 Hz, 1 H) 7.75 (s, 1 H) 8.44 (s, 1 H) 10.64 (s, 1 H); MS (ESI) m/z = 433 (M+H)+.</p><p id="p0275" num="0275">The foregoing is meant to illustrate the invention but not to limit it. Variations and changes obvious to one skilled in the art are intended to be within the scope of the invention as defined in the claims.</p></description><claims mxw-id="PCLM56984777" lang="DE" load-source="patent-office"><!-- EPO <DP n="100"> --><claim id="c-de-01-0001" num="0001"><claim-text>Eine Verbindung mit der Formel I
<chemistry id="chem0010" num="0010"><img id="ib0010" file="imgb0010.tif" wi="26" he="22" img-content="chem" img-format="tif"/></chemistry>
oder ein therapeutisch verträgliches Salz davon, worin
<claim-text>X S, 0 oder NG<sup>1</sup> ist;</claim-text>
<claim-text>G<sup>1</sup> ist H oder Alkyl;</claim-text>
<claim-text>A<sup>1</sup> ist C(O)NHR<sup>1</sup>;</claim-text>
<claim-text>B<sup>1</sup>, C<sup>1</sup> und D<sup>1</sup> sind unabhängig gewählt OR<sup>1</sup>, H, F, Br, Cl oder I;</claim-text>
<claim-text>R<sup>1</sup> ist R<sup>2</sup> oder R<sup>5</sup>;</claim-text>
<claim-text>R<sup>2</sup> ist Phenyl;</claim-text>
<claim-text>R<sup>5</sup> ist Alkyl, das unsubstituiert oder substituiert ist mit einem, zwei, drei, vier oder fünf von unabhängig gewählten R<sup>6</sup>,<!-- EPO <DP n="101"> --> OH, F, Cl, Br oder I;</claim-text>
<claim-text>R<sup>6</sup> ist R<sup>7</sup> oder R<sup>9</sup>;</claim-text>
<claim-text>R<sup>7</sup> ist Phenyl;</claim-text>
<claim-text>R<sup>9</sup> ist Heterocycloalkyl, worin Heterocycloalkyl C<sub>3</sub>-Cycloalkyl, C<sub>4</sub>-Cycloalkyl, C<sub>5</sub>-Cycloalkyl oder C<sub>6</sub>-Cycloalkyl ist, wobei ein oder zwei oder drei CH<sub>2</sub>-Anteile ersetzt sind durch unabhängig gewähltes O, S, S(O), SO<sub>2</sub> oder NH, und wobei ein oder zwei CH-Anteile nicht ersetzt sind oder ersetzt sind durch N;</claim-text>
<claim-text>worin jeder der vorhergehenden zyklischen Anteile unabhängig unsubstituiert oder substituiert ist mit einem oder zwei oder drei oder vier oder fünf von unabhängig gewählten R<sup>10</sup>, NHC(O)R<sup>10</sup>, NHC(O)NHR<sup>10</sup>, F, Cl, Br oder I;</claim-text>
<claim-text>R<sup>10</sup> ist R<sup>11</sup>, R<sup>12</sup> oder R<sup>14</sup>;</claim-text>
<claim-text>R<sup>11</sup> ist Phenyl;</claim-text>
<claim-text>R<sup>12</sup> ist Heteroaryl, worin Heteroaryl Furanyl, Imidazolyl, Isothiazolyl, Isoxazolyl, 1,2,3-Oxadiazoyl, 1,2,5-Oxadiazolyl, Oxazolyl, Pyrazinyl, Pyrazolyl, Pyridazinyl, Pyridinyl, Pyrimidinyl., Pyrrolyl, Tetrazolyl,, Thiazolyl, Thiophenyl, Triazinyl oder 1,2,3-Triazolyl ist;</claim-text>
<claim-text>R<sup>14</sup> ist Alkyl, das unsubstituiert oder substituiert ist mit einem, zwei, drei, vier oder fünf von unabhängig gewählten R<sup>15</sup>, NH<sub>2</sub>, NHC(O)R<sup>15</sup>, NHC(O)NHR<sup>15</sup>, F, Cl, Br oder I;<!-- EPO <DP n="102"> --></claim-text>
<claim-text>R<sup>15</sup> ist R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> oder R<sup>19</sup>;</claim-text>
<claim-text>R<sup>16</sup> ist Phenyl;</claim-text>
<claim-text>R<sup>17</sup> ist Heteroaryl, worin Heteroaryl Furanyl, Imidazolyl, Isothiazolyl, Isoxazolyl, 1,2,3-Oxadiazolyl, 1,2,5-Oxadiazolyl, Oxazolyl, Pyrazinyl, Pyrazolyl, Pyridazinyl, Pyridinyl, Pyrimidinyl, Pyrrolyl, Tetrazolyl, Thiazolyl, Thiophenyl, Triazinyl oder 1,2,3-Triazolyl ist;</claim-text>
<claim-text>R<sup>16</sup> ist Cycloalkyl, worin Cycloalkyl C<sub>3</sub>-Cycloalkyl, C<sub>4</sub>-Cycloalkyl, C<sub>5</sub>-Cycloalkyl oder C<sub>6</sub>-Cycloalkyl ist;</claim-text>
<claim-text>R<sup>19</sup> ist Alkyl, wobei jedes davon substituiert ist mit R<sup>20</sup>;</claim-text>
<claim-text>R<sup>20</sup> ist Phenyl;</claim-text>
<claim-text>worin die Anteile, dargestellt durch R<sup>11</sup>, R<sup>12</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> und R<sup>20</sup>, unabhängig unsubstituiert oder substituiert sind mit ein oder zwei oder drei von unabhängig gewählten R<sup>21</sup>, OR<sup>21</sup>, SR<sup>21</sup>, CN, CF<sub>3</sub>, OCF<sub>3</sub>, F, Cl, Br oder I; und</claim-text>
<claim-text>R<sup>21</sup> ist Alkyl, das unsubstituiert oder substituiert ist mit einem oder zwei oder drei von unabhängig gewählten F, Cl, Br, I oder OH.</claim-text></claim-text></claim><claim id="c-de-01-0002" num="0002"><claim-text>Eine Verbindung gemäß Anspruch 1, worin
<claim-text>X S, 0 oder NG<sup>1</sup> ist;</claim-text>
<claim-text>G<sup>1</sup> ist H oder ist Alkyl;<!-- EPO <DP n="103"> --></claim-text>
<claim-text>A<sup>1</sup> ist C(O)NHR<sup>1</sup>;</claim-text>
<claim-text>B<sup>1</sup>, C<sup>1</sup> und D<sup>1</sup> sind unabhängig gewähltes H, F, Br, Cl oder I;</claim-text>
<claim-text>R<sup>1</sup> ist R<sup>2</sup>;</claim-text>
<claim-text>R<sup>2</sup> ist Phenyl;</claim-text>
<claim-text>worin R<sup>2</sup> substituiert ist mit einem oder zwei oder drei oder vier oder fünf von unabhängig gewählten R<sup>10</sup>, NHC(O)R<sup>10</sup>, NHC(O)NHR<sup>10</sup>, F, Cl, Br oder I;</claim-text>
<claim-text>R<sup>10</sup> ist R<sup>11</sup>, R<sup>12</sup> oder R<sup>10</sup>;</claim-text>
<claim-text>R<sup>11</sup> ist Phenyl;</claim-text>
<claim-text>R<sup>12</sup> ist Heteroaryl, worin Heteroaryl Furanyl, Imidazolyl, Isothiazolyl, Isoxazolyl, 1,2,3-Oxadiazoyl, 1,2,5-Oxadiazolyl, Oxazolyl, Pyrazinyl, Pyrazolyl, Pyridazinyl, Pyridinyl, Pyrimidinyl, Pyrrolyl, Tetrazolyl, Thiazolyl, Thiophenyl, Triazinyl oder 1,2,3-triazolyl ist;</claim-text>
<claim-text>R<sup>14</sup> ist Alkyl, das unsubstituiert oder substituiert ist mit einem, zwei, drei, vier oder fünf von unabhängig gewählten R<sup>15</sup>, NH<sub>2</sub>, NHC(O)R<sup>15</sup>, NHC(O)NHR<sup>15</sup>, F, Cl, Br oder I;</claim-text>
<claim-text>R<sup>15</sup> ist R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> oder R<sup>19</sup>;</claim-text>
<claim-text>R<sup>16</sup> ist Phenyl;<!-- EPO <DP n="104"> --></claim-text>
<claim-text>R<sup>17</sup> ist Heteroaryl, worin Heteroaryl Furanyl, Imidazolyl, Isothiazolyl, Isoxazolyl, 1,2,3-Oxadiazoyl, 1,2,5-Oxadiazolyl, Oxazolyl, Pyrazinyl, Pyrazolyl, Pyridazinyl, Pyridinyl, Pyrimidinyl, Pyrrolyl, Tetrazolyl, Thiazolyl, Thiophenyl, Triazinyl oder 1,2,3-Triazolyl ist;</claim-text>
<claim-text>R<sup>18</sup> ist Cycloalkyl, worin Cycloalkyl C<sub>3</sub>-Cycloalkyl, C<sub>4</sub>-Cycloalkyl, C<sub>5</sub>-Cycloalkyl oder C<sub>6</sub>-Cycloalkyl ist;</claim-text>
<claim-text>R<sup>19</sup> ist Alkyl, wobei jedes davon substituiert ist mit R<sup>20</sup>;</claim-text>
<claim-text>R<sup>20</sup> ist Phenyl;</claim-text>
<claim-text>worin die Anteile dargestellt durch R<sup>11</sup>, R<sup>12</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> und R<sup>20</sup> unabhängig unsubstituiert oder substituiert sind mit einem oder zwei oder drei von unabhängig gewählten R<sup>21</sup>, OR<sup>21</sup>, SR<sup>21</sup>, CN, CF<sub>3</sub>, OCF<sub>3</sub>, F, Cl, Br oder I; und</claim-text>
<claim-text>R<sup>2</sup>' ist Alkyl, das unsubstituiert oder substituiert ist mit einem oder zwei oder drei von unabhängig gewählten F, Cl, Br, I oder OH.</claim-text></claim-text></claim><claim id="c-de-01-0003" num="0003"><claim-text>Eine Verbindung gemäß Anspruch 1, die Folgendes ist:
<claim-text>3-Amino-N-(3-(((((3-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((2-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,<!-- EPO <DP n="105"> --></claim-text>
<claim-text>3-Amino-N-(3-(((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((2-fluor-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-methoxyphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-methoxyphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3,4-difluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3,5-difluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-((((cyclopentylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-((((cyclohexylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-((((thien-2-ylamino)carbonyl)amino)methyl)phenyl)-1,2--benzisoxazol-4-carboxamid,<!-- EPO <DP n="106"> --></claim-text>
<claim-text>3-Amino-N-(3-((((thien-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3,5-dimethylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((2-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-((((3-methylbenzoyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-((benzoylamino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((phenylacetyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3-fluorphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((anilinocarbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3-tritluormethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-(((thien--3-ylamino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((4-methylphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,<!-- EPO <DP n="107"> --></claim-text>
<claim-text>3-Amino-N-(4-((((3-methylphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((2,4-difluorphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3,5-difluorphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3,4-difluorphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-(benzoylamino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1,2-benzisothiazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-(trifluormathyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3-fluorphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisothiazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((anilinocarbonyl)amino)phenyl)-1,2-benzisothiazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3-(2-hydroxyethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisothiazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3,4-dichlorphenyl)amino)carbonyl)amino)phenyl)-1,2-benziso xazol-4-carboxamid,<!-- EPO <DP n="108"> --></claim-text>
<claim-text>3-Amino-N-(4-((((3-methoxyphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((4-bromphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((4-tluorphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((4-chlorphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((4-methoxyphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-(((benzylamino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3-cyanophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3-(methylthio)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((4-(methylthio)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3-chlor-4-fluorphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,<!-- EPO <DP n="109"> --></claim-text>
<claim-text>3-Amino-N-(3-(((((4-(trifluormethoxy)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3--(((((3-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((anilinocarbonyl)amino)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((((3-fluorphenyl)amino)carbonyl)amino)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(1-((((3-fluorphenyl)amino)carbonyl)amino)ethyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(4-((anilinocarbonyl)amino)benzyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,<!-- EPO <DP n="110"> --></claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlor-2-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluor-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((2-fluor-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((2-fluor-5-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl-)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3,5-difluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3,4-difluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluor-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-bromphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzzsoxazol-4-carboxamid,<!-- EPO <DP n="111"> --></claim-text>
<claim-text>3-Amino-N-(4-(((anxlinocarbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-7-(2-morpholin-4-ylethoxy)-N-(3-(((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-7-methoxy-N-(3-(((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlor-2-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlor-2-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-7-(3-hydroxypropoxy)-N-(3-(((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((3,4-difluorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-((((pyridin-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-7-methoxy-N-(3-((((pyridin-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazol-4-carboxamid;<!-- EPO <DP n="112"> --></claim-text>
<claim-text>3-Amino-N-(4-((anilinocarbonyl)amino)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazol-4-carboxamid:</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-7-(2-(4-methylpiperazin-1-yl)ethoxy)-N-(3-(((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((2,4-difluorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-7-methoxy-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((2,5-difluorphenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-(difluormethoxy)phenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(4-((((3-fluorphenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(4-((((3-fluorphenyl)amino)carbonyl)amino)-3-methylphenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(4-((((2-fluorphenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazol-4-carboxamid;<!-- EPO <DP n="113"> --></claim-text>
<claim-text>3-Amino-N-(4-((((2-fluorphenyl)amino)carbonyl)amino)-3-methylphenyl)-7-methoxy-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-methyl-4-((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-7-methoxy-N-(3-methyl-4-((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlorphenyl)amino)carbonyl)amino)methyl)-4-fluorphenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(4-fluor-3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-(difluormethoxy)phenyl)amino)carbonyl)amino)methyl)-4-fluorphenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(4-fluor-3-(((((2-fluor-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlor-2-fluorphenyl)amino)carbonyl)amino)methyl)-4-fluorphenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(4-fluor-3-(((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((anilinocarbonyl)amino)methyl)-4-fluorphenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(4-fluor-3-(((((4-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(9-fluor-3-(((((3-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;<!-- EPO <DP n="114"> --></claim-text>
<claim-text>3-Amino-N-(3-(((((2,5-difluorphenyl)amino)carbonyl)amino)methyl)-4-fluorphenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((4-fluorbenzoyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((3-fluorbenzoyl)amino)methyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((anilinocarbonyl)amino)methyl)-4-methylphenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(aminomethyl)phenyl)-1,2-benzisoxazol-4-carboxamid;</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluorphenyl)amino)carbonyl)amino)methyl)pherlyl)-1-methyl-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlor-2-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazol-9-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-fluor-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((3-chlor-4-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-1-methyl-N-(3-(((((3-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-1-methyl-N-(3-(((((4-(trifluormethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,<!-- EPO <DP n="115"> --></claim-text>
<claim-text>3-Amino-N-(3-(((((4-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((2-chlorphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((2-fluorphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid,</claim-text>
<claim-text>3-Amino-N-(3-(((((4-isopropylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazol-4-carboxamid</claim-text>
oder ein therapeutisch verträgliches Salz davon.</claim-text></claim><claim id="c-de-01-0004" num="0004"><claim-text>Eine Zusammensetzung umfassend ein Bindemittel und eine therapeutisch wirksame Menge einer Verbindung mit der Formel I gemäß Anspruch 1.</claim-text></claim></claims><claims mxw-id="PCLM56984778" lang="EN" load-source="patent-office"><!-- EPO <DP n="86"> --><claim id="c-en-01-0001" num="0001"><claim-text>A compound having Formula I
<chemistry id="chem0009" num="0009"><img id="ib0009" file="imgb0009.tif" wi="31" he="34" img-content="chem" img-format="tif"/></chemistry>
or a therapeutically acceptable salt thereof, wherein
<claim-text>X is S, O or NG<sup>1</sup>;</claim-text>
<claim-text>G<sup>1</sup> is H or is alkyl;</claim-text>
<claim-text>A<sup>1</sup> is C(O)NHR<sup>1</sup>;</claim-text>
<claim-text>B<sup>1</sup>, C<sup>1</sup>, and D<sup>1</sup> are independently selected OR<sup>1</sup>, H, F, Br, Cl or I;</claim-text>
<claim-text>R<sup>1</sup> is R<sup>2</sup> or R<sup>5</sup>;</claim-text>
<claim-text>R<sup>2</sup> is phenyl;</claim-text>
<claim-text>R<sup>5</sup> is alkyl which is unsubstituted or substituted with one, two, three, four or five of independently selected R<sup>6</sup>, OH, F, Cl, Br or I;</claim-text>
<claim-text>R<sup>6</sup> is R<sup>7</sup> or R<sup>9</sup>;</claim-text>
<claim-text>R<sup>7</sup> is phenyl;</claim-text>
<claim-text>R<sup>9</sup> is heterocycloalkyl, wherein heterocycloalkyl is C<sub>3</sub>-cycloalkyl, C<sub>4</sub>-cycloalkyl, C<sub>5</sub>-cycloalkyl or C<sub>6</sub>-cycloalkyl having one or two or three CH<sub>2</sub> moieties replaced with<!-- EPO <DP n="87"> --> independently selected O, S, S(O), SO<sub>2</sub> or NH and one or two CH moieties unreplaced or replaced with N;</claim-text>
<claim-text>wherein each foregoing cyclic moiety is independently unsubstituted or substituted with one or two or three or four or five of independently selected R<sup>10</sup>, NHC(O)R<sup>10</sup>, NHC(O)NHR<sup>10</sup>, F, Cl, Br or I;</claim-text>
<claim-text>R<sup>10</sup> is R<sup>11</sup>, R<sup>12</sup> or R<sup>14</sup>;</claim-text>
<claim-text>R<sup>11</sup> is phenyl;</claim-text>
<claim-text>R<sup>12</sup> is heteroaryl, wherein heteroaryl is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thiophenyl, triazinyl or 1,2,3-triazolyl;</claim-text>
<claim-text>R<sup>14</sup> is alkyl which is unsubstituted or substituted with one, two, three, four or five of independently selected R<sup>15</sup>, NH<sub>2</sub>, NHC(O)R<sup>15</sup>, NHC(O)NHR<sup>15</sup>, F, Cl, Br or I;</claim-text>
<claim-text>R<sup>15</sup> is R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> or R<sup>19</sup>;</claim-text>
<claim-text>R<sup>16</sup> is phenyl;</claim-text>
<claim-text>R<sup>17</sup> is heteroaryl, wherein heteroaryl is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thiophenyl, triazinyl or 1,2,3-triazolyl;</claim-text>
<claim-text>R<sup>18</sup> is cycloalkyl, wherein cycloalkyl is C<sub>3</sub>-cycloalkyl, C<sub>4</sub>-cycloalkyl, C<sub>5</sub>-cycloalkyl or C<sub>6</sub>-cycloalkyl;<!-- EPO <DP n="88"> --></claim-text>
<claim-text>R<sup>19</sup> is alkyl, each of which is substituted with R<sup>20</sup>;</claim-text>
<claim-text>R<sup>20</sup> is phenyl;</claim-text>
<claim-text>wherein the moieties represented by R<sup>11</sup>, R<sup>12</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>20</sup> are independently unsubstituted or substituted with one or two or three of independently selected R<sup>21</sup>, OR<sup>21</sup>, SR<sup>21</sup>, CN, CF<sub>3</sub>, OCF<sub>3</sub>, F, Cl, Br or I; and</claim-text>
<claim-text>R<sup>21</sup> is alkyl which is unsubstituted or substituted with one or two or three of independently selected F, Cl, Br, I, or OH.</claim-text></claim-text></claim><claim id="c-en-01-0002" num="0002"><claim-text>A compound of claim 1 wherein
<claim-text>X is S, O or NG<sup>1</sup>;</claim-text>
<claim-text>G<sup>1</sup> is H or is alkyl;</claim-text>
<claim-text>A<sup>1</sup> is C(O)NHR<sup>1</sup>;</claim-text>
<claim-text>B<sup>1</sup>, C<sup>1</sup>, and D<sup>1</sup> are independently selected H, F, Br, Cl or I;</claim-text>
<claim-text>R<sup>1</sup> is R<sup>2</sup>;</claim-text>
<claim-text>R<sup>2</sup> is phenyl;</claim-text>
<claim-text>wherein R<sup>2</sup> is substituted with one or two or three or four or five of independently selected R<sup>10</sup>, NHC(O)R<sup>10</sup>, NHC(O)NHR<sup>10</sup>, F, Cl, Br or I;</claim-text>
<claim-text>R<sup>10</sup> is R<sup>11</sup> R<sup>12</sup> or R<sup>14</sup>;<!-- EPO <DP n="89"> --></claim-text>
<claim-text>R<sup>11</sup> is phenyl;</claim-text>
<claim-text>R<sup>12</sup> is heteroaryl, wherein heteroaryl is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thiophenyl, triazinyl or 1,2,3-triazolyl;</claim-text>
<claim-text>R<sup>14</sup> is alkyl which is unsubstituted or substituted with one, two, three, four or five of independently selected R<sup>15</sup>, NH<sub>2</sub>, NHC(O)R<sup>15</sup>, NHC(O)NHR<sup>15</sup>, F, Cl, Br or I;</claim-text>
<claim-text>R<sup>15</sup> is R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> or R<sup>19</sup>;</claim-text>
<claim-text>R<sup>16</sup> is phenyl;</claim-text>
<claim-text>R<sup>17</sup> is heteroaryl, wherein heteroaryl is furanyl, imidazolyl, isothiazolyl, isoxazolyl, 1,2,3-oxadiazoyl, 1,2,5-oxadiazolyl, oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, tetrazolyl, thiazolyl, thiophenyl, triazinyl or 1,2,3-triazolyl;</claim-text>
<claim-text>R<sup>18</sup> is cycloalkyl, wherein cycloalkyl is C<sub>3</sub>-cycloalkyl, C<sub>4</sub>-cycloalkyl, C<sub>5</sub>-cycloalkyl or C<sub>6</sub>-cycloalkyl;</claim-text>
<claim-text>R<sup>19</sup> is alkyl, each of which is substituted with R<sup>20</sup>;</claim-text>
<claim-text>R<sup>20</sup> is phenyl;</claim-text>
<claim-text>wherein the moieties represented by R<sup>11</sup>, R<sup>12</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> and R<sup>20</sup>are independently unsubstituted or substituted with one or two or three of independently selected R<sup>21</sup>, OR<sup>21</sup>, SR<sup>21</sup>, CN, CF<sub>3</sub>, OCF<sub>3</sub>, F, Cl, Br or I; and<!-- EPO <DP n="90"> --></claim-text>
<claim-text>R<sup>21</sup> is alkyl which is unsubstituted or substituted with one or two or three of independently selected F, Cl, Br, I, or OH.</claim-text></claim-text></claim><claim id="c-en-01-0003" num="0003"><claim-text>A compound of claim 1 which is
<claim-text>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-methoxyphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-methoxyphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3,5-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-((((cyclopentylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,<!-- EPO <DP n="91"> --></claim-text>
<claim-text>3-amino-N-(3-((((cyclohexylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-((((thien-2-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-((((thien-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3,5-dimethylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((2-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((3-methylbenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-((benzoylamino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3 -(((phenylacetyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-(((thien-3-ylamino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((4-methylphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,<!-- EPO <DP n="92"> --></claim-text>
<claim-text>3-amino-N-(4-((((3-methylphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((2,4-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3,5-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3,4-difluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-(benzoylamino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-(2-hydroxyethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3,4-dichlorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-methoxyphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((4-bromophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((4-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,<!-- EPO <DP n="93"> --></claim-text>
<claim-text>3-amino-N-(4-((((4-chlorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((4-methoxyphenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-(((benzylamino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-cyanophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-(methylthio)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((4-(methylthio)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-chloro-4-fluorophenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1 H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1 H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-(trifluoromethoxy)phenyl)amino)carbonyl)amino)methyl)phenyl)-1-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1 H-indazole-4-carboxamide,<!-- EPO <DP n="94"> --></claim-text>
<claim-text>3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-(3-hydroxypropoxy)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(1-((((3-fluorophenyl)amino)carbonyl)amino)ethyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(4-((anilinocarbonyl)amino)benzyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluoro-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((2-fluoro-5-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3,5-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluoro-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,<!-- EPO <DP n="95"> --></claim-text>
<claim-text>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-bromophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-7-(2-morpholin-4-ylethoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-7-methoxy-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-7-(3-hydroxypropoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((3,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-((((pyridin-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="96"> --></claim-text>
<claim-text>3-amino-7-methoxy-N-(3-((((pyridin-3-ylamino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-morpholin-4-ylethoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-((anilinocarbonyl)amino)phenyl)-7-(2-morpholin-4-ylethoxy)- 1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-7-(2-(4-methylpiperazin-1-yl)ethoxy)-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-7-(2-(4-methylpiperazin-1-yl)ethoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((2,4-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-7-methoxy-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((2,5-difluorophenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-(difluoromethoxy)phenyl)amino)carbonyl)amino)methyl)phenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-((((3-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-((((2-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="97"> --></claim-text>
<claim-text>3-amino-N-(4-((((2-fluorophenyl)amino)carbonyl)amino)-3-methylphenyl)-7-methoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-methyl-4-((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-7-methoxy-N-(3-methyl-4-((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-fluoro-3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-(difluoromethoxy)phenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-fluoro-3-(((((2-fluoro-5-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-fluoro-3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-fluoro-3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(4-fluoro-3-(((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((2,5-difluorophenyl)amino)carbonyl)amino)methyl)-4-fluorophenyl)-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="98"> --></claim-text>
<claim-text>3-amino-N-(3-(((4-fluorobenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((3-fluorobenzoyl)amino)methyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((anilinocarbonyl)amino)methyl)-4-methylphenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(aminomethyl)phenyl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-chloro-2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3 -amino-N-(3-(((((4-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((3-fluoro-4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((3-chloro-4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-mdazole-4-carboxamide;</claim-text>
<claim-text>3-amino-1-methyl-N-(3-(((((3-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3-amino-1-methyl-N-(3-(((((4-(trifluoromethyl)phenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((2-chlorophenyl)amino)carbonyl)amino)methyl)phenyl)-1-methyl-1H-indazole-4-carboxamide;<!-- EPO <DP n="99"> --></claim-text>
<claim-text>3-amino-N-(3-(((((4-methylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3 -(((((2-fluorophenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</claim-text>
<claim-text>3-amino-N-(3-(((((4-isopropylphenyl)amino)carbonyl)amino)methyl)phenyl)-1H-indazole-4-carboxamide;</claim-text>
or a therapeutically acceptable salt thereof.</claim-text></claim><claim id="c-en-01-0004" num="0004"><claim-text>A composition comprising an excipient and a therapeutically effective amount of a compound having Formula I of claim 1.</claim-text></claim></claims><claims mxw-id="PCLM56984779" lang="FR" load-source="patent-office"><!-- EPO <DP n="116"> --><claim id="c-fr-01-0001" num="0001"><claim-text>Composé ayant la formule I
<chemistry id="chem0011" num="0011"><img id="ib0011" file="imgb0011.tif" wi="21" he="23" img-content="chem" img-format="tif"/></chemistry>
ou sel thérapeutiquement acceptable de celui-ci, où
<claim-text>X est S, O ou NG<sup>1</sup>;</claim-text>
<claim-text>G<sup>1</sup> est H ou est alkyle;</claim-text>
<claim-text>A<sup>1</sup> est C(O)NHR<sup>1</sup>;</claim-text>
<claim-text>B<sup>1</sup>, C<sup>1</sup>, et D<sup>1</sup> sont OR<sup>1</sup>, H, F, Br, Cl ou I choisis indépendamment;</claim-text>
<claim-text>R<sup>1</sup> est R<sup>2</sup> ou R<sup>5</sup>;</claim-text>
<claim-text>R<sup>2</sup> est phényle;</claim-text>
<claim-text>R<sup>5</sup> est alkyle qui est non substitué ou substitué avec un, deux, trois, quatre ou cinq de R<sup>6</sup>, OH, F, Cl, Br ou I choisis indépendamment;</claim-text>
<claim-text>R<sup>6</sup> est R<sup>7</sup> ou R<sup>9</sup>;</claim-text>
<claim-text>R<sup>7</sup> est phényle;</claim-text>
<claim-text>R<sup>9</sup> est hétérocycloalkyle, où hétérocycloalkyle est C<sub>3</sub>-cycloalkyle, C<sub>4</sub>-cycloalkyle, C<sub>5</sub>-cycloalkyle ou C<sub>6</sub>-cycloalkyle ayant un ou deux ou trois groupements CH<sub>2</sub> remplacés par O, S, S(O), SO<sub>2</sub> ou NH choisis indépendamment et un ou deux groupements CH non remplacés ou remplacés par N;</claim-text>
<claim-text>où chaque groupement cyclique précédent est indépendamment non substitué ou substitué avec un ou deux ou trois ou quatre ou cinq de R<sup>10</sup>, NHC(O)R<sup>10</sup>, NHC(O)NHR<sup>10</sup>, F, Cl, Br ou I choisis indépendamment;</claim-text>
<claim-text>R<sup>10</sup> est R<sup>11</sup>, R<sup>12</sup> ou R<sup>14</sup>;</claim-text>
<claim-text>R<sup>11</sup> est phényle;</claim-text>
<claim-text>R<sup>12</sup> est hétéroaryle, où hétéroaryle est furanyle, imidazolyle, isothiazolyle, isoxazolyle, 1,2,3-oxadiazoyle, 1,2,5-oxadiazolyle, oxazolyle, pyrazinyle,<!-- EPO <DP n="117"> --> pyrazolyle, pyridazinyle, pyridinyle, pyrimidinyle, pyrrolyle, tétrazolyle, thiazolyle, thiophényle, triazinyle ou 1,2,3-triazolyle;</claim-text>
<claim-text>R<sup>14</sup> est alkyle qui est non substitué ou substitué avec un, deux, trois, quatre ou cinq de R<sup>15</sup>, NH<sub>2</sub>, NHC(O)R<sup>15</sup>, NHC(O)NHR<sup>15</sup>, F, CI, Br ou I choisis indépendamment;</claim-text>
<claim-text>R<sup>15</sup> est R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> ou R<sup>19</sup>;</claim-text>
<claim-text>R<sup>16</sup> est phényle;</claim-text>
<claim-text>R<sup>17</sup> est hétéroaryle, où hétéroaryle est furanyle, Imidazolyle, isothiazolyle, isoxazolyle, 1,2,3-oxadiazoyle, 1,2,5-oxadiazolyle, oxazolyle, pyrazinyle, pyrazolyle, pyridazinyle, pyridinyle, pyrimidinyle, pyrrolyle, tétrazolyle, thiazolyle, thiophényle, triazinyle ou 1,2,3-triazolyle;</claim-text>
<claim-text>R<sup>18</sup> est cycloalkyle, où cycloalkyle est C<sub>3</sub>-cycloalkyle, C<sub>4</sub>-cycloalkyle, C<sub>5</sub>-cycloalkyle ou C<sub>6</sub>-cycloalkyle;</claim-text>
<claim-text>R<sup>19</sup> est alkyle, chacun desquels est substitué avec R<sup>20</sup>;</claim-text>
<claim-text>R<sup>20</sup> est phényle;</claim-text>
<claim-text>où les groupements représentés par R<sup>11</sup>, R<sup>12</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> et R<sup>20</sup> sont indépendamment non substitués ou substitués avec un ou deux ou trois de R<sup>21</sup>, OR<sup>21</sup>, SR<sup>21</sup>, CN, CF<sub>3</sub>, OCF<sub>3</sub>, F, CI, Br ou I choisis indépendamment; et</claim-text>
<claim-text>R<sup>21</sup> est alkyle qui est non substitué ou substitué avec un ou deux ou trois de F, Cl, Br, I ou OH choisis indépendamment.</claim-text></claim-text></claim><claim id="c-fr-01-0002" num="0002"><claim-text>Composé selon la revendication 1 où
<claim-text>X est S, O ou NG<sup>1</sup>;</claim-text>
<claim-text>G<sup>1</sup> est H ou est alkyle;</claim-text>
<claim-text>A<sup>1</sup> est C(O)NHR<sup>1</sup>;</claim-text>
<claim-text>B<sup>1</sup>, C<sup>1</sup> et D<sup>1</sup> sont H, F, Br, Cl ou I choisis indépendamment;</claim-text>
<claim-text>R<sup>1</sup> est R<sup>2</sup>;</claim-text>
<claim-text>R<sup>2</sup> est phényle;</claim-text>
<claim-text>où R<sup>2</sup> est substitué avec un ou deux ou trois ou quatre ou cinq de R<sup>10</sup>, NHC(O)R<sup>10</sup>, NHC(O)NHR<sup>10</sup>, F, CI, Br ou I choisis indépendamment;</claim-text>
<claim-text>R<sup>10</sup> est R<sup>11</sup>, R<sup>12</sup> ou R<sup>14</sup>;</claim-text>
<claim-text>R<sup>11</sup> est phényle;<!-- EPO <DP n="118"> --></claim-text>
<claim-text>R<sup>12</sup> est hétéroaryle, où hétéroaryle est furanyle, imidazolyle, isothiazolyle, isoxazolyle, 1,2,3-oxadiazoyle, 1,2,5-oxadiazolyle, oxazolyle, pyrazinyle, pyrazolyle, pyridazinyle, pyridinyle, pyrimidinyle, pyrrolyle, tétrazolyle, thiazolyle, thiophényle, triazinyle ou 1,2,3-triazolyle;</claim-text>
<claim-text>R<sup>14</sup> est alkyle qui est non substitué ou substitué avec un, deux, trois, quatre ou cinq de R<sup>15</sup>, NH<sub>2</sub>, NHC(O)R<sup>15</sup>, NHC(O)NHR<sup>15</sup>, F, Cl, Br ou I choisis indépendamment;</claim-text>
<claim-text>R<sup>15</sup> est R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> ou R<sup>19</sup>;</claim-text>
<claim-text>R<sup>16</sup> est phényle;</claim-text>
<claim-text>R<sup>17</sup> est hétéroaryle, où hétéroaryle est furanyle, imidazolyle, isothiazolyle, isoxazolyle, 1,2,3-oxadiazoyle, 1,2,5-oxadiazolyle, oxazolyle, pyrazinyle, pyrazolyle, pyridazinyle, pyridinyle, pyrimidinyle, pyrrolyle, tétrazolyle, thiazolyle, thlophényle, triazinyle ou 1,2,3-triazolyle;</claim-text>
<claim-text>R<sup>18</sup> est cycloalkyle, où cycloalkyle est C<sub>3</sub>-cycloalkyle, C<sub>4</sub>-cycloalkyle, C<sub>5</sub>-cycloalkyle ou C<sub>6</sub>-cycloalkyle;</claim-text>
<claim-text>R<sup>19</sup> est alkyle, chacun desquels est substitué avec R<sup>20</sup>;</claim-text>
<claim-text>R<sup>20</sup> est phényle;</claim-text>
<claim-text>où les groupements représentés par R<sup>11</sup>, R<sup>12</sup>, R<sup>16</sup>, R<sup>17</sup>, R<sup>18</sup> et R<sup>20</sup> sont indépendamment non substitués ou substitués avec un ou deux ou trois de R<sup>21</sup>, OR<sup>21</sup>, SR<sup>21</sup>, CN, CF<sub>3</sub>, OCF<sub>3</sub>, F, Cl, Br ou I choisis indépendamment; et</claim-text>
<claim-text>R<sup>21</sup> est alkyle qui est non substitué ou substitué avec un ou deux ou trois de F, Cl, Br, I ou OH choisis indépendamment.</claim-text></claim-text></claim><claim id="c-fr-01-0003" num="0003"><claim-text>Composé selon la revendication 1 qui est
<claim-text>le 3-amino-N-(3-(((((3-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((2-fluorophényl)amino)carbonyl)amino)méthyl)-phenyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((anilinocarbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-(trifluorométhyl)phényl)amino)carbonyl)amino)-méthyl)phényl)-1,2-benzisoxazol-4-carboxamide,<!-- EPO <DP n="119"> --></claim-text>
<claim-text>le 3-amino-N-(3-(((((4-méthylphényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((2-fluoro-5-méthylphényl)amino)carbonyl)amino)-méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-méthoxyphényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-méthoxyphényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3,4-difluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3,5-difluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-((((cyclopentylamino)carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-((((cyclohexylamino)carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-((((thién-2-ylamino)carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-((((thién-3-ylamino)carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-méthylphényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3,5-diméthylphényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((2-(triluorométhyl)phényl)amio)carbonyl)-amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((3-méthylbenzoyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-((benzoylamino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((phénylacétyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,<!-- EPO <DP n="120"> --></claim-text>
<claim-text>le 3-amino-N-(4-((((3-fluorophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((anilinocarbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-(trifluorométhyl)phényl)amino)carbonyl)amino)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-(((thién-3-ylamino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((4-méthylphényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-méthylphényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((2,4-difluorophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3,5-difluorophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3,4-difluorophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-(benzoylamino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((anilinocarbonyl)amino)méthyl)-phényl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-(trifluorométhyl)phényl)amino)carbonyl)amino)-méthyl)phényl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-fluorophényl)amino)carbonyl)amino)phényl)-1,2-benzisotbiazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((anilinocarbonyl)amino)phényl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-(2-hydroxyéthyl)phényl)amino)carbonyl)amino)-phényl)-1,2-benzisothiazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3,4-dichlorophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-méthoxyphényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,<!-- EPO <DP n="121"> --></claim-text>
<claim-text>le 3-amino-N-(4-((((4-bromophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((4-fluorophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole -4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((4-chlorophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((4-méthoxyphényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-(((benzylamino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-cyanophényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-(méthylthio)phényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((4-(méthylthio)phényl)amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-chloro-4-fluorophényl)amino)carbonyl)amino)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-(trifluorométhoxy)phényl)amino)carbonyl)amino)-méthyl)phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-méthylphényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-(trifluorométhyl)phényl)amino)carbonyl)amino)-méthyl)phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-(trifluorométhyl)phényl)amino)carbonyl)amino)-méthyl)phényl)-1H-indazole-4 carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-((anilinocarbonyl)amino)phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((((3-fluorophényl)amino)carbonyl)amino)phényl)-1H-indazole-4-carboxamide,<!-- EPO <DP n="122"> --></claim-text>
<claim-text>le 3-amino-N-(3-(((((3-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-(3-hydroxypropoxy)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((anilinocarbonyl)amino)méthyl)phényl)-7-(3-hydroxy-propoxy)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(1-((((3-fluorophényl)amino)carbonyl)amino)éthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(4-((anilinocarbonyl)amino)benzyl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((anilinocarbonyl)amino)méthyl)phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chloro-2-fluorophényl)amino)carbonyl)amino)-méthyl)phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-fluoro-4-méthylphényl)amino)carbonyl)amino)-méthyl)phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((2-fluoro-5-méthylphényl)amino)carbonyl)amino)-méthyl)phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((2-fluoro-5-(trifluorométhyl)phényl)amino)carbonyl)-amino)méthyl)phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3,5-difluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3,4-difluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-fluoro-4-méthylphényl)amino)carbonyl)amino)-méthyl)phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-bromophényl)amino)carbonyl)amino)méthyl)-phényl)-1,2-benzisoxazole-4-carboxamide,</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-(2-morpholin-4-yléthoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((anilinocarbonyl)amino)méthyl)phényl)-7-(2-morpholin-4-yléthoxy)-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="123"> --></claim-text>
<claim-text>le 3-amino-7-(2-morpholin-4-yléthoxy)-N-(3-(((((4-(trifluorométhyl)-phényl)amino)carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((anilinocarbonyl)amino)méthyl)phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-7-méthoxy-N-(3-(((((4-(trifluorométhyl)phényl)amino)-carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chloro-2-fluorophényl)amino)carbonyl)amino)-méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chloro-2-fluorophényl)amino)carbonyl)amino)-méthyl)phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-7-(3-hydroxypropoxy)-N-(3-(((((4-(trifluorométhyl)phényl)-amino)carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((3,4-difluorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-((((pyridin-3-ylamino)carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-7-méthoxy-N-(3-((((pyridin-3-ylamino)carbonyl)amino)-méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-(2-morpholin-4-yléthoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-((anilinocarbonyl)amino)phényl)-7-(2-morpholin-4-yléthoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-(2-(4-méthylpipérazin-1-yl)éthoxy)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-7-(2-(4-méthylpipérazin-1-yl)éthoxy)-N-(3-(((((4-(trifluoro-méthyl)phényl)amino)carbonyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-méthylphényl)amino)carbonyl)amino)méthyl)-phényl)-7-(2-(4-méthylpipérazin-1-yl)éthoxy)-1,2-benzisoxazole-4-carboxamlde;</claim-text>
<claim-text>le 3-amino-N-(3-(((((2,4-difluorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="124"> --></claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-7-méthoxy-N-(3-(((((4-méthylphényl)amino)carbonyl)amino)-méthyl)phényl)-1,2-benzisoxazole-4-carboxam</claim-text>
<claim-text>le 3-amino-N-(3-(((((2,5-difluorophényl)amino)carbonyl)amino)méthyl)-phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-(difluorométhoxy)phényl)amino)carbonyl)amino)-méthyl)phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-((((3-fluorophényl)amino)carbonyl)amino)-3-méthyl-phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-((((3-fluorophényl)amino)carbonyl)amino)-3-méthyl-phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-((((2-fluorophényl)amino)carbonyl)amino)-3-méthyl-phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-((((2-fluorophényl)amino)carbonyl)amino)-3-méthyl-phényl)-7-méthoxy-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-méthyl-4-((((4-(trifluorométhyl)phényl)amino)carbonyl)-amino)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-7-méthoxy-N-(3-méthyl-4-((((4-(trifluorométhyl)phényl)-amino)carbonyl)amino)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chlorophényl)amino)carbonyl)amino)méthyl)-4-fluorophényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-fluoro-3-(((((4-méthylphényl)amino)carbonyl)amino)-méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-(difluorométhoxy)phényl)amino)carbonyl)amino)-méthyl)-4-fluorophényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-fluoro-3-(((((2-fluoro-5-méthylphényl)amino)carbonyl)-amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chloro-2-fluorophényl)amino)carbonyl)amino)-méthyl)-4-fluorophényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-fluoro-3-(((((4-(trifluorométhyl)phényl)amino)carbonyl)-amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((anilinocarbonyl)amino)méthyl)-4-fluorophényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(4-fluoro-3-(((((4-fluorophényl)amino)carbonyl)amino)-méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;<!-- EPO <DP n="125"> --></claim-text>
<claim-text>le 3-amino-N-(4-fluoro-3-(((((3-(trifluorométhyl)phényl)amino)carbonyl)-amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((2,5-difluorophényl)amino)carbonyl)amino)méthyl)-4-fluorophényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((4-fluorobenzoyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((3-fluorobenzoyl)amino)méthyl)phényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((anilinocarbonyl)amino)méthyl)-4-méthylphényl)-1,2-benzisoxazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(aminométhyl)phényl)-1,2-benzisoxazole-4-carboxamide; le 3-amino-N-(3-(((((3-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1-méthyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chloro-2-fluorophényl)amino)carbonyl)amino)-méthyl)phényl)-1-méthyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-1-méthyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-fluoro-4-méthylphényl)amino)carbonyl)amino)-méthyl)phényl)-1-méthyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((3-chloro-4-fluorophényl)amino)carbonyl)amino)-méthyl)phényl)-1-méthyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-1-méthyl-N-(3-(((((3-(trifluorométhyl)phényl)amino)carbonyl)-amino)méthyl)phényl)-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-1-méthyl-N-(3-(((((4-(trifluorométhyl)phényl)amino)carbonyl)-amino)méthyl)phényl)-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1-méthyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((2-chlorophényl)amino)carbonyl)amino)méthyl)-phényl)-1-méthyl-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-méthylphényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((2-fluorophényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide;</claim-text>
<claim-text>le 3-amino-N-(3-(((((4-isopropylphényl)amino)carbonyl)amino)méthyl)-phényl)-1H-indazole-4-carboxamide;</claim-text>
ou sel thérapeutiquement acceptable de celui-ci.<!-- EPO <DP n="126"> --></claim-text></claim><claim id="c-fr-01-0004" num="0004"><claim-text>Composition comprenant un excipient et une quantité thérapeutiquement efficace d'un composé ayant la formule I selon la revendication 1.</claim-text></claim></claims><copyright>User acknowledges that Fairview Research LLC and its third party providers retain all right, title and interest in and to this xml under applicable copyright laws.  User acquires no ownership rights to this xml including but not limited to its format.  User hereby accepts the terms and conditions of the Licence Agreement</copyright></patent-document>
